

**A study of the transmission pathways of organisms associated with
nosocomial infections at a veterinary academic hospital**

Dikeledi Carol Sebola

26235286

Thesis submitted in the fulfilment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

in the

Department of Paraclinical Sciences

Faculty of Veterinary Science

University of Pretoria

Supervisor : Prof. Daniel Nenene Qekwana

Co-supervisor: Prof. James Wabwire Oguttu

Co-supervisor: Prof. Marleen Kock

2023

Declaration

I, Dikeledi Carol Sebola declare that the thesis, which I hereby submit for the degree DOCTOR OF PHILOSOPHY in Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, is my work and has not previously been submitted at this or any other tertiary institution.

SIGNATURE:

DATE:

Ethics statement

The author whose name appears on the title page of this thesis has obtained the required ethics approval for the research described in this work.

The author declares that they have observed the ethical standards required in terms of the University's Code of ethics for scholarly activities.

Dedication

This thesis is dedicated to the Sebola family, in particular, my parents Mrs Makoma Sophie Sebola, and my late father Mr Mabusha Sebola for their continuous support in getting this far.

Acknowledgments

First and foremost, I give all the glory to the most high GOD for carrying me through this process. It has been a rollercoaster ride and I acknowledge that I wouldn't have been able to do it without God's help.

I want to express my gratitude to my mentor and supervisor, Prof DN Qekwana, for believing in me even when I didn't believe in myself at times. Thank you for consistently sharing your knowledge, providing guidance, offering continuous support, making sacrifices, going the extra mile for my well-being, and teaching. I am also grateful to my co-supervisors: Prof JW Oguttu and Prof MM Kock for always being available to assist me with this project and providing the necessary support when things got tough. To Prof Karama, thank you for opening your doors to me and for your guidance. Mme Segomotso Lebogo, and Ms. Madelyn deWet, I can never thank you enough for the kindness you showed me.

I would like to extend my gratitude to my friends, who were my great cheerleaders and supporters throughout this journey. Thank you for the continuous support and the laughter we shared. Special thanks to my bestie, Benjamin Shilakwe, for your consistent support, for always pushing me and ensuring my PhD journey is as doable as possible, and for lending an ear whenever it got tough. To Vutlhari bja ka Maluleke, thank you for carrying me throughout this journey.

To my churches, Canon Worship Centre Church (Pretoria) and Lenyenye AFM (Tzaneen), your prayers and support have carried me throughout. I am counted among the blessed because of you.

Last but not least, I want to thank my family, Ditlou tja ga Sebola. Thank you for the love, and support, and for cheering me all the way. I am grateful and I am who I am because of all of you. To my siblings Sewela Sewela, Joey Sebola, Mapula Kgatle, Motjatji Letsoalo,

Motlatjo Rasebotsa, and my babies Itumeleng, Maria, Bohlale, Bonolo and Boitumelo
Steve, this is for all of us. We have made it.

I know I have made all of you proud.

Research outputs

Conference Presentations

1. **Dikeledi C. Sebola**, James W. Oguttu, Marleen M. Kock and Daniel N. Qekwana. Hospital-acquired and zoonotic bacterial organisms and their associated antimicrobial-susceptibility profile in veterinary hospitals: A Systematic Review. 23 August 2023 SASVEPM 2023 (ORAL).
2. **Dikeledi C. Sebola**, James W. Oguttu, Mogaugedi Malahlela, Marleen. Kock, Daniel N. Qekwana. Occurrence and characterization of ESKAPE pathogens on the hands of healthcare workers in the intensive care unit at a veterinary academic hospital in South Africa 16 June 2023 American Society of Microbiology at Microbe 2023 (POSTER).

Publications

1. **Dikeledi C. Sebola**, James W. Oguttu, Marleen M. Kock and Daniel N. Qekwana. Antimicrobial resistance patterns of *Acinetobacter baumannii* and *Klebsiella pneumoniae* isolated from dogs presented at a veterinary academic hospital in South Africa. *Veterinary World*. 2023.
2. **Dikeledi C. Sebola**, James W. Oguttu, Marleen M. Kock and Daniel N. Qekwana. Hospital-acquired and zoonotic bacteria from a veterinary hospital and their associated antimicrobial-susceptibility profiles: A systematic review. *Frontier for. Veterinary. Science*. 2023.

Manuscripts under review and to be submitted

1. **Dikeledi C. Sebola**, James W. Oguttu, Mogaugedi Malahlela, Marleen. Kock, Daniel N. Qekwana. Occurrence and characterization of ESKAPE pathogens on the hands of healthcare workers in the intensive care unit at a veterinary academic hospital in South Africa.

2. **Dikeledi C. Sebola**, James W. Oguttu, Marleen M. Kock, Daniel N. Qekwana.
Knowledge and perception of veterinary students on the transmission of hospital-acquired infections and zoonotic diseases at the Veterinary Academic Hospital.

Abstract

Background: Hospital-acquired infections (HAIs) are a major concern in human and veterinary medicine. They are caused by bacterial organisms mainly from the ESKAPE group (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter species*). Within the veterinary settings, this group of organisms is often zoonotic and tends to acquire resistance determinants. As a result, most of these bacteria are multidrug-resistant, which limits treatment options and patient prognosis. Organisms associated with HAIs are transmitted mainly through the hands of healthcare workers (HCWs), making hand hygiene the most effective measure to prevent and control infections in healthcare facilities. However, low compliance to hand hygiene has been reported in both human and veterinary hospitals, which increases the risk of transmission of HAIs and zoonotic organisms. To reduce the risk of transmission, a multimodal approach has been recommended. As such, this study aims to use a multimodal approach to assess the pre-intervention required to reduce the transmission of organisms associated with HAIs and zoonotic diseases at a veterinary academic hospital.

Methods: In order to achieve the objectives of this study, a systematic literature review using the PRISMA method was undertaken to describe the organisms responsible for HAIs and zoonotic infections. In addition, antimicrobial resistance genes associated with these organisms were also described. Since the results of the systematic literature review showed there was limited information on the burden of ESKAPE pathogens in South Africa, data on dog clinical cases presented at the veterinary academic hospital between 2007 and 2013 were reviewed. *Klebsiella pneumoniae* and *A. baumannii* isolates were assessed in terms of their burden and antimicrobial resistance patterns. Hands of healthcare workers were also assessed for the presence of organisms associated with HAIs and zoonotic diseases using the polymerase chain reaction (PCR). In addition, each isolate was subjected

to antimicrobial sensitivity testing following the Kirby-Bauer disk diffusion method. In order to assess the level of knowledge of veterinary students regarding the transmission of HAIs, a questionnaire survey was performed assessing the knowledge of students on infection prevention and control (IPC) and the transmission of organisms associated with HAIs.

Results: Bacterial organisms associated with HAIs and zoonosis were reported from clinical cases, environmental surfaces, and items used during patient treatment and care. *Staphylococcus* species was the most reported organism, and some isolates seem to share similar clonal lineage to those reported in humans. In terms of resistant genes, the *mecA* gene was identified in both Methicillin-resistant *Staphylococcus aureus* (MRSA) and Methicillin-resistant *Staphylococcus pseudintermedius* (MRSP), the *bla*CMY-2 gene in *E. coli* and *Salmonella* spp., *flo* genes in *E. coli*, and the *vanA* gene in *E. faecium* isolates. *Acinetobacter baumannii* (n=20) and *K. pneumoniae* (n=56) isolates were isolated from bronchoalveolar lavage, foreign objects, bone, urine, skin, blood, ear, nasal, and oral cavity. Sixty percent (60%) of *A. baumannii* were multidrug-resistant (MDR) while 98% were MDR *K. pneumoniae*. Of the students tested (62), at least one of the ESKAPE pathogens were isolated from their hands. *Escherichia coli* was the most isolated (76%, 47/62), followed by *E. faecium* (52%, 22/62), *P. aeruginosa* (48%, 30/62). *A. baumannii* (47%, 29/62), *K. pneumoniae* (27%, 17/62), and *S. aureus* (24%, 15/62). Resistance to at least one antibiotic was high among *E. coli* isolates (100%, 9/9), followed by *E. faecium* (67%, 4/6), *P. aeruginosa* (100%, 13/13), *A. baumannii* (57%, 4/7), *K. pneumoniae* (100%, 7/7), and *S. aureus* (67%, 2/3). Only *E. coli* (42%, 5/12), *E. faecium* (40%, 2/5), *P. aeruginosa* (100%, 13/13), and *S. aureus* (33%, 1/3) were multidrug resistant. Of the 147 students interviewed most were female (69%, 102/147) followed by male (29%, 43/147). Two (1%, 2/147) students did not indicate their sex. Less than half (41%, 60/147) of the respondents indicated they heard about IPC practices. However, they were aware that jewellery, stethoscopes, ward telephones, and leashes are possible sources of pathogens associated with HAIs.

Conclusion: Bacterial organisms associated with hospital-acquired and zoonotic diseases were reported from clinical cases, environmental surfaces, and items used in veterinary service. The hospital environment where there is human contact had the highest burden of organisms associated with HAIs. Moreover, the ESKAPE organisms were identified in the hands of the students working in the ICU. Organisms associated with HAIs in this study were often MDR which is likely to impact patient care and prognosis. In addition, if contaminated, students would likely pass on these pathogens to other persons and animals. The results of this study further support suggestions that human behaviour plays a crucial role in the transmission of HAIs in veterinary hospitals. The study also shows from the survey that students do not have a good understanding of IPC measures and their role in the prevention of HAIs and zoonotic diseases although taught during lectures.

Table of Content

Chapter 1 Introduction	1
1.1 Background	1
1.2 Justification.....	3
1.3 Aim and objectives.....	3
1.3.1 Objectives	4
1.4 Benefits.....	4
1.5 Structure of the thesis	4
1.6 References	7
Chapter 2 Literature Review	12
2.1 Background	12
2.1.1 Infectious diseases and zoonotic infections in veterinary medicine.....	12
2.1.2 Hospital acquired infections.....	12
2.1.3 Bacterial identification and characterization.....	13
2.1.4 Sources of organisms associated with hospital-acquired infections.....	15
2.1.5 Zoonotic aspect of organisms associated with hospital-acquired infections.....	16
2.1.6 Control of organisms associated with hospital acquired infections: Antimicrobials.....	17
2.1.7 Infection prevention and control in the control of organisms associated with hospital-acquired and zoonotic infections.....	22
2.1.8 One health approach.....	29
2.1.9 Multimodal approach.....	30
2.2 References	37
Chapter 3 Systematic Literature Review.....	50
3.1 Introduction.....	53
3.2 Materials and methods.....	54
3.2.1 Information source.....	54
3.2.2 Eligibility criteria	55
3.2.3 Study selection.....	56
3.3 Results	56
3.3.1 Study selection.....	56
3.3.2 Risk of bias.....	58
3.3.3 Sources of data	58
3.3.4 Bacterial isolates associated with hospital-acquired infections	59
3.3.5 Sources of organisms associated with hospital-acquired infections.....	62
3.3.6 Antimicrobial resistance patterns of bacteria associated with hospital acquired infections	64
3.3.7 Zoonosis	66

3.4	Discussion	66
3.4.1	<i>Sources of organisms associated with hospital acquired infection</i>	67
3.4.2	<i>Bacterial isolates associated with hospital-acquired infections</i>	68
3.5	Conclusion.....	72
3.6	References	73
Chapter 4	80
4.1	Introduction.....	82
4.2	Materials and methods.....	84
4.2.1	<i>Study area</i>	84
4.2.2	<i>Data source</i>	84
	<i>Bacterial isolates and antimicrobial susceptibility testing</i>	84
4.2.3	<i>Data management and analysis</i>	85
4.2.4	<i>Ethical consideration</i>	86
4.3	Results	86
4.3.1	<i>Acinetobacter baumannii</i>	86
4.3.2	<i>Klebsiella pneumonia</i>	89
4.4	Discussion	94
4.4.1	<i>Antibiotic resistance patterns of Acinetobacter baumannii</i>	94
4.4.2	<i>Antibiotic resistance patterns of Klebsiella pneumoniae</i>	96
4.5	Limitations	97
4.6	Conclusion.....	97
4.7	References	98
Chapter 5	105
5.1	Introduction.....	108
5.2	Materials and methods.....	109
5.2.1	<i>Study area</i>	109
5.2.2	<i>Study population</i>	109
5.2.3	<i>Sample collection</i>	109
5.2.4	<i>Screening</i>	110
5.2.5	<i>Identification of ESKAPE bacteria</i>	110
5.2.6	<i>Antimicrobial sensitivity</i>	112
5.3	Results	114
5.3.1	<i>Isolated bacteria</i>	114
5.3.2	<i>Antimicrobial susceptibility profile</i>	114
5.3.3	<i>Multidrug-resistant Organisms</i>	114
5.4	Discussion	117
5.4.1	<i>Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium</i>	117
5.4.2	<i>Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa</i> ...	117

5.4.3	<i>Antimicrobial resistance</i>	118
5.5	Conclusion.....	118
5.6	Declarations.....	118
5.6.1	<i>Ethics approval and consent to participate</i>	118
5.6.2	<i>Consent for publication</i>	119
5.6.3	<i>Availability of data and materials</i>	119
5.6.4	<i>Competing interests</i>	119
5.6.5	<i>Funding</i>	119
5.6.6	<i>Authors' Contribution</i>	119
5.6.7	<i>Acknowledgements</i>	119
5.7	References	120
Chapter 6	127
6.1	Introduction.....	129
6.2	Materials and methods.....	129
6.2.1	<i>Study area and study population</i>	129
6.2.2	<i>Ethics and confidentiality</i>	131
6.3	Results	131
6.3.1	<i>Knowledge of respondents on infection prevention control program</i>	131
6.4	Discussions	133
6.4.1	<i>Knowledge of respondents on infection prevention control program and hospital acquired infections</i>	133
6.5	Conclusion	134
6.6	References	135
Chapter 7	Summary of Discussions and Recommendations.....	138
7.1	Discussions and conclusions	138
7.1.1	<i>Limitations of the study</i>	140
7.2	Recommendations.....	140
Chapter 8	Annexures.....	142

Table of tables

Table 2. 1: Antibiotic resistance mechanism of gram-positive and gram-negative bacteria	19
Table 2. 2: This table illustrates the World Health Organization multimodal hand hygiene improvement strategy and tools for implementation. Source (71).....	35
Table 2. 3: Definitions of the hand hygiene five moments: Source (94).....	36
Table 3. 1: Search terms and databases utilized to search for articles included in this review about hospital-acquired and/or zoonotic infections in veterinary facilities between 2000 and 2020.	55
Table 3. 2: Inclusion and exclusion criteria of articles reporting on hospital-acquired and/or zoonotic infections in veterinary facilities between 2000 and 2020.....	56
Table 3. 3: Organism reported in hospital-acquired and/or zoonotic infections in veterinary facilities between 2000 and 2020.....	61
Table 3. 4: Sources of hospital acquired organisms based on the systematic reviewed papers published from 2000 to 2020.....	63
Table 3. 5: Phenotypic antimicrobial resistance profile of hospital-acquired infection organisms based on the systematically reviewed papers published from 2000 to 2020.....	65
Table 3. 6: The antimicrobial resistant genes isolated from bacteria associated with hospital-acquired infection bacteria, published data between 2000 and 2020.....	66
Table 4. 1: Antimicrobial resistance and multidrug resistance profile of <i>Acinetobacter baumannii</i> isolated from dog clinical samples tested at a veterinary academic hospital, South Africa.	88
Table 4. 2: Antibiotics resistance patterns of <i>Acinetobacter baumannii</i> isolated from dog clinical samples presented in a veterinary academic hospital in South Africa.	89
Table 4. 3: Antimicrobial resistance and multidrug resistance profile of <i>Klebsiella pneumoniae</i> isolated from dog clinical samples tested at a veterinary academic hospital, South Africa.	91
Table 4. 4: Antibiotics resistance patterns of <i>Klebsiella pneumoniae</i> isolated from dog clinical samples presented in a veterinary academic hospital in South Africa.	92
Table 5. 1: Nucleotide sequences used as primers in the PCR reaction to identify ESKAPE organisms.....	111

Table 5. 2: Panel of antibiotics tested against the ESKAPE organisms isolated from the hands of healthcare workers in the intensive care unit.....	113
Table 5. 3: The proportions of bacteria isolated from the hands of students before contact with patients in the intensive care unit at a veterinary academic hospital; South Africa	115
Table 5. 4: Antimicrobial resistance profile of ESKAPE organisms isolated from hand samples of students working at a veterinary academic hospital, in South Africa.....	116
Table 6. 1: The analysis and interpretation of the 5-point Likert scale based on the weighted average of students working in the ICU at a veterinary academic hospital.	131
Table 6. 2: Questions relating to the knowledge of students on infection prevention and control as well as hospital-acquired infections.	132
Table 6. 3: The perception of students on whether equipment could lead to possible transmission of hospital-acquired infection.....	133
Table 8. 1: List of documents in the annexure section with chapters associated.	142

Table of figures

Figure 1. 1: This figure summarizes the structure of the thesis and show the main approach used in each chapter.	6
Figure 3. 1: Summary of study selection and exclusion using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.	57
Figure 4. 1: Distribution of <i>Acinetobacter baumannii</i> in the various dog clinical samples tested by the Bacteriology Laboratory that services that Veterinary Academic Teaching Hospital, 2007 - 2013.....	87
Figure 4. 2: Distribution of <i>Klebsiella pneumoniae</i> in the various dog clinical samples tested by the bacteriology laboratory at the faculty of veterinary science between 2007 and 2013.....	90

Abbreviations

Abbreviation	Definition
aac(6')-Ib-cr	Acetylating aminoglycoside-(6)-N-acetyltransferase
ABHS	Alcohol-based hand sanitizers
AME	Aminoglycoside modifying enzymes
AMR	Antimicrobial resistance
APEC	Avian pathogenic <i>Escherichia coli</i>
Bp	Base pairs
CACS	Companion animal clinical studies
CAI	Community-acquired infection
CA-UTI	Catheter-associated urinary tract infections
CC	Clonal complexes
CLABI	Central line-associated bloodstream infections
CLSI	Clinical and laboratory standards institute
DNA	Deoxyribose nucleic Acid
dNTPs	Deoxynucleotide triphosphates
EEA	European economic area
AME	Enzymatic modification enzymes
erm	Erythromycin ribosomal methylase
ESBL	Extended-spectrum beta-lactamase
ESKAPE	<i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , <i>Klebsiella pneumoniae</i> , <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , and <i>Enterobacteriaceae</i> species.
ET	Endotracheal tubes
EU	European union
GIT	Gastrointestinal tract
GyrA	Gyrase A
HAIs	Hospital-acquired infections
HCWs	Healthcare workers
ICU	Intensive care unit
IDT	Integrated deoxyribose nucleic acid technologies
IPC	Infection prevention and control
KAP	Knowledge attitude and practice
LB agar	Luria Bertani agar
MALDI-TOF-MS	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
mcr-genes	Mobilized colistin resistance genes

MDR	Multidrug
MHA	Mueller Hinton agar
MIC	Minimum inhibitory concentration
MRSA	Methicillin-Resistant <i>Staphylococcus aureus</i>
MRSP	Methicillin-resistant <i>Staphylococci pseudintermedius</i>
PBP2a	Penicillin-binding protein
PBW	Buffered phosphate water
PCR	Polymerase chain reaction
PFGE	Pulse field gel electrophoresis
PPE	Personal protective equipment
PRISMA	Preferred reporting items for systematic reviews
Qnr	Quinolone resistance gene
RAPD-PCR	Rapid polymerase chain reaction
RFLP	Restriction fragment length polymorphism
SAS	Statistical analysis system
SCC _{mec}	<i>Staphylococcal</i> cassette chromosome mec
SDGs	Sustainable development goals
SHV-1	sulfhydryl reagent variable-1
Spp.	Species
SPSS	Statistical package for social sciences
16S- RMTases	16S rRNA methyltransferases
STROBE-Vet	Strengthening the reporting of observational studies in epidemiology veterinary
TAE	Tris-acetate-ethylenediamine tetra acetic acid
Taq polymerase	<i>Thermus aquaticus</i> polymerase
UTI	Urinary tract infection
UV	Ultraviolet
VAP	Ventilator-associated pneumonia
VPH	Veterinary public health
VRE	Vancomycin-resistant enterococci
WGS	Whole genome sequencing
WHO	World health organization
WOAH	World organization for animal health
β -lactamases	Beta-lactamase

1 **Chapter 1 Introduction**

2 **1.1 Background**

3 Hospital-acquired infections (HAIs) are a growing concern in veterinary and human medicine
4 (1–5). They are defined as infections that are neither present nor incubating at the time of
5 hospitalization (5). *Staphylococcus aureus*, *S. pseudintermedius*, *Pseudomonas* species, *Klebsiella*
6 spp., *Enterococcus* spp., *Salmonella* spp., and *Escherichia coli* are among the pathogens commonly
7 associated with HAIs in veterinary hospitals (1,6,7). These bacteria are of increasing concern in
8 veterinary medicine as they acquire resistance determinants. In both human and animal studies,
9 these bacteria have been reported to be multidrug resistant (MDR), which impacts patient prognosis
10 (7,8). Examples of such bacteria included Vancomycin-Resistant Enterococci (VRE), multidrug *E.*
11 *coli*, and Methicillin-Resistant *Staphylococcus aureus* (MRSA) (5,9,10).

12 Most bacteria responsible for HAIs are commensal to the intestinal tracts of both humans
13 and animals. Those reported in animals have also been shown to be zoonotic and zoonothonotic
14 (10). This is not surprising as the veterinary setting is an interphase for the transmission of pathogens
15 between humans, animals, and the environment. Therefore, veterinary personnel, students, and
16 patient owners are at an increased risk of infection (7). In developing countries, this is likely to put a
17 financial strain on an already compromised human health system (7). Moreover, there are reports of
18 human cases associated with HAI pathogens known to cause diseases in animals (11). For example,
19 Weese et al (12) reported an outbreak of MRSA skin infection among healthcare workers (HCWs)
20 after contact with hospitalized horses. Similarly, Johnson et al (13) reported similarities between
21 Avian pathogenic *Escherichia coli* (APEC) isolates from humans and animals.

22 The transmission of HAIs in hospitals can either be directly through contaminated hands of
23 HCWs or animal-to-animal contact (14,15) or indirectly through contact with contaminated hospital
24 environments, equipment, and fomites (16,17). Healthcare workers are at an increased risk of
25 infection through animal bites, scratches or indirectly through contaminated air in the hospital (18).
26 Furthermore, contaminated veterinary personnel can also carry pathogens from facilities to their
27 homes resulting in community-associated infections (17–19).

28 Clinical symptoms in both humans and animals differ depending on the bacteria involved. In
29 animals, MRSA is associated with wound infections, septic arthritis, and pneumonia (20,21). While
30 *Enterococcus* species are commonly isolated among urinary tract infection (UTI) cases (22). Among
31 the Gram-negatives, *E. coli*, *P. aeruginosa* and *A. baumannii* have been implicated in clinical
32 conditions such as pyoderma, otitis externa, UTIs (22), pyothorax, upper airway obstruction,
33 bloodstream infections, and wound infections (23). Similarly, MDR *E. coli*, *Enterobacteriaceae* and
34 MRSA have been associated with UTIs, intra-abdominal infections (24), and skin infections in
35 humans(12).

36 Antibiotic therapy is often required in most HAI cases and penicillins, aminoglycosides, third
37 and fourth-generation cephalosporins, tetracycline, sulfonamides, enrofloxacin, and marbofloxacin
38 are among the most commonly used antibiotics in both humans and animals (25,26). However, there
39 is a high prevalence of antimicrobial resistance among HAI-associated bacteria, which is a major
40 concern for treatment outcomes. For example, the use of vancomycin (27), and carbapenems in the
41 treatment of MDR pathogens (24). These MDR pathogens have been reported in several outbreaks
42 in veterinary hospitals, especially among large animals (12,28–31)

43 Infection prevention and control (IPC) remains the cornerstone of the prevention of HAIs in
44 human medicine and has slowly been adopted in veterinary medicine (1,5,30,32). These practices
45 are referred to as standard and transmission-based precautions and they are effective in reducing
46 the burden of pathogenic organisms and reliance on antimicrobials (5,33). They have been used in
47 small animal veterinary practices and include hand hygiene, environmental control, sharps
48 management, vaccination for zoonotic infections, patient management, surveillance, and personal
49 protective equipment (1,34,35). If implemented correctly, the risk of infection to patients, animal
50 owners, and veterinary personnel is reduced (36).

51 The World Health Organization (WHO) recommends the multimodal approach as the first
52 intervention strategy to be implemented for a sustained improvement of IPC (33,37). Multimodal
53 approaches have shown to be effective compared to a single approach in fields such as developing
54 technology (38), adaptability to change in the education sector (39) and adaptability to treatments in
55 health (40). In humans, these approaches have led to an improvement in hand hygiene compliance
56 and reductions in organisms associated with HAIs (41,42). For example, Salama et al (41) in Kuwait

57 observed a reduction in organisms associated with HAIs and a decrease in incidences of multidrug-
58 resistant bacterial infections due to an improvement in hand hygiene compliance from 43% to 61.4%
59 after an educational campaign. Given this, its adoption in veterinary medicine is likely to yield similar
60 results (43).

61 Since transmission of most organisms associated with HAIs occurs through the hands of
62 HCWs, effective hand hygiene remains the most effective means to prevent and control infections
63 in healthcare facilities (14,15,41,44,45). However, low levels of compliance have been reported in
64 both human and veterinary hospitals (14,41,46–48). This has been attributed to the lack of hand
65 washing facilities or alcohol-based hand sanitiser dispensers (14,41,46,49). In addition, a lack of
66 knowledge of hand hygiene compliance, attitude towards hand hygiene practices, and awareness of
67 the importance of hand hygiene compliance in reducing transmission of both HAIs and zoonotic
68 infections are among the factors contributing to low hand hygiene compliance (50).

69 **1.2 Justification**

70 Although multimodal approaches have been shown to be effective in human medicine, their
71 use in veterinary medicine is limited (47). A study done in 2019 at the Onderstepoort Academic
72 Hospital showed deficiencies in the implementation of IPC measures including hand hygiene
73 compliance among personnel. In their study, Sebola and colleagues (51) concluded that this low
74 level of compliance is likely to increase the risk of transmission of organisms associated with HAIs
75 in the Intensive Care Unit (ICU). They recommended that a multimodal approach be implemented to
76 improve hand hygiene compliance and reduce the likelihood of transmission of organisms associated
77 with HAIs and zoonosis.

78 **1.3 Aim and objectives**

79 This study aims to assess the pre-intervention IPC principles required to reduce the
80 transmission of bacteria associated with HAIs and zoonotic diseases at a veterinary hospital. The
81 pre-intervention assessments will include the level of knowledge of veterinary students on HAIs, the
82 identification of bacteria associated with HAI and zoonotic diseases from the environment, and the
83 hands of HCWs. The information generated from this study will contribute to the knowledge of the
84 epidemiology of bacteria associated with HAI and zoonosis in veterinary medicine.

85 1.3.1 Objectives

86 This study is divided into the following objectives:

- 87 1. To describe bacteria associated with HAIs and zoonotic infections and their antimicrobial-
88 resistant patterns in veterinary hospitals using a systematic literature review.
- 89 2. To describe the antimicrobial resistance patterns of *K. pneumoniae* and *A. baumannii* from
90 clinical samples of dogs presented to a veterinary academic hospital in South Africa between
91 2007 and 2013.
- 92 3. Investigate the occurrence of bacteria associated with HAIs in the hands of the students
93 working in the ICU.
- 94 4. Describing the antimicrobial resistance patterns of the isolated bacteria from students' hands
95 in the ICU.
- 96 5. Investigate the Knowledge of students on the transmission of organisms associated with
97 HAIs.

98 **1.4 Benefits**


99 The results of this study will have the following benefits:

- 100 1. The results from this study will form a baseline for the surveillance of the organisms
101 associated with HAIs in the veterinary.
- 102 2. The results of this study will also be used to guide the veterinary curriculum on infection
103 prevention and control practices.
- 104 3. This study will contribute to the national antimicrobial resistance strategic framework, drafted
105 and implemented by the National Department of Health.
- 106 4. The study will also contribute to the realization of the Sustainable Development Goals (SDGs)
107 on promoting good health and well-being.

108 **1.5 Structure of the thesis**

109 This thesis is composed of seven chapters. The first chapter presents the general
110 background, aim, and objectives of the study. The second chapter is a literature review of the study,
111 including the different multimodal strategies. Chapters three and four are published articles. Chapter

112 three consists of the systematic literature review, while Chapter four focuses on the antimicrobial
113 resistance patterns of *Acinetobacter baumannii* and *Klebsiella pneumoniae* isolated from clinical
114 isolates of dogs presented at the veterinary academic hospital. Chapter five describes the
115 occurrence of ESKAPE (*Enterococcus faecium*, *S. aureus*, *K. pneumoniae*, *A. baumannii*, *P.*
116 *aeruginosa*, and *Enterobacter* species) organisms from hands of students working in the ICU.
117 Chapter six describes the knowledge survey of veterinary students on the transmission of organisms
118 associated with HAIs and zoonotic diseases. Finally, chapter seven is a summary of the entire thesis,
119 highlighting the important results and recommendations for future studies (**Figure 1.1**).



120

121 **Figure 1. 1:** This figure summarizes the structure of the thesis and show the main approach used
122 in each chapter.

123 **1.6 References**

- 124 1. Stull JW, Weese JS. Hospital-Associated Infections in small animal practice. *Veterinary Clinics of*
125 *North America - Small Animal Practice*. 2015;45(2):217–33.
- 126 2. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *New England*
127 *Journal of Medicine*. 2010 May 13;362(19):1804-13.
- 128 3. Guardabassi L. Veterinary hospital-acquired infections: the challenge of MRSA and other
129 multidrug-resistant bacterial infections in veterinary medicine. *Veterinary Journal (London,*
130 *England: 1997)*. 2012 Jun 29;193(2):307-8.
- 131 4. World Health Organization. Report on the Burden of Endemic Health Care-Associated Infection
132 Worldwide: Clean Care is Safer Care [Internet]. 2011 [cited 2021 Mar 9]. Available from:
133 www.who.int.
- 134 5. Kisani AI, Awasum A, Udegbonam S, Nnaji T, Muhammed B, Melekwa G, Ankwedel Y.
135 Management of Nosocomial Diseases in Small Animal Practice: A Review. *Vom Journal of*
136 *Veterinary Science*. 2016;11:94-100.
- 137 6. Wieler LH, Ewers C, Guenther S, Walther B, Lübke-Becker A. Methicillin-resistant *staphylococci*
138 (MRS) and extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae in
139 companion animals: Nosocomial infections as one reason for the rising prevalence of these
140 potential zoonotic pathogens in clinical sample. *International Journal of Medical Microbiology*.
141 2011 Dec;301(8):635–41.
- 142 7. Walther B, Tedin K, Lübke-Becker A. Multidrug-resistant opportunistic pathogens challenging
143 veterinary infection control. *Veterinary microbiology*. 2017 Feb 1;200:71-8.
- 144 8. Taylor LH, Latham SM, Woolhouse MEJ. Risk factors for human disease emergence.
145 *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2001 Jul
146 29;356(1411):983–9.
- 147 9. Machado IC, Nunes T, Maximino M, Malato J, Tavares L, Almeida V, Sepúlveda N, Gil S.
148 Epidemiologic factors supporting triage of infected dog patients admitted to a veterinary hospital
149 biological isolation and containment unit. *Veterinary Sciences*. 2023 Mar 1;10(3):186.

- 150 10. Day MJ, Breitschwerdt E, Cleaveland S, Karkare U, Khanna C, Kirpensteijn J, et al. Surveillance
151 of zoonotic infectious disease transmitted by small companion animals. *Emerging Infectious*
152 *Diseases*. 2012 Dec;18(12): e1.
- 153 11. Moses IB, Santos FF, Gales AC. Human Colonization and Infection by *Staphylococcus*
154 *pseudintermedius*: An Emerging and Underestimated Zoonotic Pathogen. *Microorganisms*. 2023
155 Feb 25;11(3):581.
- 156 12. Weese JS, Caldwell F, Willey BM, Kreiswirth BN, McGeer A, Rousseau J, et al. An outbreak of
157 methicillin-resistant *Staphylococcus aureus* skin infections resulting from horse to human
158 transmission in a veterinary hospital. *Veterinary Microbiology*. 2006 Apr 16;114(1–2):160–4.
- 159 13. Johnson TJ, Miller EA, Flores-Figueroa C, Munoz-Aguayo J, Cardona C, Fransen K, Lighty M,
160 Gonder E, Nezworski J, Haag A, Behl M. Refining the definition of the avian pathogenic
161 *Escherichia coli* (APEC) pathotype through inclusion of high-risk clonal groups. *Poultry science*.
162 2022 Oct 1;101(10):102009
- 163 14. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. *Journal*
164 *of hospital infection*. 2009 Dec 1;73(4):305-15
- 165 15. Nakamura RK, Tompkins E, Braasch EL, Martinez Jr JG, Bianco D. Hand hygiene practices of
166 veterinary support staff in small animal private practice. *Journal of Small Animal Practice*. 2012
167 Mar;53(3):155-60.
- 168 16. Murphy CP, Reid-Smith RJ, Boerlin P, Weese JS, Prescott JF, Janecko N, Hassard L, McEwen
169 SA. *Escherichia coli* and selected veterinary and zoonotic pathogens isolated from environmental
170 sites in companion animal veterinary hospitals in southern Ontario. *The Canadian veterinary*
171 *journal*. 2010 Sep;51(9):963.
- 172 17. Singh A, Walker M, Rousseau J, Monteith GJ, Weese JS. Methicillin-resistant *staphylococcal*
173 contamination of clothing worn by personnel in a veterinary teaching hospital. *Veterinary Surgery*.
174 2013 Aug 1;42(6):643–8.
- 175 18. Rahman MT, Sobur MA, Islam MS, Levy S, Hossain MJ, El Zowalaty ME, Rahman AT, Ashour
176 HM. Zoonotic diseases: etiology, impact, and control. *Microorganisms*. 2020 Sep 12;8(9):1405.

- 177 19. Anderson MEC, Wimmers M, Weese JS. Infection Prevention and Control Best Practices for
178 Small Animal Veterinary Clinics [Internet]. 2020 [cited 2024 Apr 14]. Available from:
179 <https://oahn.ca/resources/ipc-best-practices/>.
- 180 20. Van Duijkeren E, Box AT, Heck ME, Wannet WJ, Fluit AC. Methicillin-resistant *Staphylococci*
181 isolated from animals. *Veterinary microbiology*. 2004 Oct 5;103(1-2):91-7.
- 182 21. Weese JS, Rousseau J, Willey BM, Archambault M, McGeer A, Low DE. Methicillin-resistant
183 *Staphylococcus aureus* in horses at a veterinary teaching hospital: frequency, characterization,
184 and association with clinical disease. *Journal of Veterinary Internal Medicine*. 2006
185 Jan;20(1):182-6.
- 186 22. Comerlato CB, Resende MC, Caierão J, d'Azevedo PA. Presence of virulence factors in
187 *Enterococcus faecalis* and *Enterococcus faecium* susceptible and resistant to vancomycin.
188 *Memórias do Instituto Oswaldo Cruz*. 2013;108:590-5.
- 189 23. Ng S, Abdul Aziz S, Bejo SK, Dhaliwal GK. Occurrence of multidrugresistant *Acinetobacter*
190 *baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *Jurnal*
191 *Veterinar Malaysia*. 2016;28(2):12-6.
- 192 24. Smith A, Wayne AS, Fellman CL, Rosenbaum MH. Usage patterns of carbapenem antimicrobials
193 in dogs and cats at a veterinary tertiary care hospital. *Journal of veterinary internal medicine*.
194 2019 Jul;33(4):1677-85.
- 195 25. Pirš T, Avberšek J, Zdovc I, Krt B, Andlovic A, Lejko-Zupanc T, Rupnik M, Ocepek M.
196 Antimicrobial susceptibility of animal and human isolates of *Clostridium difficile* by broth
197 microdilution. *Journal of medical microbiology*. 2013 Sep;62(9):1478-85.
- 198 26. Xia J, Gao J, Tang W. Nosocomial infection and its molecular mechanisms of antibiotic
199 resistance. *Bioscience trends*. 2016;10(1):14-21.
- 200 27. Stella AE, Lima TF, Moreira CN, De Paula E. Characterization of *Staphylococcus aureus* Strains
201 Isolated from Veterinary Hospital. *International Journal of Microbiology*. 2020 Aug 1;2020.
- 202 28. Soza-Ossandón P, Rivera D, Tardone R, Riquelme-Neira R, García P, Hamilton-West C, Adell
203 AD, González-Rocha G, Moreno-Switt AI. Widespread environmental presence of multidrug-
204 resistant *Salmonella* in an equine veterinary hospital that received local and international horses.
205 *Frontiers in Veterinary Science*. 2020:346.

- 206 29. Ward MP, Brady TH, Couëtill LL, Liljebjelke K, Maurer JJ, Wu CC. Investigation and control of an
207 outbreak of salmonellosis caused by multidrug-resistant *Salmonella* typhimurium in a population
208 of hospitalized horses. *Veterinary microbiology*. 2005 May 20;107(3-4):233-40.
- 209 30. Stull JW, Brophy J, Weese JS. Reducing the risk of pet-associated zoonotic infections. *CMAJ*.
210 2015;187(10):736–43.
- 211 31. Goeman VR, Tinkler SH, Hammac GK, Ruple A. Evaluation of environmental sampling methods
212 for detection of *Salmonella enterica* in a large animal veterinary hospital. *The Canadian Veterinary*
213 *Journal*. 2018 Apr;59(4):408.
- 214 32. Stull JW, Weese JS. Infection control in veterinary small animal practice. *Veterinary Clinics: Small*
215 *Animal Practice*. 2015 Mar 1;45(2):xi-i.
- 216 33. World Health Organization. Improving infection prevention and control at the health facility: Interim
217 practical manual supporting national implementation of the WHO Guidelines on Core
218 Components of Infection Prevention and Control Programmes. 2017;1–77.
- 219 34. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection.
220 *Journal of hospital Infection*. 2009 Dec 1;73(4):378-85.
- 221 35. Willemsen A, Cobbold R, Gibson J, Wilks K, Lawler S, Reid S. Infection control practices
222 employed within small animal veterinary practices—A systematic review. Vol. 66, *Zoonoses and*
223 *Public Health*. 2019 Aug;66(5):439–57.
- 224 36. Traverse M, Aceto H. Environmental cleaning and disinfection. *Veterinary Clinics: small animal*
225 *practice*. 2015 Mar 1;45(2):299-330.
- 226 37. World Health Organization. A guide to the implementation of the WHO multimodal hand hygiene
227 improvement strategy. World Health Association Press. Geneva; 2009.
- 228 38. Sebe N, Cohen I, Gevers T, Huang TS. Multimodal approaches for emotion recognition: a survey.
229 *In* *Internet Imaging VI* 2005 Jan 17 (Vol. 5670, pp. 56-67). SPIE.
- 230 39. Barton G, Ryan M. Multimodal approaches to reflective teaching and assessment in higher
231 education. *Higher Education Research & Development*. 2014 May 4;33(3):409-24.
- 232 40. Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of
233 hepatocellular carcinoma. *Nature Reviews Gastroenterology & Hepatology*. 2009 Mar;6(3):159-
234 69.

- 235 41. Salama MF, Jamal WY, Al Mousa H, Al-AbdulGhani KA, Rotimi VO. The effect of hand hygiene
236 compliance on hospital-acquired infections in an ICU setting in a Kuwaiti teaching hospital.
237 *Journal of infection and public health*. 2013 Feb 1;6(1):27-34.
- 238 42. Monistrol O, Calbo E, Riera M, Nicolás C, Font R, Freixas N, Garau J. Impact of a hand hygiene
239 educational programme on hospital-acquired infections in medical wards. *Clinical microbiology
240 and infection*. 2012 Dec 1;18(12):1212-8.
- 241 43. Anderson MEC, Sargeant JM, Weese JS. Video observation of hand hygiene practices during
242 routine companion animal appointments and the effect of a poster intervention on hand hygiene
243 compliance. *BMC Veterinary Research*. 2014 May 7;10(1):106
- 244 44. O'Boyle CA, Henly SJ, Larson E. Understanding adherence to hand hygiene recommendations:
245 the theory of planned behavior. *American journal of infection control*. 2001 Dec 1;29(6):352-60.
- 246 45. Boyce J, Chartier Y, Chraiti M, Cookson B, Damani N, Dharan S, et al. Guidelines on hand
247 hygiene in health care. *Journal of advanced nursing*. 2006;53(5):613–4.
- 248 46. Weese JS. Barrier precautions, isolation protocols, and personal hygiene in veterinary hospitals.
249 *Veterinary Clinics of North America - Equine Practice*. 2004 Dec;20(3):543–59.
- 250 47. Shea A, Shaw S. Evaluation of an educational campaign to increase hand hygiene at a small
251 animal veterinary teaching hospital. *Journal of the American Veterinary Medical Association*.
252 2012 Jan 1;240(1):61-4.
- 253 48. Anderson ME. Contact precautions and hand hygiene in veterinary clinics. *Veterinary Clinics:
254 Small Animal Practice*. 2015 Mar 1;45(2):343-60.
- 255 49. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, Boyce JM. Evidence-
256 based model for hand transmission during patient care and the role of improved practices. *The
257 Lancet infectious diseases*. 2006 Oct 1;6(10):641-52.
- 258 50. Kelčíkova S, Skodova Z, Straka S. Effectiveness of hand hygiene education in a basic nursing
259 school curricula. *Public Health Nursing*. 2012 Mar;29(2):152-9.
- 260 51. Sebola DC, Boucher C, Maslo C, Qekwana DN. Hand hygiene compliance in the intensive care
261 unit of the Onderstepoort Veterinary Academic Hospital. [Preprint] 2019 [Accessed 2024 April
262 10]. Available from: <https://doi.org/10.21203/rs.2.17130/v1>

263 **Chapter 2 Literature Review**

264 **2.1 Background**

265 *2.1.1 Infectious diseases and zoonotic infections in veterinary medicine*

266 Infectious diseases in animals have been associated with significant financial losses,
267 high morbidity, suffering, and increased mortality (1,2). Agents that are responsible for
268 infectious disease conditions can be classified into bacterial, viral, fungal, and parasitic (3).
269 *Bovine tuberculosis*, brucellosis, rift valley fever, and foot-and-mouth disease are among the
270 most prevalent infectious diseases affecting livestock, and wild animals (3,4). Whereas in
271 small animal settings rabies, parvovirus infection, babesia, leptospirosis, distemper, and
272 diseases associated with multidrug-resistant bacteria are the most common (5). Furthermore,
273 there is evidence that 60% of emerging infectious diseases in humans may have originated
274 from animals (6,7).

275 Infectious disease transmission can be direct or indirect, airborne, or vector-borne
276 transmission (5). In veterinary hospitals, transmission can occur as a result of patient-to-
277 patient contact, contact with contaminated environmental surfaces, contaminated fomites, and
278 contaminated hands of healthcare workers and visitors including owners (8–11).

279 *2.1.2 Hospital acquired infections.*

280 Hospital-acquired infections (HAIs) are those infections that patients get after
281 admission into the hospital and infectious agents or toxins that were neither present nor
282 incubating at the time of hospitalization (8,9). Animals are admitted to the hospital for infectious
283 and non-infectious conditions including surgical cases. Most pathogens associated with
284 infectious diseases are involved in either community-acquired infections (CAIs) or HAIs.
285 However, there is evidence to suggest that bacteria associated with HAIs exhibit a high
286 prevalence of resistance to critical, critically important, and important antimicrobials (10–15).

287 Management of HAIs particularly in the intensive care unit (ICU) remains a significant
288 challenge in both human and veterinary hospitals (8,16–18). However, 30% of these HAIs are

289 preventable in human and veterinary care facilities. Nonetheless, HAIs are responsible for
290 increased mortality rates, longer hospital stays, increased hospital costs, reduced mobility,
291 and increased antimicrobial drug prescription and costs of treatment in both humans and
292 animals (8,19).

293 Most HAIs are related to invasive procedures, such as urinary catheters and
294 intravenous catheters, the patient's immune system, and the lack or insufficient
295 implementation of IPC measures (20–22). Hence organisms associated with HAIs have been
296 reported in bloodstream infections, urinary tract infections, and ventilator-associated
297 pneumonia in human and animal studies (8,16,23,24).

298 Most organisms associated with HAIs are bacterial (22,25) and include
299 *Staphylococcus species*, *Escherichia coli*, *Salmonella species*, *Enterococcus species*,
300 *Acinetobacter baumannii*, and *Clostridium difficile* (26,27). Among these organisms is a group
301 of bacteria termed ESKAPE, which are responsible for outbreaks in humans and veterinary
302 clinical settings globally (28,29). These bacteria include *Enterococcus faecium*, *S. aureus*, *K.*
303 *pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *Enterobacter species* (ESKAPE) (14,16,28).
304 This ESKAPE group deserves special attention because they are known to escape the biocidal
305 action of antimicrobials and are associated with increased mortality, morbidity, and healthcare
306 costs in both human and animal medicine (14,29,30). In addition, the World Health
307 Organization (WHO) has listed this group as among the pathogens for which urgent
308 antimicrobial therapy is required due to their tendency to exhibit a high prevalence of multidrug
309 resistance (MDR) (28,29). As such, it is crucial that veterinary medicine also increase the
310 understanding of the virulence, resistance, transmission, and pathogenicity of these bacteria.

311 2.1.3 Bacterial identification and characterization

312 These bacteria associated with HAIs can be laboratory identified traditionally by culture
313 and biochemical tests (31). Although the traditional method is still widely used, including,
314 morphology, physiology, chemistry, and biochemical characterization, it is timely, labour

315 intensive, and not useful enough to identify unambiguously the microorganism to its species
316 level or strain level (31).

317 The recent advancements in technology have introduced high-tech methods that allow
318 molecular-based techniques, such as the 16S rRNA polymerase chain reaction (PCR)
319 sequencing, Real-Time PCR, Random Amplification of Polymorphic DNA-RAPD-PCR,
320 Restriction Fragment Polymorphism-RFLP, Pulsed-Field Gel Electrophoresis- (PFGE),
321 Whole-Genome Sequencing (WGS), and matrix-assisted laser desorption/ionization time-of-
322 flight mass spectrometry (MALDI-TOF-MS) (31,32).

323 2.1.3.1 *Phenotypic methods*

324 Identification of bacteria using phenotypic methods is done based on their cellular
325 morphology, gram staining, or specialized staining, by assessing growth requirements such
326 as oxygen, pH, temperature, observing colony morphology, and conducting biochemical
327 reactions using enterotubes, selective, and/or differential media types (32,33).

328 2.1.3.2 *Genotypic methods*

329 Molecular techniques have become popular in detecting and identifying bacterial
330 organisms. In surveillance studies, these methods provide reliable epidemiological data that
331 can be used to help trace infections including foodborne disease outbreaks. Most molecular
332 methods are based on DNA analysis, either through amplification or sequencing. Most
333 molecular approaches are DNA-based, utilizing either amplification or sequencing (31). These
334 methods vary from relatively simple DNA amplification-based techniques, such as PCR, real-
335 time PCR, and RAPD-PCR, to more complex ones that use restriction fragment analysis,
336 targeted gene and whole-genome sequencing, and mass spectrometry (31). In addition,
337 approaches based on unique protein signatures, such as MALDI-TOF-MS and similar
338 variations, have also been explored (31,33). In this study, PCR was used for the
339 characterization of ESKAPE pathogens.

340 2.1.3.3 *Polymerase Chain Reaction*

341 Polymerase Chain Reaction is an automated laboratory technique that enables
342 researchers to produce millions of copies of a specific DNA sequence in about two hours and
343 analyzed by gel electrophoresis. Short synthetic DNA fragments called primers are important
344 in this technique because they are used to select a segment of the genome to be amplified,
345 and then multiple rounds of DNA synthesis to amplify that segment. Unlike traditional methods
346 that require bacteria to amplify DNA, PCR is quicker, more efficient, and doesn't require a
347 living organism. It is particularly useful in quickly identifying the causative agent(s) of
348 infections, which is crucial in determining effective treatment intervention (33–35).

349 Polymerase Chain Reaction is a standard method for identifying bacterial DNA through
350 amplification of the 16S rRNA gene, used in both laboratory and clinical settings. The 16S
351 rRNA gene is highly specific to each bacterial species, making it an ideal target for
352 identification. Although it is a reliable and straightforward method in research laboratories,
353 various factors may influence the results of PCR when applied to clinical settings (31).

354 2.1.3.4 *Antimicrobial susceptibility testing*

355 Antimicrobial susceptibility testing is mainly used to guide clinical therapy and the
356 results are interpreted using clinical breakpoints. It can also be done to establish patterns of
357 susceptibility in selected organisms using epidemiological breakpoints as a cut-off. In clinical
358 cases of organisms associated with HAIs, clinical breakpoints help identify alternative
359 antibiotics, especially in MDR organisms which are significantly associated with high morbidity
360 and mortality (36).

361 2.1.4 *Sources of organisms associated with hospital-acquired infections*

362 Bacteria associated with HAIs have been identified from several sources including
363 colonized patients (37–39), HCWs (40), commonly used equipment (40–42), HCWs' protective
364 wear (43), and contaminated environments (44,45) within the veterinary hospitals. Since some
365 of the infected patients do not show clinical signs, contaminated environments and

366 asymptomatic carriers remain the most important sources of bacteria associated with HAIs in
367 veterinary settings (45). As animals tend to explore with their noses and mouths, they may
368 come into contact with contaminated environmental surfaces (45,46). Moreover,
369 environmental surfaces have been found to harbour *E. coli*, Methicillin- Resistant
370 *Staphylococcus aureus* (MRSA), Methicillin- Resistant *Staphylococcus pseudintermedius*
371 (MRSP), and *C. difficile* known to cause HAIs and zoonotic diseases (40,45,47–50).
372 Contaminated personnel and fomites have also been linked to the transmission of HAIs in
373 equine clinics (46,51).

374 *2.1.5 Zoonotic aspect of organisms associated with hospital-acquired infections*

375 The close interaction between humans, animals, and the environment increases the
376 risk of transmission of infectious agents in hospital settings (52). Of great concern is that
377 healthcare workers (HCWs) can carry or be infected with some of the organisms associated
378 with HAIs. Furthermore, handling of infected patients, animal bites, and injuries at work may
379 further increase the risk of exposure to HCWs' and animal owners to zoonotic diseases (53).
380 Furthermore, HCWs may also carry organisms associated with HAIs to their households,
381 resulting in infection at the household level and, subsequently, spreading it into the community
382 (26,54–56). Moreover, Singh et al (43) have isolated MRSA and MRSP from the clothing worn
383 by HCWs during patient care in a veterinary Hospital in Canada. Similarly, pet owners can
384 also be infected with organisms associated with HAIs when visiting a veterinary hospital (57).

385 **Summary**

386 Given that humans, the environment, and animals, in veterinary settings, are reservoirs
387 for agents associated with infectious diseases, it is crucial to prioritize a comprehensive
388 intervention package, that includes but is not limited to prudent anti-ineffective use of drugs,
389 vaccination, antimicrobial stewardship, infection prevention and control practices and
390 identification and isolation of high-risk patients. (3). Implementing these measures helps
391 reduce the spread of infections, as emphasized by Andeson et al (52), Machado et al (4) and
392 Sebola et.al (58).

393 2.1.6 Control of organisms associated with hospital acquired infections:

394 Antimicrobials

395 Antimicrobials are a treatment of choice in HAI cases (25). Depending on the organism
396 involved, the most used antibiotics belong to the following groups: penicillins,
397 aminoglycosides, third and fourth-generation cephalosporins, tetracycline, fluoroquinolones
398 and sulfonamides (59). However, persistent infections from HAI-associated pathogens have
399 resulted in the misuse and overuse of antibiotics (59).

400 2.1.6.1 Antimicrobial resistance among hospital-acquired infections in veterinary Intensive care unit

401 The high proportion of antimicrobials used in the ICU makes it a suitable place for
402 the presence of multidrug-resistant organisms (60). The intensive care unit in humans and
403 veterinary hospitals is regarded as a commonplace for the occurrence of antimicrobial
404 resistance (AMR) pathogens (17,60). This is because most patients have high morbidity
405 therefore requiring antimicrobial therapy (60). The ICU is also an interface for patients and
406 environmental surfaces which is known to harbour MDR pathogens. Among the MDR
407 pathogens that have been reported in veterinary medicine especially the ICU are MRSA and
408 MRSP, Extended Spectrum β -lactamase- *E. coli*, *Salmonella*, *Enterococcus* spp., *C. difficile*,
409 *A. baumannii*, and *E. coli* (26,27) (**Table 2.1**).

410 Bacteria responsible for HAIs may contain resistance genes and virulence factors that
411 enable them to be resistant to antibiotics and survive on different hospital surfaces for longer
412 periods, leading to limited treatment options and worsening the patient's prognosis (8–10,26).
413 These features can either be inherent or acquired from other-resistant bacteria or as a result
414 of selection pressure. For example, an inherent resistance has been reported in β -lactam
415 resistance associated with the presence of the penicillin-binding protein (PBP2a) encoded by
416 the *mecA* or *mecC* gene (26). Whereas, acquired resistance has been reported in *E. coli*
417 associated with plasmids encoding ESBL genes (61,62).

418 2.1.6.2 *Mechanisms of resistance*

419 Antibiotic resistance is mediated by several mechanisms including modification of the
420 target sites, enzymatic inactivation, active efflux, and decreased influx of drugs (63,64).
421 Although organisms may possess more than one mechanism of resistance, there seem to be
422 resistance mechanisms that are agent-specific, for example, resistance to macrolides occurs
423 due to a modification in the ribosomal target. While a mutation in penicillin-binding proteins
424 leads to resistance to β -lactam antibiotics. Similarly, aminoglycoside resistance is mainly
425 enzymatic inactivation (64). In addition, pathogens may acquire resistant genes from other
426 organisms through plasmid-mediated genetic transfer (25).

427 Although gram-negative and gram-positive bacteria use similar mechanisms of
428 resistance, they differ based on their cell structure and physiology. For example, gram-
429 negative bacteria compared to gram-positive have an outer membrane barrier that can alter
430 porins making them more resistant to many antibiotics. The ability of the bacterium to possess
431 several mechanisms of resistance as indicated above makes it resistant to multiple
432 antimicrobials therefore multidrug resistant (65).

433 **Table 2. 1:** Antibiotic resistance mechanism of gram-positive and gram-negative bacteria

Bacteria	Mechanism of resistance	Example of antibiotics	Reference
Gram- Positive bacteria			
<i>S. aureus</i> and <i>Enterococcus</i> spp.	Use of efflux pumps to actively expel antibiotics from the cell.	Various antibiotics	(25,64–66)
<i>S. aureus</i>	Produces extra Penicillin-binding proteins like PBP2a, which reduces affinity for penicillin and β -lactams.	β -lactams	(25,64–66)
<i>S. aureus</i> and <i>Enterococcus</i> spp.	Modification of antibiotic target sites		(25,64–66)
	Modification of the ribosomal binding sites	Macrolides, clindamycin	
	Mutation of genes encoding DNA gyrase and topoisomerase IV	Fluoroquinolones	
	Enzymatic inactivation		(25,64–66)
	β -lactamases hydrolyses β -lactams	β -lactams	
	Production of aminoglycoside-modifying enzymes such as acetyltransferases, phosphotransferases, and adenytransferases that modify aminoglycosides	Aminoglycosides (gentamycin, tobramycin, kanamycin)	
	Acquisition of resistance genes		(25,64–66)
	<i>Erm</i> (erythromycin resistance) and <i>msr</i> (macrolide efflux pump)	Macrolide and lincosamides	
	Tet genes such as <i>tetM</i> and <i>tetL</i>	Tetracyclines	
	Mutation in the 23S rRNA genes reduces the binding affinity of of the antibiotic to the ribosome	Linezolid	(25,64–66)
<i>Enterococcus</i> species	Mutation in Penicillin-binding proteins and hypersecretion of β -lactamases reduce affinity for β -lactams.	β -lactams	(25,64–66)
Gram- Negative bacteria			
<i>Enterobacteriaceae</i> species	Synthesis of β-lactamases	Third generation cephalosporins	(25,64–66)
<i>A. baumannii</i>	ESBLs	Broad spectrum cephalosporin	(25,64–66)
<i>P. aeruginosa</i>		Monobactams	

		Penicillins	
	Class A β -lactamases such as SHV-1, TEM-1, and TEM-2	Ampicillin, Amoxicillin	(25,64–66)
	Production of the β -lactamases	Carbapenems	(25,64–66)
	Overexpression of the multidrug efflux pumps	A variety of antibiotics including Imipenem	(25,64–66)
	Production of aminoglycoside-modifying enzymes such as acetyltransferases, phosphotransferases, and adenytransferases that modify aminoglycosides	Aminoglycosides	(25,64–66)
	Alteration of porins which are proteins found in the outer membrane	Carbapenems	(25,64–66)

434

435 2.1.6.3 *Antimicrobial genes in bacteria associated with HAIs in veterinary medicine.*

436 Numerous antimicrobial genes are present in gram-negative and gram-positive
437 bacteria associated with HAIs (25). In *C. difficile*, the *GyrA* subunit confers resistance to
438 fluoroquinolones (59), while the presence of erythromycin ribosomal methylase (*ermB*) genes
439 confer resistance to both erythromycin and clindamycin among *Staphylococcus*, *C. difficile*
440 and *Enterococcus* species (67). The *TetM* gene has been shown to confer resistance to
441 tetracyclines, while *optrA* phenicols in both *E. faecalis* and *E. faecium* have been reported to
442 confer resistance to oxazolidinones. Methicillin resistance among *Staphylococcus* species is
443 associated with the presence of *mecA* gene (47,49,50,67). Additionally, the presence of *cfr*
444 gene in staphylococci has been linked to resistance to linezolid. While the presence of *aac(6)*-
445 *Ib* gene confers resistance to aminoglycosides (27). Xia, Gao and Tang (25) have also shown
446 that the colistin resistance in *E. coli* is associated with the presence of *mcr*-genes.

447 **Summary**

448 The presence of antimicrobial genes among organisms of animal origin remains an
449 important issue not only for patient care but also for public health (25). Moreover, Pirš et al
450 (59) have demonstrated that resistant pathogens (*C. difficile*) can be transmitted from infected
451 animals to susceptible human hosts. This study is not unique as other studies have also
452 reported other MDR organisms including MRSA and *E. coli* known to cause diseases in
453 humans (26,40,45,54,55). Measures must be implemented in veterinary medicines to reduce
454 the likelihood of transmission of resistant genes by implementing infection prevention and
455 control (IPC), prudent use, and effective patient management systems (59,68).

456

457 *2.1.7 Infection prevention and control in the control of organisms associated with*
458 *hospital-acquired and zoonotic infections*

459 The WHO has put together regulations on the core components of IPC practices
460 required to improve the quality and safety of health service delivery and patient health
461 outcomes (69). These practices remain the cornerstone of patient care and management in
462 human medicine (68) and are effective measures addressing HAIs (26,70–72). They have
463 slowly been adopted in veterinary medicine (72,73). In veterinary medicine, IPC practices are
464 designed to protect patients, animal owners, personnel, and communities from HAIs and
465 zoonotic diseases (21,72,73). In addition, they help reduce the burden of pathogens on the
466 hospital environment and the overuse of antimicrobial agents (68,74). Hand hygiene,
467 environmental control, sharps management, vaccination for zoonotic infections, and personal
468 protective equipment (PPE) have been recommended as some of the IPC measures that can
469 be implemented in small animal veterinary hospitals (73). Furthermore, patient management
470 (9,56,75) and surveillance (9) have been described as effective IPC measures in preventing
471 the transmission of organisms associated with HAIs and zoonotic infections. Therefore,
472 personnel and visitors at the veterinary facilities must familiarise themselves with infection
473 control policies (26,74,76–78).

474 *2.1.7.1.1 Environmental control*

475 Several organisms have been isolated from environmental surfaces including bed
476 sites, intravenous stands, surfaces of lockers, and over-bed tables in veterinary medicine
477 (45,47,49,79) as well as on environmental fomites such as cage doors, computer keyboards
478 and mice, stethoscopes, thermometers, and mouth gags (79,80). Some of these pathogens
479 including *C. difficile* are resistant to commonly used disinfections (21,45,54,79) and able to
480 survive on hospital surfaces for a longer period (up to five months) and remain a source of
481 infection to susceptible patients (45,54,79). Therefore, environmental surfaces should be
482 cleaned regularly with disinfectants that are virucidal, bactericidal, mycocidal, non-irritant, non-
483 corrosive, and non-staining (9). Applications may include prepackaged wipes containing

484 disinfectants such as accelerated hydrogen peroxide or quaternary ammonium compounds or
485 footbaths at the entrance of high-risk areas such as isolation and colic wards/units (79).

486 Hospital linens and animal bedding, when soiled, pose a threat of infection to patients
487 and staff. They may also contribute to environmental cross-contamination. As a result, any
488 reusable linens and bedding contaminated with bodily fluids or exudates, such as blood, urine,
489 or faeces, must undergo a decontamination process, as outlined in hospital cleaning protocols.
490 Moreover, individuals responsible for handling soiled PPE must receive adequate training
491 (79).

492 2.1.7.1.2 *Patient management*

493 Patient management is another key part of minimizing the incidence of HAIs in
494 veterinary settings (21,75). This area of IPC focuses on patient admission, housing, diagnostic
495 procedures, and treatment. It seeks to identify high-risk patients to prevent transmission of
496 infectious agents in the hospital (56,75). This can be done by strict movement control of
497 patients between services such as diagnostic imaging and surgery (21,75). Where possible,
498 isolation facilities must be available in the hospital to prevent transmission of pathogens from
499 high-risk patients to low-risk patients or to quarantine high-risk patients while waiting for
500 laboratory results (41,81). Patients showing clinical signs or with known bacterial infections
501 must be identified and isolated (56,82). Moreover, effective management of patients with
502 infectious conditions is likely to protect veterinary staff, volunteers, and animal owners from
503 the risk of infection (81).

504 2.1.7.1.3 *Surveillance*

505 Surveillance is the systematic collection, analysis, and interpretation of health data
506 necessary for public health planning, implementation, and evaluation (9). The WHO and the
507 World Organization for Animal Health (WOAH) have developed guidelines for disease
508 surveillance (71,83). This approach can be used to gather data on HAIs and zoonotic
509 diseases. It can also be used to identify critical areas in the hospital and develop strategies
510 for intervention. For example, studies have shown that implementing disease surveillance in

511 the ICU is important in reducing the risk of HAIs (9,61,72). The surveillance may also be used
512 to monitor the occurrence of MDR organisms (83).

513 Microbiological surveillance of the hospital environment surfaces is a critical
514 component of a successful infection control program. Hospital environment surveillance can
515 be done either as culture-based, meaning that a sample is taken and processed for results.
516 Or nonculture-based, meaning that the activity relies on the observation of situations and their
517 various outcomes. Either way, surveillance, when implemented correctly, can be a useful and
518 meaningful aspect of a complete hospital infection control program (79).

519 The South African National Department of Health together with other government
520 agencies developed the South African Antimicrobial Resistance Strategy Framework from
521 2014 to 2024. This framework consists of five strategic objectives supported by four key
522 enablers, which include optimizing surveillance and early detection of AMR and antimicrobial
523 usage, enhancing infection prevention and control and biosecurity, and promoting appropriate
524 use of antimicrobials in human and animal health through antimicrobial stewardship (84). The
525 framework encourages the sharing of data between laboratories to improve understanding of
526 trends and resistance patterns in the country across animal, human, and environmental health.
527 Furthermore, the framework emphasises a need to build expertise that will incorporate the
528 interventions to tackle AMR in the curricula of undergraduate and postgraduate healthcare
529 professionals. This could be done in collaboration with the health professional councils and
530 training institutions and aligned with relevant WOH recommendations such as the Veterinary
531 Core Curriculum (85). In 2021, data on the surveillance of AMR and consumption of
532 antimicrobials from human and animal medicine demonstrated sufficient information from
533 human medicine and food-producing animals, but limited data from companion animals (86).
534 With research being among the enablers in the strategic framework, priority research areas
535 including antimicrobial stewardship, IPC and healthcare behaviour change must be prioritised.
536

537 2.1.7.1.4 *Antimicrobial stewardship*

538 The rapid increase in antimicrobial resistance among organisms associated with HAIs
539 in small animals is concerning (9,56). To combat this development, hospitals should implement
540 clear antimicrobial prudent use policies including bacterial culture (9,75). These policies
541 should be tailored for each veterinary practice or hospital. Veterinarians should ensure correct
542 prescribing following the manufacturers' instructions and where applicable adjust antimicrobial
543 therapy following the results of the antibiogram (9,84). In addition to mitigating the risk of
544 antimicrobial resistance, the prudent use of antimicrobials reduces the risk of adverse events
545 including disruption to commensal flora, promotion of resistance, colonization or infection with
546 opportunistic pathogens, patient toxicity, and drug reactions including anaphylaxis (56). The
547 risk assessment must be conducted to ensure the responsible use of antimicrobials and make
548 recommendations on the current mitigation strategies (84).

549 2.1.7.1.5 *Personal protective clothing*

550 Hospital protective clothing is designed to protect workers from occupational health
551 hazards including bacteria. However, if incorrectly managed it may become a source of
552 pathogens and increase spread in veterinary hospitals (43). Most zoonotic diseases, including
553 ringworm and diarrhoea, are transmitted via direct contact with contaminated body surfaces,
554 body fluids, or a fecal-oral route involving contaminated hands or clothing (43,73,82). For
555 example, MRSA has been reported on personnel clothing working in a veterinary teaching
556 hospital (43). Furthermore, PPE can potentially act as a source of bacteria associated with
557 community-acquired infections (43). HCWs must adhere to appropriate PPE when handling
558 animals with potentially infectious conditions as well as when handling apparently healthy
559 animals (82). Therefore, veterinary hospital infection control protocols must include changing
560 of protective clothing whenever soiled, or when leaving the hospital.

561 2.1.7.1.6 *Sharps management*

562 Sharps mishandling has been associated with high incidences of needle injuries that
563 can subsequently lead to transmission of zoonotic disease (73,82). Wright et al (82) have

564 reported a high incidence of needlesticks among HCWs who do not recap needles compared
565 to those who recap their needles before disposal.

566 2.1.7.1.7 *Vaccination*

567 Vaccination is an important part of IPC in companion animals. It is important in
568 reducing the risk of infections among both patients and HCWs, especially against zoonotic
569 diseases such as Q- fever and Rabies (56,73,73,82). In such cases, appropriate measures
570 for infection control should be taken, including transmission precautions to prevent
571 accidental exposure to saliva (56).

572 2.1.7.1.8 *Hand hygiene*

573 Transmission of most organisms associated with HAIs including MRSA is mostly
574 through contaminated hands of HCWs (54,55). Studies in both human and veterinary medicine
575 have demonstrated that hand hygiene practices such as hand washing using water and soap
576 and disinfecting hands reduce the transmission of HAIs and antimicrobial-resistant pathogens
577 (54,77,78,80). It remains the cornerstone of IPC in the intensive care unit (54,55,77). Despite
578 this, hand hygiene compliance rates in veterinary hospitals are often low (55,76,82).
579 Willemsen et al (73) reported low hand hygiene compliance among veterinarians, with high
580 compliance after dirty procedures while low compliance was mainly before clean procedures
581 such as needle administration or before patient care. Similarly, in a video observation, overall
582 hand hygiene compliance was found to be 14% in companion animal hospitals in Ontario (87).
583 Veterinary healthcare workers have attributed the low compliance to high workload (55,81),
584 lack of reachable hand washing resources, underlying clinical conditions like skin irritation,
585 forgetfulness, and inadequate knowledge about hand hygiene practices (55,73,76,78,80). To
586 improve hand hygiene compliance, most studies suggest the use of alcohol-based sanitizers
587 as it is less irritating on the skin and requires less time compared to washing hands with water
588 and soap (54,88). Notwithstanding the effectiveness of alcohol-based sanitizers, mechanical
589 hand washing with running water and liquid soap should be used where possible as alcohol-

590 based sanitizers are less effective against certain pathogens including spore-forming bacteria
591 (54,78).

592 *2.1.7.2 Methods to evaluate Infection Prevention and Control.*

593 The ability to monitor and evaluate infection control practices is important from both
594 research and infectious disease management perspectives. Regular audits in healthcare
595 facilities are to be conducted to help maintain good IPC practices. It involves checking current
596 practices against published national standards of practice (89). Audits of veterinary facilities
597 should include observation of daily practices by hospital staff and assessment of their
598 knowledge of infection control principles and policies, evaluation of the physical facilities, and
599 review of the hospital's written infection control and patient management protocols (80,89,90).
600 Direct observations can be done by an observer on the clinic floor. However, direct observation
601 is prone to bias due to knowledge and experience of the assessor, so it may suffer from
602 "Hawthorne effect" (91,92). Video observation can also be done, however, its feasibility has
603 not been evaluated in small animal veterinary clinics (87,93). The observations made in the
604 audits are then compared with national standards for compliance with standards and
605 identifying areas for improvement. The final step in any audit is planning and implementing
606 changes that will improve practice and commending areas in which infection control principles
607 and practices are implemented well. Communicating audit findings to clinic staff in group
608 meetings is an effective means of keeping everyone invested and working together to maintain
609 good infection control practices (75,79).

610 Hand hygiene compliance in healthcare facilities can be monitored through direct or
611 indirect methods (94). Direct monitoring involves directly observing hand hygiene practices
612 during patient care. Indirect monitoring involves tracking the usage of hand hygiene products
613 such as liquid soap, hand rub sanitizers, and automated hand rub dispensers (94). Direct
614 observation is considered the gold standard for assessing hand hygiene compliance
615 (71,92,95). It includes an evaluation of HCWs' compliance with the five hand hygiene
616 moments. The five hand hygiene moments as described by the WHO are, (1) before patient

617 contact, (2) before an aseptic procedure, (3) after contact with body fluids, (4) after touching
618 a patient, and (5) after contact with patient surroundings (**Table 2.2**). In addition, the
619 antimicrobial-resistant profile of organisms present in the hands of HCWs can be assessed before
620 and after an intervention (15,96,97). Microbial sampling can also be done to collect baseline
621 data at any of the five moments of hand hygiene for example before washing hands after
622 washing hands (15), and before contact with patients in both pre- and post-intervention (97).
623 This allows for evaluation of the effectiveness of intervention strategies. The glove juice
624 method is predominantly used in most human studies to quantify the bacterial load on the
625 hands of HCWs as it is more sensitive than the imprint methods (98). For example, is the
626 evaluation of the impact of an intervention to minimise contamination of Vancomycin-Resistant
627 Enterococci (VRE) (99).

628 2.1.7.3 *Challenges of implementing infection, prevention, and control in veterinary hospital*

629 Several factors are known to impact the implementation of IPC measures in veterinary
630 settings. These factors are classified into systematic, organisational, environmental, and
631 individual (100). Systematic factors include material and human resource issues, and policies
632 that affect the implementation of IPC measures. Studies have also reported a lack of written
633 protocols as a barrier to implementing IPC practices in veterinary clinics and hospitals
634 (56,101). The lack of IPC protocols may reduce the standard of care, which can result in legal,
635 ethical, animal health, and occupational health challenges (56). Organizational factors relate
636 to managerial style and support, interprofessional relationships, and budget. Infection
637 prevention and control leaders are considered important in maintaining progress in reducing
638 the risks of HAIs and achieving continuous quality improvement in the hospital (102).
639 Environmental factors relate to the physical layout of the hospital, availability of isolation rooms
640 and hand hygiene equipment such as hand washing basins and access to hand sanitizers, as
641 well as access to PPE (101,103). The individual or personal factors relate to the knowledge,
642 attitudes, and beliefs of healthcare workers about IPC. Studies have associated the behaviour
643 of HCWs during patient care as a contributor to the insufficient implementation of IPC (55,100).

644 These have been attributed to high workload, lack of resources, underlying clinical conditions
645 including skin irritation, forgetfulness, and lack of knowledge on hand hygiene practices
646 (76,78,80,104). For example, Nakamura and colleagues (55) in the USA, reported that less
647 than 50% of veterinary technicians and veterinary support staff regularly wash their hands
648 every time between handling patients and most of them said that this is because of their busy.
649 Schedules. In addition, Willemsen et al (73) mentioned in a review that financial costs, lack of
650 perceived risk, lack of time for HCWs, and finding a medical practitioner are some of the
651 barriers to implementing an effective IPC in small animal veterinary practice.

652 *2.1.8 One health approach*

653 The One Health approach is a collaborative, multisectoral, and transdisciplinary
654 approach that recognizes the interconnectedness of human health, animal health, and
655 environmental health. It emphasizes the need for cooperation among various disciplines,
656 including medicine, veterinary science, ecology, public health, environmental science, and
657 others, to address complex health challenges effectively (6). One health approach addresses
658 issues such as:

659 **1. Interconnectedness of Human, Animal, and Environmental Health:** The

660 interconnectedness of humans, animals, and the environment can allow for the
661 emergence of diseases, emphasizing the importance of understanding and addressing
662 these connections (105–109).

663 **2. Prevention and Control of Zoonotic Diseases:** Many infectious diseases are zoonotic,
664 meaning they can be transmitted between animals and humans. Examples include Ebola,
665 Zika, and COVID-19. The One Health approach emphasizes collaborative efforts to
666 prevent and control such diseases at their source, often involving surveillance, early
667 detection, and coordinated responses across sectors (105–108).

668 **3. Antimicrobial Resistance (AMR):** The misuse and overuse of antimicrobial drugs in both
669 human and veterinary medicine contribute to the development of antimicrobial resistance.

670 One Health recognizes the shared responsibility in addressing this global health threat
671 and advocates for coordinated efforts to promote prudent antimicrobial use, antimicrobial
672 stewardship, and surveillance of antimicrobial resistance in humans, animals, and the
673 environment. (105–108).

674 4. **Environmental Health:** Environmental factors such as pollution, habitat destruction,
675 climate change, and biodiversity loss can impact human and animal health. One Health
676 emphasizes the importance of understanding and mitigating these environmental
677 stressors to protect the health of all species and ecosystems (105–108).

678 5. **Food Safety and Security:** The safety and security of the food supply are essential for
679 both human and animal health. One Health approaches integrate efforts to ensure the
680 safety of food production, processing, and distribution systems, considering the health
681 implications for consumers, producers, and the environment (105–108).

682 As a way to support countries in taking a One Health approach to address zoonotic
683 diseases, the tripartite organizations (FAO, WHO, and WOA) have jointly developed a
684 guide to use for other health threats and the human-animal-environmental interface such
685 as AMR referred to as Tripartite Zoonotic Guide (TZG)(110).

686 *2.1.9 Multimodal approach*

687 Hand hygiene compliance remains a challenge and long-lasting improvements are
688 difficult to sustain (58,70,93,94). The multimodal approach has been used in fields such as
689 developing technology (111), adaptability to change in the education sector (112), and
690 adaptability to treatments in health and they have proven to be effective compared to a single
691 approach (17,113) in healthcare settings (54,77,78,114).

692 The World Health Organization (WHO) recommends multimodal approaches as an
693 intervention strategy for sustained improvement of hand hygiene compliance (69,71). The goal
694 is to make hand hygiene a part of the healthcare facility's culture (71) (**Table 2.3**). There are
695 five key components of the multimodal strategy, which are, system change, training/education,

696 evaluation and feedback, reminders in the workplace, and institutional safety climate (71). In
697 addition, the WHO outlines the five step-by-step approaches to implement the multimodal
698 approach to improve hand hygiene (71). The steps include facility preparedness (readiness
699 for action), baseline evaluation (establishing knowledge of the current knowledge),
700 implementation (introducing the improvement activities), follow-up evaluation (evaluating the
701 implementation impact), and ongoing planning and review cycle (developing a plan for the
702 next five years minimum) (71). Smith et al (104) have included four of the five approaches by
703 the WHO to the ongoing planning and review cycle to improve hand hygiene compliance of
704 HCWs in the ICU of a small animal veterinary teaching hospital of Georgia College. The results
705 of the study showed no significant improvement in overall compliance with hand hygiene,
706 which was below 50% pre-and post-intervention.

707 The five key components together with the five key approaches and their relevant tools
708 encourage the HCWs to comply with the five moments for hand hygiene which are: (1) before
709 patient contact, (2) before an aseptic procedure, (3) after contact with body fluids, (4) after
710 touching a patient, and (5) after contact with patient surroundings (**Table 2.2**) within health
711 facilities. Studies have shown that healthcare workers are compliant to hand hygiene after
712 contact with bodily fluid which is typically intended to protect HCWs from infections and not to
713 protect patients (104).

714 2.1.9.1.1 *System change*

715 Hand hygiene improvement tools and improvement of existing infrastructure can be
716 used at the start of the journey to improve hand hygiene compliance within hospitals. These
717 tools can also be used for routine or periodic monitoring of product use and infrastructure (71).

718 2.1.9.1.2 *Training and education*

719 Education plays a crucial role in implementing effective hand hygiene strategies and it
720 is strongly linked to the other five key components of IPC multimodal strategies. In fact, without
721 proper training, it is unlikely that any system changes will result in behavioral changes, such
722 as adopting the use of alcohol-based hand rubs and maintaining proper hand hygiene.

723 Training can differ depending on the need, in some cases, education on basic principles might
724 be required and in some complex cases practical scenarios may be used to apply theoretical
725 principles (71). Amongst all preventative methods, education is often the first IPC intervention
726 strategy to ensure compliance with IPC protocols (78,114). Educating personnel and clients
727 on HAIs and zoonotic risks help reduce the incidences of these diseases (76). Salama et al.
728 (77) in Kuwait reported an improvement in hand hygiene compliance among healthcare
729 workers after an educational campaign from 43% to 61.4% compliance respectively.
730 Therefore, personnel and visitors in the veterinary facilities must be familiar with infection
731 control policies (26,74,77,78).

732 2.1.9.1.3 *Evaluation and feedback*

733 Hand hygiene compliance in healthcare facilities can be monitored through direct or
734 indirect methods (71). Direct monitoring involves directly observing hand hygiene practices
735 during patient care. Indirect monitoring involves tracking the usage of hand hygiene products
736 such as soap, hand rub, and automated hand rub dispensers. Direct observation is considered
737 the gold standard for assessing hand hygiene compliance with an emphasis on the five hand
738 hygiene moments (71).

739 Knowledge among HCWs must be assessed to gather baseline information in order to
740 determine the need for intervention that may include education and training. The results of the
741 assessment of HCW's knowledge can be disseminated through written reports or
742 communicated during meetings or hospital-structured feedback sessions (71). In South Africa,
743 evaluation of the IPC practices has been done in human medicine with no study evaluating
744 IPC practices in veterinary medicine. One such study is that by Mehtar et al. (115) which
745 evaluated infection control practices in public dental care services. This study reported a lack
746 of knowledge among the HCWs on the application of IPC in clinical practice and suggests this
747 is likely to increase the risk transmit blood-borne viruses in public dental facilities. If a
748 healthcare facility cannot provide sufficient hand hygiene training due to resource constraints
749 such as a lack of trained facilitators and finances especially in resource-limited facilities, an

750 action plan should be developed to embed training and education within the facility's culture
751 (71). Once the interventions have been implemented a follow-up assessment must be
752 undertaken to assess the effectiveness of the intervention strategies on hand hygiene
753 compliance.

754 2.1.9.1.4 *Reminders in the Workplace*

755 The use of reminders and communication tools is crucial in the workplace to prompt
756 and remind healthcare workers about the significance of hand hygiene, proper indications,
757 and procedures for performing it. These tools also serve as a means of educating patients and
758 visitors about the standard of care that they should anticipate from healthcare workers (71).
759 Reminders can be done in the form of posters, this has to be done with caution as Anderson
760 et al (87) have reported limited improvement in hand hygiene compliance after the poster
761 campaign initiative.

762 2.1.9.1.5 *Surveillance*

763 Furthermore, several studies in human hospitals indicated a need for a better
764 understanding of the number of antimicrobial-resistant organisms present on hands and to
765 identify ways to improve adherence to hand hygiene practices. During these campaigns,
766 HCWs' hands were sampled for culture before and after multimodal campaign interventions
767 during different stages of patient care to measure the difference in microbial load (15,96,97).
768 The five moments of hand hygiene were also noted in this campaign, for example, Matuka et
769 al (15) isolated *Staphylococcus* spp. and *E. coli* from sampling HCWs before washing hands
770 and after washing hands. Monistrol et al (97) observed a reduction in both resident and
771 transient flora counts on the hands of HCWs sampled before contact with patients during an
772 educational intervention. While Tenorio et al (99) demonstrated the effectiveness of glove use
773 in minimizing contamination of Vancomycin-Resistant Enterococci (VRE) during patient care.

774 2.1.9.2 *Multimodal approach case studies in veterinary hospitals*

775 Although common in human healthcare facilities, some veterinary facilities have also
776 implemented multimodal approaches to improve hand hygiene with differing success. Shea
777 and Shaw (76) in a small animal hospital in the United States of America, observed a
778 significant increase in hand hygiene compliance after an education campaign, from 20.6% to
779 41.7%. Contrary to the study by Shea and Shaw, Smith and colleagues (81) at a small animal
780 hospital in the United States of America observed no significant improvement in hand hygiene
781 compliance after an intervention. Instead, glove donning was a confounding matter in the
782 study. Similarly, Anderson et al (87) have limited improvement in hand hygiene compliance
783 after the poster campaign initiative.

784 **Table 2. 2:** This table illustrates the World Health Organization multimodal hand hygiene
785 improvement strategy and tools for implementation. Source (71).

Tools for System Change	Tools for Training / Education	Tools for Evaluation and Feedback	Tools for Reminders in the Workplace	Tools for Institutional Safety Climate
Ward Infrastructure Survey	Slides for the Hand Hygiene Co-ordinator Slides for Education Sessions for Trainers, Observers and Health-Care Workers	Hand Hygiene Technical Reference Manual	Your 5 Moments for Hand Hygiene Poster How to Handrub Poster	Template Letter to Advocate Hand Hygiene to Managers
Alcohol-based Handrub Planning and Costing Tool Guide to Local Production:	Hand Hygiene Training Films	Observation Tools: Observation Form and Compliance Calculation Form	How to Handwash Poster	Template Letter to Communicate Hand Hygiene Initiatives to Managers
WHO-recommended Handrub Formulations	Slides Accompanying the Training Films	Ward Infrastructure Survey	Hand Hygiene:	Guidance on Engaging Patients and Patient
Soap / Handrub Consumption Survey	Hand Hygiene Technical Reference Manual	Soap / Handrub Consumption Survey	When and How Leaflet SAVE LIVES:	Organizations in Hand Hygiene Initiatives
Protocol for Evaluation of Tolerability and Acceptability of	Observation Form	Perception Survey for Health-Care Workers	Clean Your Hands Screensaver	Sustaining Improvement – Additional Activities for Consideration by Health-Care Facilities
Alcohol-based Handrub in Use or Planned to be Introduced: Method 1	Slides for the Hand Hygiene Co-ordinator Slides for Education Sessions for Trainers, Observers and Health-Care Workers	Perception Survey for Senior Managers		SAVE LIVES: Clean Your Hands Promotional DVD
	Hand Hygiene Training Films	Hand Hygiene Knowledge Questionnaire for Health-Care Workers		
	Slides Accompanying the Training Films	Protocol for Evaluation of Tolerability and Acceptability of		
	Hand Hygiene Technical Reference Manual	Alcohol-based Handrub in Use or Planned to be Introduced: Method 1		
	Observation Form	Protocol for Evaluation and Comparison of Tolerability and Acceptability of Different Alcohol-based Handrubs: Method 2		
	Health-Care Workers	Data Entry Analysis Tool		
	Hand Hygiene Training Films	Instructions for Data Entry and Analysis		
	Slides Accompanying the Training Films	Data Summary Report Framework		

786
787

788 **Table 2. 3:** Definitions of the hand hygiene five moments: Source (94).

MOMENT	WHEN AND WHY
BEFORE PATIENT CONTACT	<p>Healthcare workers in direct contact must perform hand hygiene before touching a patient to remove any potential pathogens that were picked up from previous patients. Even if the healthcare worker does not touch the patient directly, they may encounter a patient’s clothing or personal objects with harmful microorganisms</p>
BEFORE AN ASEPTIC PROCEDURE	<p>This moment occurs before any clean or aseptic procedure within a patient zone. A clean procedure may include opening a venous access line, giving an injection, or performing wound care. Importantly, hand hygiene required at this moment aims at preventing hospital-acquired infections.</p> <p>Some procedures on clean sites require glove use. In this case, hand hygiene is required before putting on gloves because gloves alone may not entirely prevent contamination and after removal of the gloves.</p>
AFTER CONTACT BODY FLUID EXPOSURE	<p>Hand hygiene is required instantly after a procedure associated with a risk to expose hands to body fluids. It must take place before any next hand-to-surface exposure, even within the same patient zone.</p> <p>This hand hygiene action may reduce the risk of colonization or infection of healthcare workers with infectious agents that may occur even without visible soiling. Additionally, it may reduce the risk of transmission of microorganisms from a “colonized” to a “clean” body site within the same patient.</p>
AFTER PATIENT CONTACT	<p>Hand hygiene should happen when leaving the patient zone after a care sequence, before touching an object in the area outside the patient zone and before a subsequent hand exposure to any surface in the health-care area. hand hygiene minimizes the risk of dissemination to the health-care environment, substantially reduces contamination of HCWs’ hands with the flora from one patient to the other patient and protects the HCWs themselves.</p>
AFTER CONTACT WITH PATIENT SURROUNDING	<p>This moment occurs after hand exposure to any surface in the patient zone, and before a subsequent hand exposure to any surface in the health-care area, even if a patient is not touched.</p>

789

790 **2.2 References**

- 791 1. Weese JS. Staphylococcal control in the veterinary hospital. *Veterinary Dermatology*. 2012
792 Aug;23(4):292-e58.
- 793 2. Dargatz DA, Traub-Dargatz JL. Multidrug-resistant Salmonella and nosocomial infections.
794 *Veterinary Clinics: Equine Practice*. 2004 Dec 1;20(3):587-600.
- 795 3. Poje DK, Miljković N, Polidori P, Kohl S. Infectious diseases and antimicrobial resistance.
796 *European Journal of Hospital Pharmacy*. 2023 Sep 1.
- 797 4. Machado IC, Nunes T, Maximino M, Malato J, Tavares L, Almeida V, Sepúlveda N, Gil S.
798 Epidemiologic factors supporting triage of infected dog patients admitted to a veterinary hospital
799 biological isolation and containment unit. *Veterinary Sciences*. 2023 Mar 1;10(3):186.
- 800 5. Fèvre EM, Bronsvoort BM, Hamilton KA, Cleaveland S. Animal movements and the spread
801 of infectious diseases. *Trends in microbiology*. 2006 Mar 1;14(3):125-31.
- 802 6. Mazet JA, Clifford DL, Coppolillo PB, Deolalikar AB, Erickson JD, Kazwala RR. A “one
803 health” approach to address emerging zoonoses: the HALI project in Tanzania. *PLoS medicine*.
804 2009 Dec 15;6(12):e1000190.
- 805 7. Day MJ, Breitschwerdt E, Cleaveland S, Karkare U, Khanna C, Kirpensteijn J, Kuiken T,
806 Lappin MR, McQuiston J, Mumford E, Myers T. Surveillance of zoonotic infectious disease
807 transmitted by small companion animals. *Emerging Infectious Diseases*. 2012 Dec;18(12):e1.
- 808 8. Milton AAP. Nosocomial infections and their surveillance in veterinary hospitals. *Advances*
809 *in Animal and Veterinary Sciences*. 2015;3(2s):1–24.
- 810 9. Iku Kisani A, Awasum A, Udegbumam S, Nnaji T, Muhammed B, Melekwa G, Ankwedel Y.
811 Management of Nosocomial Diseases in Small Animal Practice: A Review. *Vom Journal of*
812 *Veterinary Science*. 2016;11:94-100.
- 813 10. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *New*
814 *England Journal of Medicine*. 2010 May 13;362(19):1804-13.

- 815 11. Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA,
816 Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G,
817 Álvarez-Hernández DA, Moncaleano Guzmán V. *Acinetobacter baumannii* resistance: a real
818 challenge for clinicians. *Antibiotics*. 2020 Apr 23;9(4):205.
- 819 12. Eliasi UL, Sebola D, Oguttu JW, Qekwana DN. Antimicrobial resistance patterns of
820 *Pseudomonas aeruginosa* isolated from canine clinical cases at a veterinary academic hospital in
821 South Africa. *Journal of the South African Veterinary Association*. 2020 Jan 1;91(1):1-6.
- 822 13. Van der Kolk JH, Endimiani A, Graubner C, Gerber V, Perreten V. *Acinetobacter* in
823 veterinary medicine, with an emphasis on *Acinetobacter baumannii*. *Journal of global antimicrobial*
824 *resistance*. 2019 Mar 1;16:59-71.
- 825 14. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens.
826 *Expert review of anti-infective therapy*. 2013 Mar 1;11(3):297-308.
- 827 15. Matuka DO, Binta B, Carman HA, Singh T. *Staphylococcus aureus* and *Escherichia coli*
828 levels on the hands of theatre staff in three hospitals in Johannesburg, South Africa, before and
829 after handwashing. *South African Medical Journal*. 2018 May 25;108(6):474.
- 830 16. European Centre for Disease Prevention and Control. Healthcare-associated infections
831 acquired in intensive care units. *ECDC Annual Epidemiological Report for 2017*. 2019.
- 832 17. Migliara G, Di Paolo C, Barbato D, Baccolini V, Salerno C, Nardi A, Alessandri F, Giordano
833 A, Tufi D, Marinelli L, Cottarelli A. Multimodal surveillance of healthcare associated infections in an
834 intensive care unit of a large teaching hospital. *Annali di Igiene, Medicina Preventiva e di*
835 *Comunita*. 2019 Jul 1;31(5).
- 836 18. Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and
837 cost associated with hospital-acquired infections in trauma patients. *Archives of surgery*. 2011 Jul
838 18;146(7):794-801.
- 839 19. Mendelson M. Antimicrobial Stewardship in South Africa. In: *Antimicrobial Stewardship*.
840 2017. p. 309–11.

- 841 20. Pandey R, Mishra SK, Shrestha A. Characterisation of ESKAPE pathogens with special
842 reference to multidrug resistance and biofilm production in a Nepalese hospital. *Infection and Drug*
843 *Resistance*. 2021 Jun 14;2201-12.
- 844 21. Stull JW, Weese JS. Hospital-associated infections in small animal practice. *Veterinary*
845 *Clinics: Small Animal Practice*. 2015 Mar 1;45(2):217-33.
- 846 22. Sikora A, Zahra F. *Nosocomial Infections*. 2022
- 847 23. Dell AJ, Gray S, Kloppers JC, Navsaria PH. Nosocomial infections: A further assault on
848 patients in a high-volume urban trauma centre in South Africa. *South African Medical Journal*. 2020
849 Feb 1;110(2):123-5.
- 850 24. Lowman W. Active surveillance of hospital-acquired infections in South Africa:
851 Implementation, impact and challenges. *South African Medical Journal*. 2016 Jun 24;106(5):489
- 852 25. Xia J, Gao J, Tang W. Nosocomial infection and its molecular mechanisms of antibiotic
853 resistance. *Bioscience trends*. 2016;10(1):14-21.
- 854 26. Walther B, Tedin K, Lübke-Becker A. Multidrug-resistant opportunistic pathogens
855 challenging veterinary infection control. *Veterinary Microbiology*. 2017 Feb 1;200:71–8.
- 856 27. Sebola DC, Oguttu JW, Kock MM, Qekwana DN. Hospital-acquired and zoonotic bacteria
857 from a veterinary hospital and their associated antimicrobial-susceptibility profiles: A systematic
858 review. *Frontiers in Veterinary Science*. 2023 Jan 9;9:1087052.
- 859 28. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to
860 combat ESKAPE pathogens in the era of antimicrobial resistance: a review. *Frontiers in*
861 *microbiology*. 2019 Apr 1;10:539.
- 862 29. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of
863 ESKAPE pathogens in Kwazulu-Natal, South Africa: a five-year retrospective analysis. *African*
864 *journal of laboratory medicine*. 2018 Jun 1;7(2):1-8.

- 865 30. Santaniello A, Sansone M, Fioretti A, Menna LF. Systematic review and meta-analysis of
866 the occurrence of ESKAPE bacteria group in dogs, and the related zoonotic risk in animal-assisted
867 therapy, and in animal-assisted activity in the health context. *International journal of environmental*
868 *research and public health*. 2020 May;17(9):3278.
- 869 31. Franco-Duarte R, Černáková L, Kadam S, S. Kaushik K, Salehi B, Bevilacqua A, Corbo
870 MR, Antolak H, Dybka-Stępień K, Leszczewicz M, Relison Tintino S. Advances in chemical and
871 biological methods to identify microorganisms—from past to present. *Microorganisms*. 2019 May
872 13;7(5):130.
- 873 32. Talaiekhosani A. Guidelines for quick application of biochemical tests to identify unknown
874 bacteria. *Account of Biotechnology Research* (2013). 2013.
- 875 33. Libretexts Biology [Internet]. 2001 [cited 2023 Oct 1]. Introduction to Bacterial Identification
876 using Genotypic methods. Available from: <https://bio.libretexts.org/@go/page/52312>
- 877 34. Zhu H, Zhang H, Xu Y, Laššáková S, Korabečná M, Neužil P. PCR past, present and
878 future. *Biotechniques*. 2020 Jul;69(4):317-25.
- 879 35. Sibley CD, Peirano G, Church DL. Molecular methods for pathogen and microbial
880 community detection and characterization: current and potential application in diagnostic
881 microbiology. *Infection, Genetics and Evolution*. 2012 Apr 1;12(3):505-21.
- 882 36. Balouiri M, Sadiki M, Ibensouda SK. Methods for in vitro evaluating antimicrobial activity: A
883 review. *Journal of pharmaceutical analysis*. 2016 Apr 1;6(2):71-9.
- 884 37. Weese JS, van Duijkeren E. Methicillin-resistant *Staphylococcus aureus* and
885 *Staphylococcus pseudintermedius* in veterinary medicine. *Veterinary microbiology*. 2010 Jan
886 27;140(3-4):418-29.
- 887 38. Van Duijkeren E, Box AT, Heck ME, Wannet WJ, Fluit AC. Methicillin-resistant
888 *staphylococci* isolated from animals. *Veterinary microbiology*. 2004 Oct 5;103(1-2):91-7.

- 889 39. Weese JS, Caldwell F, Willey BM, Kreiswirth BN, McGeer A, Rousseau J, Low DE. An
890 outbreak of methicillin-resistant *Staphylococcus aureus* skin infections resulting from horse to
891 human transmission in a veterinary hospital. *Veterinary microbiology*. 2006 Apr 16;114(1-2):160-4.
- 892 40. Yang Baek J, Kim SH, Kang BJ, Youn HY. Antimicrobial susceptibility and distribution of
893 multidrug-resistant organisms isolated from environmental surfaces and hands of healthcare
894 workers in a small animal hospital. *Japanese Journal of Veterinary Research*. 2018 Aug;66(3):193-
895 202.
- 896 41. Weese JS. Methicillin-resistant *Staphylococcus aureus* in horses and horse personnel.
897 *Veterinary Clinics: Equine Practice*. 2004 Dec 1;20(3):601-13.
- 898 42. Julian T, Singh A, Rousseau J, Weese JS. Methicillin-resistant staphylococcal
899 contamination of cellular phones of personnel in a veterinary teaching hospital. *BMC research*
900 *notes*. 2012 Dec;5(1):1-5.
- 901 43. Singh A, Walker M, Rousseau J, Monteith GJ, Weese JS. Methicillin-resistant
902 staphylococcal contamination of clothing worn by personnel in a veterinary teaching hospital.
903 *Veterinary Surgery*. 2013 Aug 1;42(6):643–8.
- 904 44. Heller J, Armstrong SK, Girvan EK, Reid SW, Moodley A, Mellor DJ. Prevalence and
905 distribution of methicillin-resistant *Staphylococcus aureus* within the environment and staff of a
906 university veterinary clinic. *Journal of Small Animal Practice*. 2009 Apr;50(4):168-73.
- 907 45. Murphy CP, Reid-Smith RJ, Boerlin P, Weese JS, Prescott JF, Janecko N, Hassard L,
908 McEwen SA. *Escherichia coli* and selected veterinary and zoonotic pathogens isolated from
909 environmental sites in companion animal veterinary hospitals in southern Ontario. *The Canadian*
910 *veterinary journal*. 2010 Sep;51(9):963.
- 911 46. Weese JS, Rousseau J, Willey BM, Archambault M, McGeer A, Low DE. Methicillin-
912 resistant *Staphylococcus aureus* in horses at a veterinary teaching hospital: frequency,
913 characterization, and association with clinical disease. *Journal of Veterinary Internal Medicine*.
914 2006 Jan;20(1):182-6.

- 915 47. Hoet AE, Johnson A, Nava-Hoet RC, Bateman S, Hillier A, Dyce J, Gebreyes WA, Wittum
916 TE. Environmental methicillin-resistant *Staphylococcus aureus* in a veterinary teaching hospital
917 during a nonoutbreak period. *Vector-borne and zoonotic diseases*. 2011 Jun 1;11(6):609-15.
- 918 48. Ng S, Abdul Aziz S, Bejo SK, Dhaliwal GK. Occurrence of multidrug resistant *Acinetobacter*
919 *baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *Jurnal*
920 *Veterinar Malaysia*. 2016;28(2):12-6.
- 921 49. Rojas I, Barquero-Calvo E, Van Balen JC, Rojas N, Muñoz-Vargas L, Hoet AE. High
922 Prevalence of Multidrug-Resistant Community-Acquired Methicillin-Resistant *Staphylococcus*
923 *aureus* at the Largest Veterinary Teaching Hospital in Costa Rica. *Vector-Borne and Zoonotic*
924 *Diseases*. 2017 Sep 1;17(9):645–53.
- 925 50. Stella AE, Lima TF, Moreira CN, De Paula E. Characterization of *Staphylococcus aureus*
926 Strains Isolated from Veterinary Hospital. *International Journal of Microbiology*. 2020 Aug 1;2020.
- 927 51. Mount R, Schick AE, Lewis TP, Newton HM. Evaluation of bacterial contamination of
928 clipper blades in small animal private practice. *Journal of the American Animal Hospital*
929 *Association*. 2016 Mar 1;52(2):95-101.
- 930 52. Anderson MEC, Wimmers M, Weese JS. Infection Prevention and Control Best Practices
931 for Small Animal Veterinary Clinics [Internet]. 2020 [cited 2024 Apr 14]. Available from:
932 <https://oahn.ca/resources/ipc-best-practices/>.
- 933 53. Stull JW, Brophy J, Weese JS. Reducing the risk of pet-associated zoonotic infections.
934 *Canadian Medical Association Journal*. 2015;187(10):736–43.
- 935 54. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention.
936 *Journal of hospital infection*. 2009 Dec 1;73(4):305-15.
- 937 55. Nakamura RK, Tompkins E, Braasch EL, Martinez Jr JG, Bianco D. Hand hygiene practices
938 of veterinary support staff in small animal private practice. *Journal of Small Animal Practice*. 2012
939 Mar;53(3):155-60.

- 940 56. Murphy CP, Reid-Smith RJ, Weese JS, McEwen SA. Evaluation of specific infection control
941 practices used by companion animal veterinarians in community veterinary practices in southern
942 Ontario. *Zoonoses and public health*. 2010 Sep;57(6):429-38.
- 943 57. Fritz S, Byers CG. Personnel Precautions for Patients with Zoonotic Disease. *Advanced
944 Monitoring and Procedures for Small Animal Emergency and Critical Care*. 2023 May 12:845-57.
- 945 58. Sebola DC, Boucher C, Maslo C, Qekwana DN. Hand hygiene compliance in the intensive
946 care unit of the Onderstepoort Veterinary Academic Hospital. [Preprint] 2019 [Accessed 2024 April
947 10]. Available from: <https://doi.org/10.21203/rs.2.17130/v1>
- 948 59. Pirš T, Avberšek J, Zdovc I, Krt B, Andlovic A, Lejko-Zupanc T, Rupnik M, Ocepek M.
949 Antimicrobial susceptibility of animal and human isolates of *Clostridium difficile* by broth
950 microdilution. *Journal of medical microbiology*. 2013 Sep;62(9):1478-85.
- 951 60. Santana JA, Paraguassu AO, Santana RS, Xavier RG, Freitas PM, Aburjaile FF, Azevedo
952 VA, Brenig B, Bojesen AM, Silva RO. Risk Factors, Genetic Diversity, and Antimicrobial
953 Resistance of *Staphylococcus* spp. Isolates in Dogs Admitted to an Intensive Care Unit of a
954 Veterinary Hospital. *Antibiotics*. 2023 Mar 21;12(3):621.
- 955 61. Benklaouz MB, Aggad H, Benameur Q. Resistance to multiple first-line antibiotics among
956 *Escherichia coli* from poultry in Western Algeria. *Veterinary World*. 2020 Feb;13(2):290.
- 957 62. Vo AT, van Duijkeren E, Fluit AC, Gaastra W. Characteristics of extended-spectrum
958 cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates from horses.
959 *Veterinary microbiology*. 2007 Oct 6;124(3-4):248-55.
- 960 63. Müller S, Janssen T, Wieler LH. Multidrug resistant *Acinetobacter baumannii* in veterinary
961 medicine—emergence of an underestimated pathogen. *Berl. Münch. Tierärztl. Wochenschr*.
962 2014;127:435-46.
- 963 64. Cesur S, DEMİRÖZ A. Antibiotics and the mechanisms of resistance to antibiotics. *world*.
964 2013;1:3.

- 965 65. Bharadwaj A, Rastogi A, Pandey S, Gupta S, Sohal. J.S. Multidrug-Resistant Bacteria:
966 Their mechanism of action and prophylaxis. *Biomed Research International*. 2022;2022.
- 967 66. Wright GD. Mechanisms of resistance to antibiotics. *Current opinion in chemical biology*.
968 2003 Oct 1;7(5):563-9.
- 969 67. Moon JSS, Lee ARR, Kang HMM, Lee ESS, Kim MNN, Paik YH, et al. Phenotypic and
970 genetic antibiogram of methicillin-resistant staphylococci isolated from bovine mastitis in Korea. **J**
971 *Dairy Sci*. 2007 Mar 1;90(3):1176–85.
- 972 68. Lonks JR. *Infection Control and Antimicrobial Stewardship*. *Rhode Island Medical Journal*.
973 2018 Jun 1;101(5):35-7.
- 974 69. World Health Organization. Improving infection prevention and control at the health facility:
975 Interim practical manual supporting national implementation of the WHO Guidelines on Core
976 Components of Infection Prevention and Control Programmes. 2017;1–77.
- 977 70. Ogoina D, Pondei K, Adetunji B, Chima G, Isichei C, Gidado S. Knowledge, attitude and
978 practice of standard precautions of infection control by hospital workers in two tertiary hospitals in
979 Nigeria. *Journal of Infection Prevention*. 2015 Aug 31;16(1):16–22.
- 980 71. World Health Organization. A guide to the implementation of the WHO multimodal hand
981 hygiene improvement strategy. World Health Association Press. Geneva; 2009.
- 982 72. Stull JW, Weese JS. Infection control in veterinary small animal practice. *Veterinary Clinics:*
983 *Small Animal Practice*. 2015 Mar 1;45(2):xi-i.
- 984 73. Willemsen A, Cobbold R, Gibson J, Wilks K, Lawler S, Reid S. Infection control practices
985 employed within small animal veterinary practices—A systematic review. *Zoonoses Public Health*.
986 2019 Aug 1;66(5):439–57.
- 987 74. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection.
988 *Journal of hospital Infection*. 2009 Dec 1;73(4):378-85.

- 989 75. Guptill L. Patient management. *Veterinary Clinics: Small Animal Practice*. 2015 Mar
990 1;45(2):277-98.
- 991 76. Shea A, Shaw S. Evaluation of an educational campaign to increase hand hygiene at a
992 small animal veterinary teaching hospital. *Journal of the American Veterinary Medical Association*.
993 2012 Jan 1;240(1):61-4.
- 994 77. Salama MF, Jamal WY, Al Mousa H, Al-AbdulGhani KA, Rotimi VO. The effect of hand
995 hygiene compliance on hospital-acquired infections in an ICU setting in a Kuwaiti teaching hospital.
996 *Journal of infection and public health*. 2013 Feb 1;6(1):27-34.
- 997 78. Anderson MEC. Contact precautions and hand hygiene in veterinary clinics. *Veterinary
998 Clinics of North America - Small Animal Practice*. 2015;45(2):343–60.
- 999 79. Traverse M, Aceto H. Environmental cleaning and disinfection. *Veterinary Clinics: small
1000 animal practice*. 2015 Mar 1;45(2):299-330.
- 1001 80. Weese JS. Barrier precautions, isolation protocols, and personal hygiene in veterinary
1002 hospitals. *Veterinary Clinics of North America - Equine Practice*. 2004 Dec;20(3):543–59.
- 1003 81. Veterinary Infection Control Committee. Compendium of Veterinary Standard Precautions
1004 for Zoonotic Disease Prevention in Veterinary Personnel. *J Am Vet Med Assoc*. 2015 Oct
1005 1;247(11):1253–1048.
- 1006 82. Wright JG, Jung S, Holman RC, Marano NN, McQuiston JH. Infection control practices and
1007 zoonotic disease risks among veterinarians in the United States. *Journal of the American
1008 Veterinary Medical Association*. 2008 Jun 15;232(12):1863-72.
- 1009 83. World Organisation for Animal Health. Surveillance and Epidemiology [Internet]. 2018 [cited
1010 2023 Sep 19]. Available from: [https://rr-asia.woah.org/wp-content/uploads/2019/09/seacfmd-
1011 manual-5.pdf](https://rr-asia.woah.org/wp-content/uploads/2019/09/seacfmd-manual-5.pdf)
- 1012 84. Departments of Health and Agriculture F and F for the R of SA. South African antimicrobial
1013 resistance national strategy framework; A one health approach 2017–2024.

- 1014 85. National Department of Health. South African Antimicrobial Resistance National Strategy
1015 Framework 2018 - 2024. *AMR Control*. 2018;54–61.
- 1016 86. National Department of Health. Surveillance for antimicrobial resistance and Consumption
1017 of Antimicrobials in South Africa, 2021.
- 1018 87. Anderson MEC, Sargeant JM, Weese JS. Video observation of hand hygiene practices
1019 during routine companion animal appointments and the effect of a poster intervention on hand
1020 hygiene compliance. *BMC Vet Res*. 2014 May 7;10(1):106.
- 1021 88. Picheansathian W. A systematic review on the effectiveness of alcohol-based solutions for
1022 hand hygiene. *International journal of nursing practice*. 2004 Feb;10(1):3-9.
- 1023 89. Khamis N, van Knippenberg-Gordebeke G. Audits in Infection Prevention and Control.
1024 *Concepts of Infection Control*. International Federation of Infection Control (IFIC); 2016. 1–8.
- 1025 90. Traub-Dargatz JL, Weese JS, Rousseau JD, Dunowska M, Morley PS, Dargatz DA. Pilot
1026 study to evaluate 3 hygiene protocols on the reduction of bacterial load on the hands of veterinary
1027 staff performing routine equine physical examinations. *Canadian Veterinary Journal*.
1028 2006;47(7):671–6
- 1029 91. Luangsanatip N, Hongsuwan M, Limmathurotsakul D, Lubell Y, Lee AS, Harbarth S, et al.
1030 Comparative efficacy of interventions to promote hand hygiene in hospital: Systematic review and
1031 network meta-analysis. Vol. 351, *British Medical Journal (Online)*. 2015. p. h3728.
- 1032 92. Gould DJ, Creedon S, Jeanes A, Drey NS, Chudleigh J, Moralejo D. Impact of observing
1033 hand hygiene in practice and research: a methodological reconsideration. *Journal of hospital
1034 infection*. 2017 Feb 1;95(2):169-74.
- 1035 93. Anderson MEC, Weese JS. Video observation of hand hygiene practices at a petting zoo
1036 and the impact of hand hygiene interventions. *Epidemiology Infect*. 2012;140(1):182–90.
- 1037 94. World Health Organization. WHO Guidelines on Hand Hygiene in Health Care: First Global
1038 Patient Safety Challenge Clean Care is Safer Care [Internet]. 2009 [cited 2019 Oct 30]. Available
1039 from: <https://www.who.int/gpsc/5may/tools/9789241597906/en/>.

- 1040 95. Erasmus V, Daha TJ, Brug H, Richardus JH, Behrendt MD, Vos MC, van Beeck EF.
1041 Systematic review of studies on compliance with hand hygiene guidelines in hospital care. *Infection*
1042 *Control & Hospital Epidemiology*. 2010 Mar;31(3):283-94.
- 1043 96. Monistrol O, Calbo E, Riera M, Nicolás C, Font R, Freixas N, et al. Impact of a hand
1044 hygiene educational programme on hospital-acquired infections in medical wards. *Clinical*
1045 *Microbiology and Infection*. 2012 Dec 1;18(12):1212–8.
- 1046 97. Monistrol O, Lopez ML, Riera M, Font R, Nicolas C, Escobar MA, Freixas N, Garau J,
1047 Calbo E. Hand contamination during routine care in medical wards: the role of hand hygiene
1048 compliance. *Journal of medical microbiology*. 2013 Apr;62(4):623-9.
- 1049 98. Waterman TR, Smeak DD, Kowalski J, Hade EM. Comparison of bacterial counts in glove
1050 juice of surgeons wearing smooth band rings versus those without rings. *Am J Infect Control*. 2006
1051 Sep;34(7):421–5
- 1052 99. Tenorio AR, Badri SM, Sahgal NB, Hota B, Matushek M, Hayden MK, Trenholme GM,
1053 Weinstein RA. Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant
1054 enterococcus species by health care workers after patient care. *Clinical Infectious Diseases*. 2001
1055 Mar 1;32(5):826-9.
- 1056 100. Henderson J, Willis E, Blackman I, Verrall C, McNeill L. Comparing infection control and
1057 ward nurses' views of the omission of infection control activities using the Missed Nursing Care
1058 Infection Prevention and Control (MNCIPC) Survey. *J Nurs Manag*. 2021 Jul 1;29(5):1228–38.
- 1059 101. Schmidt JS, Kuster SP, Nigg A, Dazio V, Brillhante M, Rohrbach H, et al. Poor infection
1060 prevention and control standards are associated with environmental contamination with
1061 carbapenemase-producing Enterobacterales and other multidrug-resistant bacteria in Swiss
1062 companion animal clinics. *Antimicrob Resist Infect Control*. 2020 Jun 23;9(1):1–13.
- 1063 102. Gould D, Gallagher R, Allen D. Leadership and management for infection prevention and
1064 control: what do we have and what do we need? *Journal of Hospital Infection*. 2016;94(2):165–8.

- 1065 103. Murphy D. Antibiotic resistance in veterinary medicine. *Veterinary Nursing*
1066 *Journal*.2014;27(11):422–3.
- 1067 104. Smith JR, Packman ZR, Hofmeister EH. Multimodal evaluation of the effectiveness of a
1068 hand hygiene educational campaign at a small animal veterinary teaching hospital. *Journal of the*
1069 *American Veterinary Medical Association*. 2013 Oct 1;243(7):1042-8.
- 1070 105. Food and Agriculture Organization of the United Nations (FAO). *One Health*. 2021.
- 1071 106. World Organisation for Animal Health (OIE). *One Health*. 2020.
- 1072 107. American Veterinary Medical Association (AVMA). *One Health*. 2021.
- 1073 108. Centers for Disease Control and Prevention (CDC). *One Health Basics*. 2021.
- 1074 109. Ogunseitan OA. *One Health and the Environment: From Conceptual Framework to*
1075 *Implementation Science*. *Environment*. 2022;64(2):11–21.
- 1076 110. World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and
1077 Agriculture Organization of the United Nations (FAO). *A Tripartite Guide to Addressing Zoonotic*
1078 *Diseases in Countries Taking a Multisectoral, One Health Approach* [Internet]. 2019 [cited 2024
1079 Mar 9]. Available from: [https://iris.who.int/bitstream/handle/10665/325620/9789241514934-](https://iris.who.int/bitstream/handle/10665/325620/9789241514934-eng.pdf?sequence=1)
1080 [eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/325620/9789241514934-eng.pdf?sequence=1)
- 1081 111. Sebe N, Cohen I, Gevers T, Huang TS. Multimodal approaches for emotion recognition: a
1082 survey. *Internet Imaging VI 2005 Jan 17* (Vol. 5670, pp. 56-67). SPIE.
- 1083 112. Barton G, Ryan M. Multimodal approaches to reflective teaching and assessment in higher
1084 education. *Higher Education Research & Development*. 2014 May 4;33(3):409-24.
- 1085 113. Giuseppe Cabibbo, Federica Latteri MA& AC. Multimodal approaches to the
1086 treatment of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2009;159–69.
- 1087 114. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, Boyce JM.
1088 Evidence-based model for hand transmission during patient care and the role of improved
1089 practices. *The Lancet infectious diseases*. 2006 Oct 1;6(10):641-52.

1090 115. Mehtar S, Shisana O, Mosala T, Dunbar R. Infection control practices in public dental care
1091 services: findings from one South African Province. *Journal of Hospital Infection*. 2007;66(1):65–
1092 70.

1093

1094 **Chapter 3 Systematic Literature Review**

1095 **Hospital-acquired and zoonotic bacterial organisms and their associated**
1096 **antimicrobial-susceptibility profile in veterinary hospitals: A Systematic Review**

1097 **Dikeledi C. Sebola¹, James W. Oguttu², Marleen M. Kock^{3,4}, Daniel N. Qekwana¹**

1098 ¹Section Veterinary Public Health, Department of Paraclinical Sciences, Faculty of Veterinary
1099 Science, University of Pretoria, Pretoria, South Africa

1100 ²Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences,
1101 University of South Africa, Johannesburg, South Africa

1102 ³Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa

1103 ⁴Tshwane Academic Division, National Health Laboratory Service, Pretoria, South Africa

1104

1105

1106 This chapter is a manuscript that has been published in the journal *Frontiers of Veterinary Science*
1107 (2023) Available online at:

1108 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868922/pdf/fvets-09-1087052.pdf>

1109

1110 My contribution to the paper includes study design, data analysis, interpretation of results, writing
1111 of manuscript as well as extensive editing of the manuscript.

1112

1113 **Abstract**

1114 **Background:** Hospital-acquired infections (HAIs) are associated with increased mortality,
1115 morbidity, and an economic burden due to costs associated with extended hospital stays.
1116 Furthermore, most pathogens associated with HAIs in veterinary medicine are zoonotic. This study
1117 used published data to identify organisms associated with HAIs and zoonosis in veterinary medicine.
1118 Furthermore, the study also investigated the antimicrobial-susceptibility profile of these bacterial
1119 organisms.

1120 **Methods:** A systematic literature review was conducted in accordance with the Preferred
1121 Reporting Items for Systematic Reviews and Meta-analyses” (PRISMA) guidelines. Search terms
1122 and five electronic databases were used to identify studies published over 20 years (2000-2020).
1123 The risk of bias was assessed using the “Strengthening the Reporting of Observational Studies in
1124 Epidemiology-Vet” (STROBE-Vet) checklist.

1125 **Results:** Out of the identified 628 papers, 27 met the inclusion criteria for this study. Most
1126 studies (63%, 17/27) included were either from small animal or companion animals’ clinics/hospitals,
1127 while 5% (4/27) were from large animal clinics inclusive of bovine and equine medicine. Hospital-
1128 acquired bacteria were reported from environmental surfaces (33.3%), animal clinical cases (29.6%),
1129 and items such as cell phones, clippers, stethoscopes, and computers (14.8%). *Staphylococcus*
1130 species. was the most (63%; 17/27) reported organism, followed by *Escherichia coli* (19; 5/27),
1131 *Enterococcus* spp. (15%, 4/27), *Salmonella* spp. (15%; 4/27), *Acinetobacter baumannii* (15%, 4/27),
1132 *Clostridium difficile* (4%, 1/27), and *Pseudomonas aeruginosa* (4%; 1/27). Multidrug-resistant (MDR)
1133 organisms were reported in 71% (12/17) of studies linked to Methicillin-resistant *Staphylococcus*
1134 *aureus* (MRSA), Methicillin-resistant *Staphylococcus pseudintermedius* (MRSP), *Enterococcus* spp.,
1135 *Salmonella Typhimurium*, *A. baumannii*, and *E. coli*. The *mecA* gene was identified in both MRSA
1136 and MRSP, *bla*_{CMY-2} gene in *E. coli* and *Salmonella* spp., *flo* genes in *E.coli*, and *vanA* gene in *E.*
1137 *faecium* isolate. Six studies reported organisms from animals with similar clonal lineage to those
1138 reported in human isolates.

1139 **Conclusion:** Organisms associated with hospital-acquired infections and zoonosis have
1140 been reported from clinical cases, environmental surfaces, and items used during patient treatment
1141 and care. *Staphylococcus* species is the most reported organism in cases of HAIs and some isolates

1142 shared similar clonal lineage to those reported in humans. Some of the bacteria associated with
1143 HAIs exhibited a high level of resistance and contain genes associated with antibiotic resistance.
1144

1145 **3.1 Introduction**

1146 Hospital-acquired infections (HAIs) in both veterinary and human medicine are associated
1147 with increased mortality, morbidity, and are an economic burden due to the increased cost of
1148 extended hospital stay and treatment options (1,2). The most reported HAIs include surgical wounds,
1149 urinary tract, and gastrointestinal infections (1–3) and are often associated with bacteria such as
1150 *Enterococcus* species (spp.), *Escherichia coli*, *Staphylococcus* spp., *Enterobacter* spp., *Klebsiella*
1151 spp., *Acinetobacter* spp., and *Pseudomonas* spp.(3–6).

1152 Available evidence suggests that HAIs associated with *Enterococcus* spp., *Escherichia coli*,
1153 *K. pneumoniae*, and *S. aureus* are on the increase in veterinary medicine (7,8). There are also
1154 reports of vancomycin-resistant enterococci (VRE), multidrug-resistant (MDR) *E. coli*, carbapenem-
1155 resistant *Acinetobacter baumannii*, carbapenem-resistant *P. aeruginosa*, carbapenem-resistant and
1156 extended-spectrum β -lactamase (ESBL) producing *Enterobacteriaceae*,(3–6,9–11) with limited
1157 treatment options and poor prognosis (1,5,6,9,11). It is estimated that 60% of emerging infectious
1158 diseases are likely to come from animals (12,13). Of concern is that bacteria associated with HAIs
1159 in veterinary settings could be contributing to the emergence of these new diseases (6,14). Since
1160 the veterinary hospital environment is a human-animal interface, it remains a potential source of
1161 zoonotic pathogens (6,15). Therefore, veterinary healthcare workers (HCWs) and animal owners are
1162 at an increased risk of contracting various zoonotic infections (12,13). This is likely to put financial
1163 stress on the human health system especially in developing countries (16). In view of this, continuous
1164 surveillance of hospital-acquired and zoonotic pathogens in veterinary medicine should be done to
1165 better quantify the risk of transmission to personnel and animal owners (17,18).

1166 Systematic review studies have suggested that improving surveillance systems is critical in
1167 the prevention of HAIs and in reducing the emergence of antimicrobial-resistant pathogens (6,19).
1168 Therefore, a holistic approach is needed to investigate the types of disease agents, hosts, the
1169 antimicrobial-resistance profile of the organism, and the virulence of the organisms associated with
1170 HAIs in veterinary medicine (15).

1171 This study describes the occurrence and antimicrobial-susceptibility profiles of bacterial
1172 organisms associated with HAIs and zoonosis in veterinary medicine. It addresses the following

1173 research questions: (1) Which bacteria associated with HAIs and zoonotic diseases have been
1174 reported in veterinary hospitals? (2) What is the antimicrobial resistance profile of these bacteria?

1175 **3.2 Materials and methods**

1176 The systematic literature review was conducted using the Preferred Reporting Items for
1177 Systematic Reviews and Meta-analyses (PRISMA) guidelines (20). Keywords and synonyms used
1178 in various databases included hospital-acquired organism or infection, nosocomial organism or
1179 infection, animal to animal infections, zoonotic infection, zoonosis, animal to human infections,
1180 veterinary hospital, and veterinary clinic.

1181 *3.2.1 Information source*

1182 Search terms and electronic databases used in this study are provided in **Table 3.1**. Since
1183 each database has a different search function, alternate search terms appropriate for each database
1184 were used. Boolean operators were utilized in all searches. A data search was conducted between
1185 June 2020 and December 2020. A follow-up search was performed in January 2021, however, there
1186 were no additional studies considered based on the inclusion criteria. Mendeley reference manager
1187 was used to store all studies and documents retrieved

1188 **Table 3. 1:** Search terms and databases utilized to search for articles included in this review about
 1189 hospital-acquired and/or zoonotic infections in veterinary facilities between 2000 and 2020.

Publications	Search terms
Science Direct	Veterinary AND "Infection Control" AND "hospital acquired infection OR nosocomial" AND zoonoses OR zoonotic OR zoonosis "Veterinary hospital OR clinic" AND "hospital acquired infections" OR nosocomial AND zoonoses OR zoonotic OR zoonosis "Systematic literature review" AND "Hospital acquired infection OR nosocomial" AND "zoonoses OR zoonosis OR zoonotic" AND veterinary "Hospital acquired infection OR nosocomial" AND "zoonoses OR zoonosis OR zoonotic" AND veterinary Veterinary AND "hospital acquired infection OR nosocomial" "Veterinary hospital" AND "hospital acquired infection OR nosocomial" NOT "Human hospital"
PubMed	"Hospital acquired infections OR nosocomial" AND veterinary AND "zoonosis or zoonoses or zoonotic" "Infection prevention and control" [All Fields] AND veterinary AND "hospital acquired infection or nosocomial" AND zoonoses "Hospital acquired infections OR nosocomial" AND veterinary
Web of Science	"Hospital acquired infections" AND veterinary "Hospital acquired infections" AND "veterinary hospital" "Hospital acquired infections" AND "zoonotic infections" AND "Veterinary hospital"
Google Scholar	"Systematic literature review" AND "Hospital acquired infection OR nosocomial" AND "zoonoses OR zoonosis OR zoonotic" AND veterinary "Hospital acquired infection OR nosocomial" AND "zoonoses OR zoonosis OR zoonotic" AND veterinary "Hospital acquired infection OR nosocomial" AND "veterinary hospital"
Scopus	"Hospital acquired infection" AND zoonoses AND veterinary nosocomial AND zoonoses AND veterinary

1190 *3.2.2 Eligibility criteria*

1191 Only manuscripts published in peer-reviewed journals were considered for inclusion in this
 1192 study. Primary research articles written in English and published between 2000 and 2020 were
 1193 selected. The microbiological data included bacterial isolates from HAIs cases, hospital
 1194 environmental screening, fomites from veterinary hospitals, and zoonotic cases in veterinary
 1195 hospitals. In addition, the antimicrobial resistance profiles of the different bacteria were also

1196 extracted. The inclusion and exclusion criteria are listed in **Table 3.2**. Two investigators (DC, DN)
 1197 independently screened the titles and abstracts from the searches. Any disagreements were settled
 1198 by discussion.

1199 **Table 3. 2:** Inclusion and exclusion criteria of articles reporting on hospital-acquired and/or zoonotic
 1200 infections in veterinary facilities between 2000 and 2020.

Inclusion Criteria	Exclusion Criteria
Veterinary medicine studies	Human hospital studies
Small animal/ Companion animal	Farms, home studies
Equine/ Large animals	
Peer-reviewed research	Reviews
Year 2000- 2020	Policies, Government documents and conference reports, Book chapters
Studies in English	Non-English studies
Infection prevention and control practices (Environmental screening)	

1201 *3.2.3 Study selection*


1202 *3.2.3.1 Data collection process and data items*

1203 For each study that met the selection criteria for inclusion, the following data were extracted:
 1204 author, year, the theme of study (HAIs or zoonotic studies), and the antimicrobial resistance profile.

1205 **3.3 Results**

1206 *3.3.1 Study selection*

1207 A total of 628 studies were identified; 330 articles remained after the initial screening. Based
 1208 on the eligibility screening criteria, 48 studies remained and were further critically assessed. A total
 1209 of 27 studies met the inclusion criteria and were further analysed (**Figure 3.1**).



1210

1211 **Figure 3. 1:** Summary of study selection and exclusion using the preferred reporting items for
1212 systematic reviews and meta-analyses (PRISMA) guidelines.

1213

1214 *3.3.2 Risk of bias*

1215 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-Vet)
1216 statement is a 22-item tool that allows a systematic way of reporting on veterinary observational
1217 studies. The STROBE statement was developed to guide the reporting of observational studies
1218 related to human health. These methods have been adopted and used for standardised reporting
1219 guidelines for observational studies in veterinary medicine (19,21). Identified studies that met the
1220 inclusion criteria were cross-sectional and cohort studies (21). Each study was assessed individually
1221 according to each of the 22 items.

1222 Items were considered to have been reported sufficiently if the studies provided a detailed
1223 abstract and clear title (item one), background, and rationale (item two), stated the objectives (item
1224 three), presented key elements of the study design (item four), described the sample size (item 11),
1225 reported outcomes for the study (items 14&15), provided estimates and parameters (item 16),
1226 summarized key results regarding study objectives (item 18 &19), interpreted results (item 20),
1227 discussed the results (item 21), and stated the funding source as well as the role of authors as
1228 described by Sergeant et al (21).

1229 Only two studies (7%, 2/27) reported on all STROBE-Vet items (22,23). Based on STROBE-
1230 Vet, item 1 was partially attained by 19/27 (70%) studies as they excluded the study design and was
1231 fully attained by 8 (29%) studies. Items 6, 13,14, and 20 were fully attained by all the studies, Items
1232 2, 4, 5, and 16 were fully attained by 26 (96%) of the studies, items 3,15,17, and were fully attained
1233 by 25 (93%) of the studies, item 7 and 18 were fully attained by 24 (89%) of the studies, items 9 and
1234 19 were fully attained by 21 (78%) of the studies, items 11 and 21 were fully attained by 20 (74%)
1235 studies and item 10 was fully attained by 63% of the studies. Twelve (12; 44%) studies provided the
1236 funding sources, twelve (12; 44%) studies declared no conflict of interest, three studies (3; 11%)
1237 mentioned the contribution of each author, and three (3, 11%) provided ethical clearance
1238 declarations (**Annexures**).

1239 *3.3.3 Sources of data*

1240 All the studies reviewed were observational studies. More than half (18; 67%) of the reported
1241 studies were cross-sectional studies, three (11%) were case-controlled studies (reported following
1242 an outbreak), and six (22%) reported on retrospective data.

1243 Twenty-four (89%) studies focused on a specific bacterium, whereas the other three studies
1244 (11%) (15,24,25) reported generally on the bacteria associated with HAIs. Most studies (78%)
1245 (17,18,25–43) investigated the occurrence of HAIs in a single facility, five (19%) (3,15,22–24) studies
1246 investigated multiple facilities in an area, and one (4%) (44) study did not specify the area of study.

1247 Seventeen (17/27, 63%) studies were from either the small animal or companion animal
1248 clinics/hospitals (3,15,18,22–28,32,36–40,44). followed by both bovine (33,37,45,46) (4/27, 15%)
1249 and equine medicine (17,42,43). Three (3/27, 11%) studies were a combination of small animals,
1250 large animals, and poultry (30,31,35). One (1/27, 4 %) study did not identify the type of veterinary
1251 clinic or hospital (34).

1252 Within the hospital settings, bacteria associated with HAIs were reported from environmental
1253 surfaces (9/27; 33%) (15,18,31,34,35,37,39,40,43), animal cases (8/27; 30%)
1254 (3,17,23,26,28,30,38,43), and commonly used equipment such as clothing, cell phones, clippers,
1255 stethoscopes, and computers (4/27,15%,) (24,27,31,36). Only three studies (3/27, 11%) isolated
1256 bacteria from humans who have regular contact with animals (15,27,33).

1257 The antimicrobial resistance profile of the different organisms was provided in eighteen
1258 (17/27, 63%) studies (3,15,18,23,26,28–32,34,35,37,38,40,42,43), while nine (9/27, 33%) studies
1259 did not report on the antimicrobial resistance patterns (17,22,24,25,27,33,36,39,44). Thirteen studies
1260 (13/27, 48%) further characterized the microorganisms using pulsed-field gel electrophoresis
1261 (PFGE) and polymerase chain reaction (PCR) assays (3,17,18,23,26,28–30,32,35,41–43).

1262 3.3.4 Bacterial isolates associated with hospital-acquired infections

1263 *Staphylococcus* spp. Isolates were the most (17/27, 63%) reported pathogens associated
1264 with HAIs, followed by *Escherichia coli* (5/27; 19%), *Enterococcus* spp. (4/27; 15%), *Salmonella* spp.
1265 (4/27; 15%), *A. baumannii* (4/27; 15%), *C. difficile* (1/27; 4%), and *P. aeruginosa*. (1/27; 4%).
1266 *Enterococcus faecalis* (3/4; 75%) and *E. faecium* (3/4; 75%) were the most reported of the
1267 *Enterococcus* species.

1268 Among the *Staphylococcus* spp., 11 (11/17, 65%) were MRSA and six (6/17, 35%) were
1269 methicillin-resistant *S. pseudintermedius* (MRSP). Three out of five (3/5; 60%) studies reported MDR
1270 *E. coli* isolates and one (1/5; 20%) study reported an extended spectrum β -lactamase (ESBL)
1271 producing *E. coli*. Meanwhile, vancomycin-resistant *enterococci* were reported in one (1/4; 25%)
1272 study. *Salmonella* Typhimurium was reported as the common serotype in two of the four (2/4; 50%)
1273 studies. Two of the four (2/4; 50%) studies reported the presence of MDR *Salmonella* (**Table 3.3**).

1274 **Table 3. 3:** Organism reported in hospital-acquired and/or zoonotic infections in veterinary facilities
 1275 between 2000 and 2020.

Bacteria	Citation
<i>Staphylococcus</i> species	(3,15,17,18,22,24,25,27–29,31,32,35–37,39,40)
Methicillin-resistant <i>S. aureus</i>	(15,18,22,27,30–33,35,36,61)
Methicillin-resistant <i>S. pseudintermedius</i>	(15,22,27,36,39,40)
 <i>Clostridium difficile</i>	 (15)
<i>Enterococcus</i> species	(3,15,37,38)
<i>E. faecalis</i>	(3,37,38)
<i>E. faecium</i>	(3,37,38)
Vancomycin-resistant enterococci	(15)
 <i>Acinetobacter baumannii</i>	 (3,23,24,34)
<i>Escherichia coli</i>	(15,24,26,34,46)
Extended spectrum β -lactamase (ESBL)	(15)
Multidrug resistance <i>E. coli</i>	(15,26,34)
 <i>Salmonella</i> species	 (15,33,42,43)
Multidrug-resistant <i>Salmonella</i>	(42,43)
 <i>Pseudomonas aeruginosa</i>	 (37)

1276

1277 3.3.5 Sources of organisms associated with hospital-acquired infections

1278 The following pathogens were detected in the hospital environmental surfaces, namely
1279 MRSA (15,18,32,35), MRSP (37,39), ESBL-producing *E. coli* isolates (15), VRE (15), *A. baumannii*
1280 (34), *C. difficile* (15) and *P. aeruginosa* (37). Common pathogens identified from hospital equipment
1281 included: MRSA (17,27,31,36), MRSP (15,36,40), *Enterococcus faecalis* (37), and *A. baumannii*
1282 (24,27,34).

1283 Among patients in hospital settings, MRSA was isolated from companion (30) and equine
1284 animals (17,29). Multidrug resistant *Escherichia coli* was isolated from companion and bovine
1285 animals (26,46). Additionally, *Enterococcus faecium*, *Enterococcus faecalis* (3,42). and *A. baumannii*
1286 (3) were isolated from companion animals. *Salmonella* species were also isolated from patients
1287 (33,43), healthy animals (42), and the hospital environment (15,42) **(Table 3.4)**.

1288 The healthcare workers (HCWs) harboured MRSA (22,32,37), MRSP (27,37), *E. faecium*
1289 (37) and two studies reported MRSA among pet owners (22,29). In addition, van Duijkeren et al (30)
1290 and Hoet et al (18) reported on the zoonotic potential of MRSA with van Duijkeren et al (30)
1291 identifying MRSA clusters in animals with a similar clonal lineage to that reported in humans **(Table**
1292 **3.6)**.

1293 **Table 3. 4:** Sources of hospital acquired organisms based on the systematic reviewed papers published from 2000 to 2020.

Source	^a MRSA	^b MRSP	^c ESBL <i>E. coli</i>	^d MDR <i>Escherichia coli</i>	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i>	<i>C. Difficile</i>	<i>P. aeruginosa</i>	<i>A. baumannii</i>	<i>Salmonella spp.</i>
Animal Patients	(30)			(26)	(3)	(3)				(43)
	(29)			(46)	(38)	(38)			(3)	(33)
	(17)									
Healthy Environment										(42)
Hospital	(15)	(37)	(15)				(15)	(37)	(34)	(15)
	(18)	(39)								(42)
	(35)									
	(32)									
Equipment	(17)	(15)			(37)				(24)	
	(31)	(40)							(27)	
	(27)	(36)							(34)	
	(36)									
Healthcare workers	(37)	(37)				(37)				
	(49)	(27)								
	(22)									
Pet Owners	(22)									
	(22,29)									

 1294 ^aMethicillin-resistant *Staphylococcus aureus*

 1295 ^bMethicillin-resistant *Staphylococcus pseudintermedius*

 1296 ^cExtended-spectrum beta-lactamase producing- *E. coli*

 1297 ^dMultidrug-resistant *E. coli*

1298 3.3.6 *Antimicrobial resistance patterns of bacteria associated with hospital acquired*
1299 *infections*

1300 3.3.6.1 *Phenotypic resistance*

1301 Out of the 27 studies reviewed, 17 (63%) conducted an antimicrobial susceptibility test on
1302 the isolates. Among these, 12 (71%) studies reported isolates resistant to more than one
1303 antimicrobial. Bacteria resistant to multiple drugs identified included MRSA (18,29,35,41), MRSP
1304 (37), *A. baumannii* (23,34), *E. coli* (26,44), *Salmonella* Typhimurium (42,43), *E. faecalis* and *E.*
1305 *faecium* (38).

1306 Methicillin-resistant *Staphylococcus aureus* isolates showed resistance towards ampicillin,
1307 amoxicillin, oxacillin, clindamycin, gentamycin, ciprofloxacin, cephalixin, enrofloxacin, cefuroxime,
1308 chloramphenicol, erythromycin, and kanamycin while MRSP isolates showed resistance towards
1309 azithromycin, oxacillin, penicillin, clindamycin, gentamycin, tetracycline, and ciprofloxacin.
1310 *Clostridium difficile* showed resistance towards rifampin, moxifloxacin, and chloramphenicol.
1311 *Enterococcus faecalis* and *E. faecium* showed resistance towards ampicillin, tetracycline,
1312 ciprofloxacin, enrofloxacin, erythromycin, and rifampicin (38). *Enterococcus faecium* was also
1313 reported to be resistant to amoxicillin and vancomycin (37). *Acinetobacter baumannii* exhibited
1314 resistance to amoxicillin, tetracycline (34), ciprofloxacin (23) and imipenem (23). While *E. coli*
1315 showed resistance to ampicillin, cefoxitin, oxacillin, and penicillin (26,44) and *Salmonella* was
1316 resistant to ampicillin, amoxicillin, cefoxitin, gentamycin, tetracycline, chloramphenicol, rifampicin,
1317 and streptomycin (43) **(Table 3.5)**.

1318 **Table 3. 5:** Phenotypic antimicrobial resistance profile of hospital-acquired infection organisms based on the systematically reviewed papers published
 1319 from 2000 to 2020.

PATHOGENS	AMP	AMX	CEF	AZI	OXA	PEN	CLI	GEN	TET	CIP	VAN	CFL	ENF	CFR	CHL	ERY	KAN	RIF	MOX	CLO	CPH	IMI	STR	AMX-C	
Gram-positive bacteria																									
¹ MRSA	(30) (18) (35) (38)	(32) (30) (18) (35)	(33)	(37)	(37) (18) (35)	(37) (35)	(32) (18) (37)	(37) (30) (18)		(18) (32)		(30)	(18) (30)	(32)	(32)	(32) (30) (18) (46)	(32)								
² MRSP				(37)	(37)	(37)	(37)	(37)	(37)	(37)															
<i>E. faecium</i>	(38) (37)	(37)						(35)	(37)	(37)	(37)	(37)						(38)							
<i>E. faecalis</i>	(38)							(35)	(38)	(38)				(38)		(38)		(38)							
<i>C. difficile</i>																		(17)	(17)	(17)					
Gram-negative bacteria																									
<i>E. coli</i>	(44) (26)		(44) (26)		(44)	(44)																			(46) (28)
<i>A. baumannii</i>		(34)							(34)	(23)		(23)	(23)										(17)		(23)
<i>Salmonella spp.</i>	(42) (43)	(42)	(42)					(42) (43)	(42) (43)						(42) (43)			(42)			(42)			(42) (43)	(42) (43)

1320 AMP=Ampicillin, AMX=Amoxicillin, CEF=Cefoxitin, AMX-C=Amoxicillin-Clavulanic Acid, AZI= Azithromycin, OXA=Oxacillin, PEN=Penicillin, CLI=Clindamycin,
 1321 GEN=Gentamicin, TET=Tetracycline, CIP=Ciprofloxacin, VAN=Vancomycin, LIN=Linezolid, CFL=Cephalexin, ENF=Enrofloxacin, CFR=Cefuroxime,
 1322 CHL=Chloramphenicol, ERY=Erythromycin, KAN=Kanamycin, CHL=Chloramphenicol, STR=Streptomycin, RIF=Rifampin, IMI=Imipenem, MOX=Moxifloxacin,
 1323 CLO=Clarithromycin, IMI= Imipenem STR= Streptomycin

1324 ¹MRSA=Methicillin-resistant *Staphylococcus aureus*

1325 ²MRSP=Methicillin-resistant *Staphylococcus pseudintermedius*

1326 3.3.6.2 *Antimicrobial genes*

1327 Among *Staphylococcus* species, *mecA* was reported in five MRSA studies(18,30,31,35,45)
 1328 (33,118–121) and two MRSP studies (37,40). β -lactamase gene (*bla*_{CMY-2} gene) was reported in
 1329 *Salmonella* spp. (43) and *E. coli* isolates (15,26,44). While the vancomycin-resistant gene (*vanA*
 1330 gene) was reported by one *E. faecium* study (37). The *flo* gene was identified in one *E. coli* study
 1331 (26) (**Table 3.6**).

1332 **Table 3. 6:** The antimicrobial resistant genes isolated from bacteria associated with hospital-
 1333 acquired infection bacteria, published data between 2000 and 2020.

Pathogens	<i>mecA</i>	<i>bla</i> _{CMY-2}	<i>flo</i>	<i>vanA</i>
¹ MRSA	(27) (31) (35) (30) (45)			
² MRSP	(37)(40)			
<i>E. coli</i>		(15) (44) (26)	(26)	
<i>E. faecium</i>				(37)
<i>Salmonella</i> spp.		(43)		

1334 ^aMethicillin-resistant *Staphylococcus aureus*

1335 ^bMethicillin-resistant *Staphylococcus pseudintermedius*

1336 3.3.7 *Zoonosis*

1337 Six (22%) studies (18,29,30,35,41,46) reported HAI associated organisms that are zoonotic
 1338 in nature. For example, MRSA with a SCC*mec* type IV isolated in humans(23) has also been isolated
 1339 in hospitalized horses (41) and hospitalized dogs (35). Similarly, three studies reported clonal MRSA
 1340 lineage in animals similar to that previously reported in humans (29,30,35). A plasmid DH108/30218
 1341 in *E. coli* isolates in animals has also been identified which is similar to a cassette (18-ESBL 188)
 1342 reported in humans (46)

1343 **3.4 Discussion**

1344 Hospital-acquired infections and zoonosis are increasingly becoming a global concern (47).
 1345 In addition, there is an increasing prevalence of resistance among these organisms to commonly
 1346 used antimicrobials. Most studies that have investigated HAIs and their antimicrobial resistance
 1347 profiles are in human medicine. In view of this, studies on the occurrence and resistant profile of
 1348 organisms associated with hospital-acquired and zoonotic infections in veterinary medicine are
 1349 needed. In this study, bacterial organisms associated with hospital-acquired and zoonotic infections

1350 isolated were identified. Furthermore, most of the organisms identified were multidrug-resistant or
1351 harboured resistant genes. Several sources of bacterial organisms associated with HAIs including
1352 HCWs, commonly used instruments, equipment, and contaminated hospital environments were also
1353 identified.

1354 Bacteria associated with HAIs identified MRSA, MRSP, *Enterococcus* spp., *A. baumannii*, *P.*
1355 *aeruginosa*, *C. difficile*, *E. coli*, and *Salmonella* spp., (3,15,18,24,25). The presence of these bacterial
1356 pathogens within veterinary settings is a public health concern and emphasises the need for the
1357 implementation of infection prevention and control measures to eliminate these pathogens. The
1358 patient flora, healthcare workers, commonly used equipment, and the hospital environment were
1359 identified as possible sources of organisms associated with HAIs. Therefore, control measures being
1360 implemented should be source-specific and moment-specific during patient care (48).

1361 3.4.1 Sources of organisms associated with hospital acquired infection

1362 Identification of sources of organisms associated with HAIs in veterinary settings is critical to
1363 reducing the risk of transmission to patients and humans. Therefore, it is not surprising that most
1364 studies have largely focused on the hospital environment and commonly used instruments as
1365 potential reservoirs for organisms associated with HAIs (24,27,34,36,39). Furthermore, there are
1366 ongoing epidemiological studies to understand the relationship between environmental cleanliness
1367 and the risk of transmission of HAIs in veterinary settings (4).

1368 The intensive care unit (ICU), surgical ward, in-house laboratory, and consultation rooms
1369 were the most important environmental sources of bacteria associated with HAIs in veterinary
1370 hospitals (15,18,25,31,37). Furthermore, environmental surfaces with human contact tend to have
1371 higher contamination levels compared to those without human contact (15,18,35,37). Suggesting
1372 that humans may play a major role in the transmission of these organisms within the hospital
1373 environment. This is further emphasised by studies that have isolated similar pathogens strains from
1374 the environment and hands of HCWs (23,43,47). Therefore, HCWs in veterinary hospitals must be
1375 trained on hand hygiene compliance to reduce the risk of transmission of HAI organisms.

1376 Inanimate objects served as sources of HAI organisms and facilitated transmission between
1377 animal patients, the hospital environment, and humans (27). Inanimate objects such as clippers,

1378 personnel clothing (27,34), cell phones (36), stethoscopes (34), and weighing scales (34) were
1379 reported to be contaminated with bacteria associated with HAIs. Therefore, the development and
1380 implementation of cleaning and disinfection protocols to prevent transmission is needed (2). In
1381 addition, all surgical material, instruments, and other fomites which increase the possibility of
1382 transmission of these organisms must be sterilised before use (31).

1383 3.4.2 *Bacterial isolates associated with hospital-acquired infections*

1384 3.4.2.1 *Methicillin-resistant Staphylococcus aureus (MRSA)*

1385 Methicillin-resistant *Staphylococcus aureus* was among the most common organism
1386 associated with HAIs in this study (25,32). Furthermore, strains similar to those reported in humans
1387 were reported in this study (17,22,41). For example, Loeffler et al (22) in the UK identified MRSA
1388 clones (CC22 and CC30) among humans working with or in close proximity to animals suggesting
1389 transmission between animals and humans is precise (32). Studies also show that an unhygienic
1390 environment is a major source of MRSA (18,35,39) and implementing effective infection prevention
1391 and control (25,31,32,35,40,49) and screening animals before hospitalisation will reduce the spread
1392 of MRSA in veterinary hospitals. This is likely to reduce costs associated with increased length of
1393 hospital stay (17,18,22,31,41).

1394 Most MRSA isolates in this study were resistant to β -lactam, 2nd generation cephalosporins,
1395 lincosamides, and aminoglycosides. While one study reported intermediate sensitivity to vancomycin
1396 among MRSA isolates (31). The presence of vancomycin resistance is concerning as it is the last
1397 resort for the treatment of MRSA in humans. Similarly, the presence of β -lactam resistance among
1398 staphylococci facilitated by the *mecA* gene (18,30–32,35,45) is likely to contribute to resistance to
1399 other antimicrobials with a β -lactam ring (35,37,40,41). Therefore, the implementation and constant
1400 review of infection control protocols are needed to help reduce the risk of the transfer of resistance
1401 genes to other organisms (40,50–52). Without these interventions, patient care and treatment will
1402 likely be negatively impacted (31,35).

1403 3.4.2.2 *Methicillin-resistant Staphylococcus pseudintermedius (MRSP)*

1404 Methicillin-resistant *Staphylococcus pseudintermedius* like MRSA has emerged as a leading
1405 cause of opportunistic infections in companion animals (27,37). The organism has been reported in

1406 asymptomatic animals, implant-associated surgical sites (36), inanimate objects (27,36,40), and in
1407 the environment within the veterinary hospital (39). Therefore, colonized, and contaminated areas
1408 remain potential sources of hospital-acquired infections (27).

1409 Of concern is that MRSP is highly resistant to antimicrobials commonly used for the treatment
1410 of *S. pseudintermedius* infections (53–55). These organisms have been isolated from the
1411 environment and hands of HCWs (37), which is concerning as it limits treatment options. Similar to
1412 MRSA, MRSP can acquire the *mecA* gene (37). Shoen *et al* (40) showed coagulase positive *S.*
1413 *pseudintermedius* commonly isolated from the skin of dogs can acquire the *mecA* gene from a
1414 coagulase-negative *S. epidermidis* commonly found in humans.

1415 The zoonotic cases associated with MRSP are not common (27). However, an MRSA spa
1416 type 18/t338 from animal-related fomites has been reported in humans (36). The rise in the number
1417 of MRSP cases between dogs, pet owners, and veterinary staff is concerning, therefore, effective
1418 hand hygiene should be performed before and after contact with the patient, as well as after contact
1419 with potentially contaminated environmental sites within veterinary hospitals.

1420 3.4.2.3 *Enterococcus species*

1421 *Enterococcus* species are commensal of the gut flora of cats and dogs (3,38). However, they
1422 are also opportunistic pathogens (3). In recent years, *Enterococcus* species have emerged as
1423 causes of HAIs in veterinary medicine associated with urinary tract infections (UTIs) (56). The
1424 transmission is mainly due to faecal contaminated inanimate objects or environmental surfaces (24).
1425 These organisms can survive in a hospital environment for a long period. Furthermore, they can
1426 survive high temperatures and disinfectants such as chlorine and alcohol (37).

1427 *Enterococcus faecium* and *E. faecalis* are the most predominant species reported in dogs
1428 (38), hospital environments and in hands of HCWs (37). Of the two species, *E. faecalis* is the
1429 predominant enterococci. Multidrug-resistant enterococci have also been reported as a commensal
1430 and pathogenic organism (3,37,38). The presence of MDR among *Enterococcus* species has largely
1431 been attributed to overuse and misuse of antimicrobials (37,38). It is also possible that some may
1432 have acquired resistance through other mechanisms including genetic transfer or mutation (38). For
1433 example, resistance to erythromycin has been associated with the methylation of the ribosomal

1434 target site of these antibiotics (37,57). Nonetheless, the presence of MDR enterococci is likely to
1435 impact patient care in veterinary hospitals (37).

1436 Of concern is the emergence of vancomycin-resistant *E. faecium* (37) which is an important
1437 antimicrobial in the treatment of enterococci infections (38,57) and is mediated by the presence of
1438 *vanA* genes. These genes are important as they confer multidrug resistance and may be transmitted
1439 to other bacterial species such as *Staphylococcus* spp. and create even bigger problems in the
1440 treatment of HAIs (37). Furthermore, these gene carrying bacteria can also be transferred from
1441 animals to humans (3,38).

1442 3.4.2.4 *Clostridium difficile*

1443 *Clostridium difficile* is found in the hospital environmental and it is difficult to eradicate (15).
1444 Both humans and animals are asymptotically carriers of the organism. In humans, its presence
1445 has been attributed to the overuse of antimicrobials. However, in veterinary medicine there is limited
1446 information about the organism. Therefore, future studies should look at whether the overuse of
1447 antimicrobials could be a driver of *C. difficile* in veterinary settings (15). The ability of the pathogen
1448 to survive harsh environmental conditions and resistance to most disinfectants makes it a suitable
1449 indicator of the effective IPC measures (15). Therefore, it is possible that this organism can also be
1450 used as an indicator of effective infection prevention and control in veterinary hospitals.

1451 3.4.2.5 *Acinetobacter baumannii*

1452 *Acinetobacter baumannii* causes life-threatening infections in both humans and animals. This
1453 organism has been reported in UTIs, pyothorax, upper airway obstruction, bloodstream infection,
1454 and wound infections in animals (34). In infected animals, it is associated with increased morbidity
1455 and prolonged length of hospital stay (58). *Acinetobacter baumannii* survives on dry surfaces
1456 (24,34,59). Therefore, commonly used equipment, bed rails, cages, and examination tables could
1457 serve as reservoirs for *A. baumannii*. Most *A. baumannii* are multiple drug resistant with a high
1458 prevalence of resistance towards cephalosporins, enrofloxacin, amoxicillin-clavulanic acid,
1459 sulphamethoxazole-trimethoprim, and tetracycline (34). Resistance to the above antimicrobials is
1460 concerning as these antimicrobials are commonly used for the treatment of bacterial infections in

1461 small animal medicine (58). In addition, the *bla*OXA-51 gene reported in an *A. baumannii* isolate
1462 from pigs has also been reported in humans (57).

1463 3.4.2.6 *Escherichia coli*

1464 *Escherichia coli* is commonly reported in UTIs and bloodstream infections (15,26,34,60). The
1465 bacterium spreads from patient to patient via faecal contaminated hands of HCWs and shared
1466 equipment (26). Given, environmental surfaces could potentially be a reservoir of *E. coli*, measures
1467 to minimise faecal contamination in companion animal hospitals including cleaning and disinfection
1468 of the hospital environment should be implemented. Moreover, Sanchez et al (26) shows the transfer
1469 of *E. coli* isolates with similar antimicrobial resistance patterns between two different animals
1470 admitted to the same ICU.

1471 In the current study, *E. coli* isolates exhibited resistance towards cephalosporins and β -
1472 lactams including amoxicillin-clavulanic acid. This broad-spectrum antimicrobial resistance among
1473 *E. coli* is attributed to the presence of *ampC* like gene, *bla*_{CMY2} (15,26), which has been identified to
1474 be of public health concern (15). Another study reported resistance among *E. coli* isolates to
1475 chloramphenicol mainly due to the presence of *cmIA* homologue *flo* among gram-negative bacteria
1476 (26). The presence of these genes has also been linked to the development of resistance to other
1477 commonly used antibiotics such as gentamycin, spectinomycin, and sulfadimethoxine (26,34,46).
1478 Considering this resistance, strict guidelines should be implemented on the prudent use of
1479 antimicrobials in veterinary medicine in South Africa.

1480 3.4.2.7 *Salmonella* species

1481 Although most animals are asymptomatic carriers of *Salmonella* spp., they shed the
1482 bacterium in high quantities through their faeces (43). Asymptomatic animals have been linked to
1483 *Salmonella* outbreaks in equine veterinary medicine (42,43). Furthermore, infections associated with
1484 *Salmonella* species have also been reported in bovine and companion animals (36,42). In affected
1485 animals, the disease is characterized by high morbidity and mortality. Furthermore, the potential
1486 spread and zoonotic infection in veterinary hospitals often result in the closure of facilities with a loss
1487 of income for the hospital (33,42). Managing transmission in the veterinary settings remains a
1488 challenge as *Salmonella* can persist in the environment for a long time. In addition, personnel

1489 working in close contact with infected animals (42). Rodents and contaminated feed could also be a
1490 source (42,43). Therefore, biosecurity measures must be intensified in veterinary hospitals to reduce
1491 the risk of transmission. Additionally, education programs can also be developed targeting specific
1492 aspects of hygiene, movement control, and cleanliness of equipment.

1493 *Salmonella* isolates were resistant to ceftiofur, gentamycin, amoxicillin, ampicillin,
1494 streptomycin, and trimethoprim/ sulfadiazine (42,43). One study reported the presence of the
1495 cephalomycinase gene, *bla_{cmy-2}* (43) which has been associated with cephalosporin resistance
1496 among *Salmonella* species. This gene has also been reported to mediate resistance to amoxicillin,
1497 amoxicillin-clavulanic acid, cephalothin, cefoxitin, ceftiofur, and ceftriaxone (43).

1498 **3.5 Conclusion**

1499 Organisms associated with hospital-acquired and zoonotic diseases were reported from
1500 clinical cases, environmental surfaces, and items used in veterinary service. The hospital
1501 environment with human contact was the most reported source of organisms associated with HAIs.
1502 These results suggest that humans play a crucial role in the transmission of bacteria associated with
1503 HAIs in veterinary hospitals.

1504 Among the organisms reported, MRSA *and* MRSP were the most reported HAI organisms in
1505 veterinary facilities. Other organisms identified include *E. coli*, *C. difficile*, *A. baumannii*, *Salmonella*
1506 spp., and *Enterococcus* species. Some of these isolates reported in veterinary settings share similar
1507 clonal lineage to those reported in humans. Some organisms exhibit a high prevalence of
1508 antimicrobial resistance and contain genes known to be associated with antibiotic resistance.

1509 These results suggest that strict infection prevention and control practices must be in place,
1510 monitored and modified when necessary to curb the occurrence and transmission of organisms
1511 associated with HAIs in veterinary hospitals. In addition, continuous surveillance of HAI organisms
1512 and their antimicrobial resistance patterns in veterinary hospitals should be emphasized. Further
1513 research needs to be done on *C. difficile* as a potential indicator of effective infection prevention and
1514 control practices in veterinary facilities.

1515

1516 **3.6 References**

- 1517 1. Eggimann P, Pittet D. Infection control in the ICU. *Chest*. 2001 Dec 1;120(6):2059-93.
- 1518 2. Traverse M, Aceto H. Environmental cleaning and disinfection. *Veterinary Clinics: small*
1519 *animal practice*. 2015 Mar 1;45(2):299-330.
- 1520 3. Boerlin P, Eugster S, Gaschen F, Straub R, Schawalder P. Transmission of opportunistic
1521 pathogens in a veterinary teaching hospital. *Veterinary Microbiology*. 2001 Oct 1;82(4):347-59.
- 1522 4. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection.
1523 *Journal of hospital Infection*. 2009 Dec 1;73(4):378-85.
- 1524 5. Stull JW, Weese JS. Hospital-associated infections in small animal practice. *Veterinary*
1525 *Clinics: Small Animal Practice*. 2015 Mar 1;45(2):217-33.
- 1526 6. Walther B, Tedin K, Lübke-Becker A. Multidrug-resistant opportunistic pathogens challenging
1527 veterinary infection control. *Veterinary microbiology*. 2017 Feb 1;200:71-8.
- 1528 7. Guardabassi L. Veterinary hospital-acquired infections: the challenge of MRSA and other
1529 multidrug-resistant bacterial infections in veterinary medicine. *Veterinary Journal (London, England:*
1530 *1997)*. 2012 Jun 29;193(2):307-8.
- 1531 8. van der Kolk JH, Endimiani A, Graubner C, Gerber V, Perreten V. *Acinetobacter* in veterinary
1532 medicine, with an emphasis on *Acinetobacter baumannii*. *J Glob Antimicrob Resist* (2019) 16:59–
1533 71. doi: 10.1016/j.jgar.2018.08.011
- 1534 9. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of
1535 ESKAPE pathogens in Kwazulu-Natal, South Africa: a five-year retrospective analysis. *African*
1536 *journal of laboratory medicine*. 2018 Jun 1;7(2):1-8.
- 1537 10. Stull JW, Weese JS. Infection control in veterinary small animal practice. *Veterinary Clinics:*
1538 *Small Animal Practice*. 2015 Mar 1;45(2):xi-i.
- 1539 11. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat
1540 ESKAPE pathogens in the era of antimicrobial resistance: a review. *Frontiers in microbiology*. 2019
1541 Apr 1;10:539.

- 1542 12. Mazet JA, Clifford DL, Coppolillo PB, Deolalikar AB, Erickson JD, Kazwala RR. A “one health”
1543 approach to address emerging zoonoses: the HALI project in Tanzania. PLoS medicine. 2009 Dec
1544 15;6(12):e1000190.
- 1545 13. Day MJ, Breitschwerdt E, Cleaveland S, Karkare U, Khanna C, Kirpensteijn J, Kuiken T,
1546 Lappin MR, McQuiston J, Mumford E, Myers T. Surveillance of zoonotic infectious disease
1547 transmitted by small companion animals. Emerging Infectious Diseases. 2012 Dec;18(12):e1.
- 1548 14. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence.
1549 Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 2001 Jul
1550 29;356(1411):983-9.
- 1551 15. Murphy CP, Reid-Smith RJ, Boerlin P, Weese JS, Prescott JF, Janecko N, Hassard L,
1552 McEwen SA. Escherichia coli and selected veterinary and zoonotic pathogens isolated from
1553 environmental sites in companion animal veterinary hospitals in southern Ontario. The Canadian
1554 veterinary journal. 2010 Sep;51(9):963.
- 1555 16. Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S, Ramos-Jimenez
1556 P, Gotuzzo E, Kar K, Sanchez A, Garba A. Zoonoses and marginalised infectious diseases of
1557 poverty: where do we stand?. Parasites & vectors. 2011 Dec;4:1-6.
- 1558 17. Weese JS, Rousseau J, Willey BM, Archambault M, McGeer A, Low DE. Methicillin-resistant
1559 *Staphylococcus aureus* in horses at a veterinary teaching hospital: frequency, characterization, and
1560 association with clinical disease. Journal of Veterinary Internal Medicine. 2006 Jan;20(1):182-6.
- 1561 18. Hoet AE, Johnson A, Nava-Hoet RC, Bateman S, Hillier A, Dyce J, Gebreyes WA, Wittum
1562 TE. Environmental methicillin-resistant *Staphylococcus aureus* in a veterinary teaching hospital
1563 during a nonoutbreak period. Vector-borne and zoonotic diseases. 2011 Jun 1;11(6):609-15.
- 1564 19. Willemsen A, Cobbold R, Gibson J, Wilks K, Lawler S, Reid S. Infection control practices
1565 employed within small animal veterinary practices—A systematic review. Zoonoses and public
1566 health. 2019 Aug;66(5):439-57.
- 1567 20. Kitchenham B. Procedures for performing systematic reviews. Keele, UK, Keele University.
1568 2004 Jul;33(2004):1-26.

- 1569 21. Sargeant JM, O'Connor AM, Dohoo IR, Erb HN, Cevallos M, Egger M, Ersbøll AK, Martin
1570 SW, Nielsen LR, Pearl DL, Pfeiffer DU. Methods and processes of developing the strengthening the
1571 reporting of observational studies in epidemiology– veterinary (STROBE-Vet) statement. Preventive
1572 veterinary medicine. 2016 Nov 1;134:188-96.
- 1573 22. Loeffler A, Pfeiffer DU, Lloyd DH, Smith H, Soares-Magalhaes R, Lindsay JA. Methicillin-
1574 resistant *Staphylococcus aureus* carriage in UK veterinary staff and owners of infected pets: new
1575 risk groups. Journal of Hospital Infection. 2010 Mar 1;74(3):282-8.
- 1576 23. Pailhoriès H, Belmonte O, Kempf M, Lemarié C, Cuziat J, Quinqueneau C, Ramont C, Joly-
1577 Guillou ML, Eveillard M. Diversity of *Acinetobacter baumannii* strains isolated in humans, companion
1578 animals, and the environment in Reunion Island: an exploratory study. International Journal of
1579 Infectious Diseases. 2015 Aug 1;37:64-9.
- 1580 24. Mount R, Schick AE, Lewis TP, Newton HM. Evaluation of bacterial contamination of clipper
1581 blades in small animal private practice. Journal of the American Animal Hospital Association. 2016
1582 Mar 1;52(2):95-101.
- 1583 25. Aksoy E, Boag A, Brodbelt D, Grierson J. Evaluation of surface contamination with
1584 staphylococci in a veterinary hospital using a quantitative microbiological method. Journal of Small
1585 Animal Practice. 2010 Nov;51(11):574-80.
- 1586 26. Sanchez S, McCrackin Stevenson MA, Hudson CR, Maier M, Buffington T, Dam Q, Maurer
1587 JJ. Characterization of multidrug-resistant *Escherichia coli* isolates associated with nosocomial
1588 infections in dogs. Journal of Clinical Microbiology. 2002 Oct;40(10):3586-95.
- 1589 27. Singh A, Walker M, Rousseau J, Monteith GJ, Weese JS. Methicillin-resistant staphylococcal
1590 contamination of clothing worn by personnel in a veterinary teaching hospital. Veterinary surgery.
1591 2013 Aug;42(6):643-8.
- 1592 28. Bagcigil FA, Moodley A, Baptiste KE, Jensen VF, Guardabassi L. Occurrence, species
1593 distribution, antimicrobial resistance and clonality of methicillin-and erythromycin-resistant
1594 staphylococci in the nasal cavity of domestic animals. Veterinary microbiology. 2007 Apr 15;121(3-
1595 4):307-15.

- 1596 29. Weese JS, Caldwell F, Willey BM, Kreiswirth BN, McGeer A, Rousseau J, Low DE. An
1597 outbreak of methicillin-resistant *Staphylococcus aureus* skin infections resulting from horse to human
1598 transmission in a veterinary hospital. *Veterinary microbiology*. 2006 Apr 16;114(1-2):160-4.
- 1599 30. Van Duijkeren E, Box AT, Heck ME, Wannet WJ, Fluit AC. Methicillin-resistant *Staphylococci*
1600 isolated from animals. *Veterinary microbiology*. 2004 Oct 5;103(1-2):91-7.
- 1601 31. Stella AE, Lima TF, Moreira CN, De Paula E. Characterization of *Staphylococcus aureus*
1602 Strains Isolated from Veterinary Hospital. *International Journal of Microbiology*. 2020 Aug 1;2020.
- 1603 32. Heller J, Armstrong SK, Girvan EK, Reid SW, Moodley A, Mellor DJ. Prevalence and
1604 distribution of methicillin-resistant *Staphylococcus aureus* within the environment and staff of a
1605 university veterinary clinic. *Journal of Small Animal Practice*. 2009 Apr;50(4):168-73.
- 1606 33. Cummings KJ, Divers TJ, McDonough PL, Switt AM, Wiedmann M, Warnick LD. Temporal
1607 clusters of bovine Salmonella cases at a veterinary medical teaching hospital, 1996–2007. *Vector-*
1608 *Borne and Zoonotic Diseases*. 2010 Jun 1;10(5):471-9.
- 1609 34. Ng S, Abdul Aziz S, Bejo SK, Dhaliwal GK. Occurrence of multidrug resistant *Acinetobacter*
1610 *baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *Jurnal*
1611 *Veterinar Malaysia*. 2016;28(2):12-6.
- 1612 35. Rojas I, Barquero-Calvo E, van Balen JC, Rojas N, Munoz-Vargas L, Hoet AE. High
1613 prevalence of multidrug-resistant community-acquired methicillin-resistant *Staphylococcus aureus*
1614 at the largest veterinary teaching hospital in Costa Rica. *Vector-Borne and Zoonotic Diseases*. 2017
1615 Sep 1;17(9):645-53.
- 1616 36. Julian T, Singh A, Rousseau J, Weese JS. Methicillin-resistant staphylococcal contamination
1617 of cellular phones of personnel in a veterinary teaching hospital. *BMC research notes*. 2012
1618 Dec;5(1):1-5.
- 1619 37. Oh YI, Baek JY, Kim SH, Kang BJ, Youn HY. Antimicrobial susceptibility and distribution of
1620 multidrug-resistant organisms isolated from environmental surfaces and hands of healthcare
1621 workers in a small animal hospital. *Japanese Journal of Veterinary Research*. 2018 Aug;66(3):193-
1622 202.

- 1623 38. Ossiprandi MC, Bottarelli E, Cattabiani F, Bianchi E. Susceptibility to vancomycin and other
1624 antibiotics of 165 *Enterococcus* strains isolated from dogs in Italy. *Comparative immunology,*
1625 *microbiology and infectious diseases.* 2008 Jan 1;31(1):1-9.
- 1626 39. Lutz EA, Hoet AE, Pennell M, Stevenson K, Buckley TJ. Nonoutbreak-related airborne
1627 *Staphylococcus* spp in a veterinary hospital. *American journal of infection control.* 2013 Jul
1628 1;41(7):648-51.
- 1629 40. Shoen HR, Rose SJ, Ramsey SA, de Morais H, Bermudez LE. Analysis of *Staphylococcus*
1630 infections in a veterinary teaching hospital from 2012 to 2015. *Comparative immunology,*
1631 *microbiology and infectious diseases.* 2019 Oct 1;66:101332.
- 1632 41. Van den Eede A, Martens A, Lipinska U, Struelens M, Deplano A, Denis O, Haesebrouck F,
1633 Gasthuys F, Hermans K. High occurrence of methicillin-resistant *Staphylococcus aureus* ST398 in
1634 equine nasal samples. *Veterinary microbiology.* 2009 Jan 1;133(1-2):138-44.
- 1635 42. Soza-Ossandón P, Rivera D, Tardone R, Riquelme-Neira R, García P, Hamilton-West C,
1636 Adell AD, González-Rocha G, Moreno-Switt AI. Widespread environmental presence of multidrug-
1637 resistant *Salmonella* in an equine veterinary hospital that received local and international horses.
1638 *Frontiers in Veterinary Science.* 2020:346.
- 1639 43. Ward MP, Brady TH, Couëtil LL, Liljebjelke K, Maurer JJ, Wu CC. Investigation and control
1640 of an outbreak of salmonellosis caused by multidrug-resistant *Salmonella typhimurium* in a
1641 population of hospitalized horses. *Veterinary microbiology.* 2005 May 20;107(3-4):233-40.
- 1642 44. Sidjabat HE, Chin JJ, Chapman T, Wu K, Ulett GC, Ong CY, Schembri MA, Johnson JR,
1643 Trott DJ. Colonisation dynamics and virulence of two clonal groups of multidrug-resistant *Escherichia*
1644 *coli* isolated from dogs. *Microbes and Infection.* 2009 Jan 1;11(1):100-7.
- 1645 45. Moon JS, Lee AR, Kang HM, Lee ES, Kim MN, Paik YH, Park YH, Joo YS, Koo HC.
1646 Phenotypic and genetic antibiogram of methicillin-resistant *Staphylococci* isolated from bovine
1647 mastitis in Korea. *Journal of dairy science.* 2007 Mar 1;90(3):1176-85.
- 1648 46. Mulvey MR, Susky E, McCracken M, Morck DW, Read RR. Similar cefoxitin-resistance
1649 plasmids circulating in *Escherichia coli* from human and animal sources. *Veterinary microbiology.*
1650 2009 Mar 2;134(3-4):279-87.

- 1651 47. Milton AA, Priya GB, Aravind M, Parthasarathy S, Saminathan M, Jeeva K, Agarwal RK.
1652 Nosocomial infections and their surveillance in veterinary hospitals. *Adv. Anim. Vet. Sci.*
1653 2015;3(2s):1-24.
- 1654 48. Sebola DC, Boucher C, Maslo C, Qekwana DN. Hand hygiene compliance in the intensive
1655 care unit of the Onderstepoort Veterinary Academic Hospital. [Preprint] 2019 [Accessed 2024 April
1656 10]. Available from: <https://doi.org/10.21203/rs.2.17130/v1>
- 1657 49. Heller J, Innocent GT, Denwood M, Reid SW, Kelly L, Mellor DJ. Assessing the probability of
1658 acquisition of methicillin-resistant *Staphylococcus aureus* (MRSA) in a dog using a nested stochastic
1659 simulation model and logistic regression sensitivity analysis. *Preventive Veterinary Medicine.* 2011
1660 May 1;99(2-4):211-24.
- 1661 50. Gortel K, Campbell KL, Kakoma I, Whitem T, Schaeffer DJ, Weisiger RM. Methicillin
1662 resistance among *Staphylococci* isolated from dogs. *American Journal of Veterinary Research.* 1999
1663 Dec 1;60(12):1526-30.
- 1664 51. Soedarmanto I, Kanbar T, Ülbegi-Mohyla H, Hijazin M, Alber J, Lämmeler C, Akineden Ö,
1665 Weiss R, Moritz A, Zschöck M. Genetic relatedness of methicillin-resistant *Staphylococcus*
1666 *pseudintermedius* (MRSP) isolated from a dog and the dog owner. *Research in veterinary science.*
1667 2011 Dec 1;91(3):e25-7.
- 1668 52. Gagetti P, Wattam AR, Giacoboni G, De Paulis A, Bertona E, Corso A, Rosato AE.
1669 Identification and molecular epidemiology of methicillin resistant *Staphylococcus pseudintermedius*
1670 strains isolated from canine clinical samples in Argentina. *BMC veterinary research.* 2019
1671 Dec;15(1):1-2.
- 1672 53. Marsilio F, Di Francesco CE, Di Martino B. Coagulase-positive and coagulase-negative
1673 *Staphylococci* animal diseases. In *Pet-To-Man Travelling Staphylococci* 2018 Jan 1 (pp. 43-50).
1674 Academic Press.
- 1675 54. Gillaspay AF, Iandolo JJ. *Staphylococcus*. *Encycl Microbiol* (2009)293–303.
- 1676 55. Brooks MR, Padilla-Vélez L, Khan TA, Qureshi AA, Pieper JB, Maddox CW, Alam MT.
1677 Prophage-mediated disruption of genetic competence in *Staphylococcus pseudintermedius*.
1678 *Msystems.* 2020 Feb 18;5(1):10-128.

- 1679 56. Comerlato CB, Resende MC, Caierão J, d'Azevedo PA. Presence of virulence factors in
1680 *Enterococcus faecalis* and *Enterococcus faecium* susceptible and resistant to vancomycin.
1681 Memórias do Instituto Oswaldo Cruz. 2013;108:590-5.
- 1682 57. Argudín MA, Deplano A, Meghraoui A, Dodémont M, Heinrichs A, Denis O, Nonhoff C, Roisin
1683 S. Bacteria from animals as a pool of antimicrobial resistance genes. *Antibiotics*. 2017 Jun 6;6(2):12.
- 1684 58. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology,
1685 antimicrobial resistance, and treatment options. *Clinical infectious diseases*. 2008 Apr
1686 15;46(8):1254-63.
- 1687 59. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of *Acinetobacter*
1688 *baumannii* in health care facilities. *Clinical infectious diseases*. 2006 Mar 1;42(5):692-9.
- 1689 60. Manges AR. *Escherichia coli* and urinary tract infections: the role of poultry-meat. *Clinical*
1690 *Microbiology and Infection*. 2016 Feb 1;22(2):122-9.
- 1691 61. Weese JS, Dick H, Willey BM, McGeer A, Kreiswirth BN, Innis B, Low DE. Suspected
1692 transmission of methicillin-resistant *Staphylococcus aureus* between domestic pets and humans in
1693 veterinary clinics and in the household. *Veterinary microbiology*. 2006 Jun 15;115(1-3):148-55.
- 1694

1695 Chapter 4

1696 **Antimicrobial resistance patterns of *Acinetobacter baumannii* and *Klebsiella***
1697 ***pneumoniae* isolated from dogs presented at a veterinary academic hospital in**
1698 **South Africa**

1699 **Dikeledi C. Sebola¹, James W. Oguttu², Marleen M. Kock^{3,4}, Daniel N. Qekwana¹**

1700 ¹Section Veterinary Public Health, Department of Paraclinical Sciences, Faculty of Veterinary
1701 Science, University of Pretoria, Pretoria, South Africa

1702 ²Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences,
1703 University of South Africa, Johannesburg, South Africa

1704 ³Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa

1705 ⁴Tshwane Academic Division, National Health Laboratory Service, Pretoria, South Africa

1706

1707

1708 This chapter is a manuscript that has been published in the journal Veterinary World (2023)

1709 [Available online: <https://www.veterinaryworld.org/Vol.16/September-2023/14.html>]

1710

1711 My contribution to the paper includes study design, data analysis, interpretation of results, writing
1712 of manuscript as well as extensive editing of the manuscript.

Abstract

Background: *Acinetobacter baumannii* and *Klebsiella pneumoniae* are opportunistic bacterial pathogens responsible for hospital-acquired infections (HAIs) in veterinary medicine. Infection with these bacteria always requires urgent antimicrobial therapy. However, there is no evidence of studies that have investigated the antimicrobial drug resistance profile of these organisms in a veterinary setting in South Africa. This study investigated the antimicrobial resistance patterns of *A. baumannii* and *K. pneumoniae* from clinical specimens obtained from dogs presented at a veterinary academic hospital. The findings of the present study contribute to an improved understanding of the antimicrobial resistance profile of these bacteria in veterinary medicine.

Methods: Retrospective data of clinical samples from dogs that were positive for *A. baumannii* and *K. pneumoniae* between 2007 and 2013 were used in this study. Antimicrobial susceptibility for the isolates was determined using the disk diffusion method following the Clinical and Laboratory Standards Institute guidelines (CLSI). The *A. baumannii* isolates were subjected to a panel of 20 antibiotics, while *K. pneumoniae* isolates were subjected to a panel of 22 antibiotics. Data were analysed using descriptive statistics and presented using tables and figures.

Results: Twenty (n=20) *A. baumannii* isolates were isolated from bronchoalveolar lavage, foreign objects, bone, urine, skin, blood, ear, nasal, and oral cavity. Almost all *A. baumannii* (95%, 19/20) isolates were resistant to at least one antibiotic, and 60% (12/20) were multidrug-resistant (MDR). *Klebsiella pneumoniae* (n=56) was isolated from urine, foreign objects, abscesses, ears, eyes, tracheal aspirations, bronchoalveolar lavages, eyes, abdominal aspirates, anal glands, bones, intestinal and lung biopsies. All *K. pneumoniae* (100%, 56/56) isolates were resistant to at least one antibiotic, and 98% (55/56) were MDR.

Conclusion: Both *A. baumannii* and *K. pneumoniae* were isolated in various clinical tissue samples and exhibited a high prevalence of resistance to multiple antibiotics. In addition, these bacteria

1737 exhibited a high prevalence of resistance to β -lactam compared to other classes of antibiotics, which is
1738 likely to impact treatment options and patient prognosis.

1739 4.1 Introduction

1740 *Acinetobacter baumannii* and *klebsiella pneumoniae* belong to the group of bacteria termed
1741 'ESKAPE' pathogens, and they are responsible for outbreaks in clinical settings across the globe (1).
1742 This ESKAPE group of bacteria is known to escape the biocidal action of antimicrobials and is
1743 associated with increased mortality and healthcare costs in both human and animal medicine (1). In
1744 addition, these bacterial species are among the pathogens for which urgent antimicrobial therapy is
1745 required due to their tendency to exhibit a high prevalence of multidrug resistance (MDR) (1,2).

1746 *Acinetobacter baumannii* is an opportunistic pathogen that usually affects immunocompromised
1747 patients (3). It is a non-motile, aerobic, oxidase-negative, non-fermentative coccobacilli gram-negative
1748 bacterium (4). It is ubiquitous and has been isolated from drinking water, food, and soil (4,5).
1749 *Acinetobacter baumannii* can form biofilms that enable it to survive for long periods on dry surfaces and
1750 medical devices in the ICU. As a result, surfaces of inanimate objects in hospitals can be a source of
1751 infection for patients (4,6). In humans, *A. baumannii* has been isolated from clinical infections such as
1752 pneumonia, bloodstream infections, skin and soft tissue infections, urinary tract infections (UTIs), and
1753 meningitis, while it has been isolated in dogs from UTIs, bloodstream infections, and wound infections
1754 (4,5). *Acinetobacter baumannii* associated with hospital-acquired infections (HAIs) has been shown to
1755 be multidrug-resistant (MDR) and with a high prevalence of resistance to the β -lactam and
1756 cephalosporin groups of antibiotics (4). Among the reasons for the high prevalence of resistance to
1757 these groups is the intrinsic resistance associated with the interplay between the outer membrane
1758 providing protection, active efflux pump systems, and the low-quantity expression of small-aperture
1759 outer membrane porins (6). *Klebsiella pneumoniae* is a facultative, anaerobic gram-negative bacterium
1760 belonging to the *Enterobacteriaceae* family. It is an intestinal commensal; however, it has been reported
1761 in gastrointestinal (GIT) diseases, UTIs, pneumonia, bacteraemia, pyogenic liver abscesses, and burn

1762 and wound infections in both humans and animals (6,7). Together with *Escherichia coli*, these bacteria
1763 are among the most prevalent organisms in hospital and community settings (6,8). *Klebsiella*
1764 *pneumoniae* is an opportunistic pathogen in young, old, and immunocompromised humans (6). It is an
1765 important cause of hospital-acquired wound infections and UTIs in humans (7). In animals, the
1766 bacterium has been reported in clinical mastitis, pneumonia, septicaemia, bacteraemia, UTIs, and
1767 polyarthritis (7). *Klebsiella pneumoniae* exhibits a high prevalence of resistance to multiple antibiotics
1768 (6,7,9). It acquires and disseminates resistant genes, including those encoding for the extended
1769 spectrum β -lactamases (ESBLs), resulting in resistance to β -lactam antibiotics, including penicillin,
1770 cephalosporins, and the monobactam aztreonam (6,9), therefore, limiting treatment options (8,9).

1771 In South Africa, studies of ESKAPE pathogens have been well-documented in human medicine
1772 (2,10,11). However, studies investigating antimicrobial drug resistance among the ESKAPE group of
1773 pathogens in veterinary medicine are limited. This study investigated the antimicrobial resistance
1774 patterns of *K. pneumoniae* and *A. baumannii* isolated from clinical samples of dogs presented at a
1775 veterinary teaching hospital. The findings of this study will contribute to a better understanding of
1776 antibiotic resistance among *K. pneumoniae* and *A. baumannii* isolates of veterinary origin. In addition, it
1777 is envisaged that information generated from this study will be used to guide the treatment of *K.*
1778 *pneumoniae* and *A. baumannii* infections and improve treatment outcomes in a veterinary setting (6).

1779 **4.2 Materials and methods**

1780 *4.2.1 Study area*

1781 This study was conducted at a veterinary academic hospital in Pretoria, South Africa. The
1782 hospital provides clinical services for companion, livestock, and wildlife animals. In addition, the hospital
1783 serves as a referral for internal medicine and surgical cases for clients in and around Pretoria. The
1784 bacteriology laboratory in the Department of Veterinary Tropical Diseases that cultured the isolates
1785 provides a service to the veterinary academic hospital for routine clinical diagnosis of suspected
1786 infectious diseases.

1787 *4.2.2 Data source*

1788 Retrospective data records of dog clinical samples were submitted to the bacteriology laboratory
1789 between January 2007 and December 2013. For each isolate, the following information was extracted
1790 from the paper records: the patient's unique number, specimen type, date of sample collection, organ
1791 system, and antimicrobial susceptibility test results of the isolates. The data were then entered and
1792 stored in an electronic database for analysis.

1793 *Bacterial isolates and antimicrobial susceptibility testing*

1794 All the submitted clinical samples were cultured to isolate *A. baumannii* and *K. pneumoniae* using
1795 standard bacteriological methods described by Ricketts et al. (12). Antimicrobial susceptibility testing
1796 was performed using the disk diffusion method following the Clinical and Laboratory Standards Institute
1797 (CLSI) (13) guidelines to conduct antimicrobial susceptibility testing.

1798 *Acinetobacter baumannii* isolates were subjected to a panel of 20 antibiotics: amikacin (30 µg),
1799 ampicillin (10µg), carbenicillin (100µg), ceftazidime (30µg), cephalothin (30µg), chloramphenicol (30µg),
1800 enrofloxacin (5µg), gentamicin (10µg), imipenem (10µg), kanamycin (30µg), lincomycin (10µg),
1801 lincomycin-spectinomycin (100µg), orbifloxacin (5µg), oxytetracycline (30µg), penicillin-G (10µg),
1802 piperacillin (100µg), trimethoprim-sulphamethoxazole (25µg), amoxicillin/clavulanic acid (20/10µg),
1803 tobramycin (10µg), and tylosin (15µg) (Oxoid Ltd., Cambridge, UK).

1804 *Klebsiella pneumoniae* isolates were subjected to a panel of 22 antibiotics: amikacin (30µg),
1805 ampicillin (10µg), carbenicillin (100µg), ceftazidime (30µg), cephalothin (30µg), chloramphenicol (30µg),
1806 enrofloxacin (5µg), erythromycin (15µg), gentamicin (1µg), imipenem (10µg), kanamycin (30µg),
1807 lincomycin (10µg), lincomycin-spectinomycin (100µg), orbifloxacin (5µg), oxytetracycline (3µg),
1808 penicillin G (10µg), piperacillin (100µg), rifampin (30µg), trimethoprim-sulphamethoxazole (25µg),
1809 amoxicillin/clavulanic acid (20/10µg), tobramycin (10µg), and tylosin (15µg) (Oxoid Ltd., Cambridge,
1810 UK).

1811 The results of the antibiograms were classified as intermediate, susceptible, or resistant,
1812 following the CLSI guidelines (13). For the purposes of this study, resistance to at least one antibiotic
1813 was classified as AMR. Multidrug resistance was defined as resistance to at least one antibiotic in three
1814 or more antibiotics categories (14).

1815 Antimicrobials to which the bacteria have an inherent resistance were excluded from MDR
1816 analysis. For example, *Klebsiella pneumoniae* is known to be inherently resistant to ampicillin,
1817 carbenicillin, and erythromycin. Therefore, these groups of antibiotics were excluded from the MDR
1818 analysis. Since *A. baumannii* is inherently resistant to penicillins and lincosamides, these two groups
1819 were excluded from the analysis to determine the prevalence of MDR. In addition, antibiotics were
1820 excluded from the MDR analysis if all isolates were not tested to determine their susceptibility to these
1821 antibiotics. Based on this, imipenem, tobramycin, rifamycin, and ceftazidime were excluded from the
1822 analysis to determine MDR isolates for *K. pneumoniae*, and imipenem, tobramycin, and ceftazidime
1823 were excluded from the analysis to determine MDR isolates for *A. baumannii*.

1824 4.2.3 Data management and analysis

1825 The dataset was assessed for duplicates and missing information, such as the lack of
1826 antibiogram results. Some isolates had missing information, but there were no duplicates in the dataset.
1827 Isolates from specimens such as endotracheal (ET) tubes, screws, pins, wires, catheter tips, nails, and
1828 plates were classified as “foreign objects”, while specimens such as lung, liver, spleen, lymph node,

1829 heart, and kidney were reclassified as “organ pool”. Crude percentages of isolates of *A. baumannii* and
1830 *K. pneumoniae* that were AMR and MDR were computed and presented as figures and tables. All
1831 statistical analyses were performed using the Statistical Analysis System (SAS).


1832 4.2.4 Ethical consideration

1833 Written consent granting the academic teaching hospital permission to use information obtained
1834 from dogs presented at the hospital for teaching and research purposes was obtained from the owners
1835 of the dogs. In addition, this study followed all ethical standards for research without direct contact with
1836 human or animal subjects. Ethical clearance was also obtained from the University of Pretoria’s Faculty
1837 of Veterinary Science Research Ethics Committee, Faculty of Humanities Research Ethics Committee
1838 (Project number: REC009-21) and Faculty of Health Sciences Research Ethics Committee (Reference
1839 No: 187/2022).

1840 4.3 Results

1841 4.3.1 *Acinetobacter baumannii*

1842 A total of 20 *A. baumannii* were isolated over the study period with six (n=6; 30%) from
1843 bronchoalveolar lavage and three (n=3; 15%) from foreign objects. *Acinetobacter baumannii* was also
1844 isolated from various samples/tissues such as bone, urine, skin, blood, ear, nasal, and oral cavity
1845 (**Figure 4.1**).



1846

1847 **Figure 4. 1:** Distribution of *Acinetobacter baumannii* in the various dog clinical samples tested by the
1848 Bacteriology Laboratory that services that Veterinary Academic Teaching Hospital, 2007 - 2013.

1849 4.3.1.1 *Antimicrobial resistance and multidrug resistance*

1850 Nineteen isolates were resistant to at least one antibiotic (95%, 19/20) with the majority of *A.*
1851 *baumannii* isolates showing resistance to penicillin-G (85%) and ampicillin (65%). Forty-five per cent
1852 (45%, 9/20) of the isolates were resistant to amoxicillin/clavulanic acid. All five isolates (100%) tested
1853 were resistant to carbenicillin, piperacillin, and ceftazidime. A high prevalence of resistance was
1854 recorded towards lincomycin (95%), tylosin (68%), chloramphenicol (60%), lincomycin-spectinomycin
1855 (60%), and cephalexin (60%). A low prevalence of resistance among the *A. baumannii* was reported for
1856 aminoglycosides, except for tobramycin. Similarly, low resistance was observed against
1857 fluoroquinolones, tetracycline, and potentiated sulfonamides. One out of four (1/4, 25%) isolates was
1858 resistant to imipenem (**Table 4.1**).

1859 Sixty percent (60%, 12/20) of *A. baumannii* isolates were MDR. A high proportion of isolates
1860 exhibited resistance to cephalothin (92%), followed by chloramphenicol, trimethoprim-
1861 sulphamethoxazole, enrofloxacin, amoxicillin/clavulanic acid, and kanamycin, to which 75% of the

1862 isolates were resistant (**Table 4.1**). Three (n=3) MDR-A. *baumannii* isolates were resistant to 10
 1863 antimicrobials, two (n=2) to nine antimicrobials, and one (n=1) to 8 antimicrobials (**Table 4.2**).

1864 **Table 4. 1:** Antimicrobial resistance and multidrug resistance profile of *Acinetobacter baumannii*
 1865 isolated from dog clinical samples tested at a veterinary academic hospital, South Africa.

Antimicrobial category	Resistant	
	Isolates %(n)	MDR isolates %(n)
Macrolides		
Tylosine	68 (13/19)	-
β- lactams		
Penicillins		
Ampicillin	65 (13/20)	-
Carbenicillin	100 (5/5)	-
Penicillin-G	85 (17/20)	-
Piperacillin	100 (5/5)	-
Cephalosporins		
Ceftazidime	100 (5/5)	-
Cephalothin/lexin	60 (12/20)	92 (11/12)
Combination		
amoxicillin/clavulanic acid	45 (9/20)	75 (9/12)
Carbapenem		
Imipenem	25 (1/4)	-
Aminoglycosides		
Amikacin	30 (6/20)	50 (6/12)
Gentamicin	20 (4/20)	33 (4/12)
Kanamycin	47 (9/19)	75 (9/12)
Tobramycin	80 (4/5)	-
Lincosamides		
Lincomycin	95 (19/20)	-
lincomycin-spectinomycin	60 (12/20)	-
Potentiated sulfas		
trimethoprim-sulphamethoxazole	45 (9/20)	75 (9/12)
Fluoroquinolones		
Orbifloxacin	40 (8/20)	67 (8/12)
Enrofloxacin	45 (9/20)	75 (9/12)
Tetracycline		
Oxytetracycline	35 (7/20)	50 (6/12)
Amphenicols		
Chloramphenicol	60 (9/15)	75 (9/12)

1866


1867 **Table 4. 2:** Antibiotics resistance patterns of *Acinetobacter baumannii* isolated from dog clinical
 1868 samples presented in a veterinary academic hospital in South Africa.

Patterns	Number
AMI_CEP_CHL_OXY_ENR_GEN_KAN_ORB_SUL_SYN	3
AMI_CEP_CHL_OXY_ENR_KAN_ORB_SUL_SYN	2
CEP_CHL_SYN	2
CEP_CHL_ENR_GEN_KAN_ORB_SUL_SYN	1
CEP_OXY_ENR_ORB_SUL_SYN	1
CEP_CHL_ENR_KAN_ORB_SUL	1
AMI_CEP_KAN	1
ENR_KAN_SUL	1
Total	12

1869 AMI=Amikacin, CEP= Cephalothin/lexin, CHL=Chloramphenicol, OXY= Oxytetracycline,
 1870 ENR=Enrofloxacin, GEN=Gentamicin, KAN=Kanamycin, ORB=Orbifloxacin, SUL= trimethoprim-
 1871 sulphamethoxazole SYN=Synulox

1872 *4.3.2 Klebsiella pneumonia*

1873 A total of 56 *Klebsiella pneumoniae* isolates were recorded. Of these, 39% (22/56) were isolated
 1874 from urine samples, followed by 9% (5/56) from foreign objects. Very low proportions were isolated from
 1875 abscesses, ears, eyes, transtracheal aspirations, bronchoalveolar lavage, abdominal aspirates, anal
 1876 glands, bones, intestinal, and lung biopsies (**Figure 4.2**).



1877

1878 **Figure 4. 2:** Distribution of *Klebsiella pneumoniae* in the various dog clinical samples tested by the
1879 bacteriology laboratory at the faculty of veterinary science between 2007 and 2013.

1880 4.3.2.1 *Antimicrobial resistance and multidrug resistance*

1881 All the *K. pneumoniae* isolates were resistant to penicillin-G, ampicillin, carbenicillin, piperacillin,
1882 ceftazidime, and lincomycin. Sixty-four percent (35/56) of the isolates were resistant to cephalexin and
1883 60% to amoxicillin/clavulanic acid. None of the isolates tested were resistant to imipenem. *Klebsiella*
1884 *pneumoniae* exhibited a high prevalence of resistance to antibiotics belonging to aminoglycosides,
1885 tobramycin (88%), and kanamycin (63%). Ninety-four percent (94%) of the isolates were resistant to
1886 tylosin and 70% to oxytetracycline. One (n=1) *K. pneumoniae* isolate tested showed resistance to both
1887 erythromycin and rifampin. Ninety-eight percent (98%) of resistant *K. pneumoniae* isolates were MDR,
1888 with most being resistant to penicillin-G (100%), and tylosin tartrate (93%) (**Table 4.3**). The most
1889 common resistance pattern among the MDR *K. pneumoniae* isolates included the combination of
1890 licomycin - penicillin-G – tylosin (**Table 4.4**).

1891 **Table 4. 3:** Antimicrobial resistance and multidrug resistance profile of *Klebsiella pneumoniae* isolated
 1892 from dog clinical samples tested at a veterinary academic hospital, South Africa.

Antimicrobial category	Resistant	
	Isolates %(n)	MDR isolates %(n)
Macrolides		
Erythromycin	100 (1/1)	-
Tylosine	94 (51/54)	93 (51/55)
β - lactams		
Penicillins		
Ampicillin	100 (56/56)	-
Carbenicillin	100 (7/7)	-
Penicillin G	100 (56/56)	100 (55/55)
Piperacillin	100 (8/8)	-
Cephalosporins		
Ceftazidime	100 (8/8)	-
Cephalothin/lexin	64 (35/55)	64 (35/55)
Combination		
amoxicillin/clavulanic acid	60 (33/55)	60 (33/55)
Carbapenem		
Imipenem	0 (0/8)	-
Aminoglycosides		
Amikacin	48 (27/56)	49 (27/55)
Gentamicin	41 (23/56)	42 (23/55)
Kanamycin	63 (33/52)	60 (33/55)
Tobramycin	88 (7/8)	-
Lincosamides		
Lincomycin	100 (54/54)	-
lincomycin-spectinomycin	72 (38/53)	
Rifamycin		
Rifampin	100 (1/1)	-
Potentiated-sulfas		
trimethoprim-sulphamethoxazole	36 (20/56)	36 (20/55)
Fluoroquinolones		
Enrofloxacin	39 (22/56)	38 (21/55)
Orbifloxacin	49 (26/53)	47 (26/55)
Amphenicols		
Chloramphenicol	41 (19/46)	35 (19/55)
Tetracycline		
Oxytetracycline	70 (39/56)	71 (39/55)

1893

1894

1895 **Table 4. 4:** Antibiotics resistance patterns of *Klebsiella pneumoniae* isolated from dog clinical samples
 1896 presented in a veterinary academic hospital in South Africa.

PATTERN	Number
LIN_PNG_TYL	7
AMI_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SYN_TYL	3
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	2
AMI_CEF_CEP_CHL_OXY_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	2
AMI_CEF_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	2
AMI_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	2
AMI_CEP_OXY_GEN_KAN_LIN_LCS_PNG_SYN_TYL	2
CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
OXY_LIN_LCS_PNG_SUL_TYL	1
LIN_LCS_PNG_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
OXY_LIN_PNG_SYN_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_TYL	1
AMI_CEP_CHL_OXY_GEN_KAN_LIN_PNG_SYN_TYL	1
AMI_CEP_OXY_GEN_KAN_LIN_LCS_ORB_PNG	1
AMI_CEP_CHL_OXY_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
CEP_CHL_OXY_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
OXY_LIN_LCS_PNG_TYL	1
CEP_ENR_KAN_LIN_ORB_PNG_SYN_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TOB_TYL	1
CEP_OXY_ENR_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
CEP_CHL_OXY_ENR_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
CEP_OXY_LIN_LCS_PNG_TYL	1
ENR_LIN_PNG_TYL	1
CEP_KAN_LIN_LCS_PNG_SUL_TYL	1
AMI_CEP_OXY_LIN_LCS_PNG_SUL_TYL	1
CEP_OXY_LIN_LCS_PNG_SUL_SYN_TYL	1
AMI_CEP_PNG_TYL	1
CEP_OXY_LIN_PNG_SYN_TYL	1
AMI_CHL_OXY_ENR_GEN_LIN_PNG_SUL_TYL	1
KAN_LIN_LCS_PNG_SYN_TYL	1
AMI_OXY_KAN_LIN_LCS_PNG_TYL	1
LIN_PNG_SYN	1
AMI_CEF_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	1
OXY_KAN_LIN_LCS_PNG_TYL	1
AMI_CEF_CEP_KAN_LIN_LCS_ORB_PNG_PIP_SYN_TYL	1
OXY_LIN_LCS_PNG_SYN_TYL	1
AMI_CEP_CHL_OXY_KAN_LIN_ORB_PNG_SYN_TYL	1
OXY_LIN_PNG	1

AMK_GEN_KAN_LIN_LNC_PNG	1
CEF_CEP_CHL_OXY_ENR_ERT_GEN_KAN_LIN_LCS_ORB_PNG_PIP_RIF_SUL_SYN_TOB_T YL	1
CEF_CEP_CHL_OXY_ENR_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	1
Total	55

1897 AMI=Amikacin, CEF= Ceftazidime, CEP= Cephalothin/lexin, CHL=Chloramphenicol,
1898 OXY=Oxytetracycline, Enr=Enrofloxacin, ERT= Erythromycin, GEN= Gentamicin, KAN=Kanamycin,
1899 LIN= Lincomycin, LCS= Lincospectin, ORB=Orbifloxacin, PNG= Penicillin-G, PIP-Piperacin,
1900 RIF=Rifampin, SUL= Trimethoprim-sulphamethoxazole , SYN=Synulox, TOB= Tobramycin, TYL=
1901 Tylosine Tartrate

1902 **4.4 Discussion**

1903 This study investigated the antimicrobial resistance patterns of *A. baumannii* and *K.*
1904 *pneumoniae* isolated from dog cases presented at a veterinary hospital in South Africa. Similar to
1905 findings reported by other studies, *A. baumannii* and *K. pneumoniae* were isolated in various clinical
1906 samples. This confirms past research findings that reported these organisms as associated with
1907 various clinical infections in dogs (5,7,15–18). Even more concerning is that these organisms have
1908 been associated with HAIs can disseminate resistance genes to other bacteria (19,20). Cleaning
1909 and disinfection of the environment have proven effective in reducing the burden of these organisms
1910 in the environment (21). However, these organisms can persist in a dry environment and continue
1911 to be a source of infection to susceptible patients (15,21,22). Therefore, careful monitoring of dogs
1912 admitted to the veterinary hospital through routine surveillance is important to prevent the
1913 transmission of these pathogens between patients.

1914 *4.4.1 Antibiotic resistance patterns of Acinetobacter baumannii*

1915 Antibiotic resistance among *A. baumannii* isolates is increasing and is associated with
1916 increased morbidity, mortality, and treatment costs in the intensive care unit (ICU) (23). In this study,
1917 a high prevalence of resistance among *A. baumannii* to β -lactam antimicrobials, including penicillin,
1918 cephalosporins, and amoxicillin/clavulanic acids, was observed. This is concerning as these
1919 antimicrobials are commonly used in small animal practices to treat uncomplicated infections (4).
1920 The high prevalence of resistance observed in this study is consistent with that reported in veterinary
1921 studies done in the United States of America (24), Switzerland (25), and Malaysia (4). This is
1922 attributed to the wide array of antimicrobial-inactivating enzymes, including β -lactamases, that confer
1923 resistance to the β -lactam groups of antimicrobials (19,25,26) and the overexpression of the
1924 chromosomally encoded *AmpC* cephalosporinases conferring resistance to broad-spectrum
1925 cephalosporins (26,27).

1926 A low prevalence of resistance to imipenem among *A. baumannii* has been reported in a
1927 study by Pailhories (15). In the present study, only one (1/4) isolate was resistant to imipenem.

1928 However, a larger sample size is needed to determine the carbapenem susceptibility profile of *A.*
1929 *baumannii*, considering it is the treatment of choice in humans (5).

1930 *Acinetobacter baumannii* was resistant to trimethoprim-sulphamethoxazole, which is
1931 consistent with findings in other studies (28,29). This could be due to the overproduction or alteration
1932 in plasmid-mediated dihydrofolate reductase associated with trimethoprim resistance (30). Although
1933 *A. baumannii* exhibited resistance to trimethoprim-sulphamethoxazole, evidence suggests that it
1934 should be considered for uncomplicated infections (29,31,32).

1935 Resistance to aminoglycosides among *A. baumannii* was generally not common in this study,
1936 with the exception of tobramycin. This was expected given that resistance to tobramycin among *A.*
1937 *baumannii* increased (33,34), mainly associated with the synthesis of aminoglycoside-modifying
1938 enzymes (AME) and efflux pump systems (33,35). This finding has significant public health
1939 implications, given that aminoglycosides are commonly used to treat *A. baumannii* infections. In view
1940 of this, trends in the susceptibility of these organisms should be monitored (26,33).

1941 Fluoroquinolones are generally used to treat *A. baumannii* infections in small animals (4). In
1942 this study, a low prevalence of resistance to fluoroquinolones was observed. These organisms'
1943 resistance to fluoroquinolones could be due to the overuse of the antibiotics and is mediated by the
1944 efflux-mediated quinolones resistance (27,36–38). Therefore, care is needed to prevent misuse and
1945 overuse of fluoroquinolones to curb the development of resistance (39,40). A low prevalence of
1946 resistance to oxytetracycline was also observed in this study. This is encouraging because of the
1947 potential use of tetracyclines as monotherapy or in combination with other antimicrobials for the
1948 treatment of *A. baumannii* infections (28,41,42).

1949 Forty-five percent (n=5; 45%) of *A. baumannii* isolates were MDR. However, a higher
1950 prevalence of *A. baumannii* (83.3%, 5/6) from environmental samples exhibiting MDR was reported
1951 by Ng et al (4) in a study conducted in Malaysia. The high prevalence of MDR-*A. baumannii* is not
1952 uncommon (43). Given this, available evidence suggests that the choices for treatment of MDR *A.*
1953 *baumannii* infections may include carbapenems, colistin and combination antimicrobials
1954 (4,26,33,44).

1955 4.4.2 Antibiotic resistance patterns of *Klebsiella pneumoniae*

1956 Similar to the findings by Haenni et al (45) in France and Lee et al (21) in South Korea, most
1957 *K. pneumoniae* isolates in this study were resistant to β -lactam antimicrobials. The β -lactam
1958 resistance among *K. pneumoniae* isolates is attributed to the production of the plasmid-mediated
1959 sulfhydryl variable (SHV-1) a penicillinase (9,18,45–47). On the other hand, none of the *K.*
1960 *pneumoniae* isolates in this study exhibited resistance to carbapenems. This is consistent with the
1961 findings by Haenni et al (45) in the study conducted in France. These findings suggest that
1962 carbapenem could be considered as part of the treatment option for *K. pneumoniae* (47,48).

1963 The prevalence of resistance to aminoglycosides varied in this study. For example, low
1964 resistance was observed to amikacin and gentamycin (49,50), while high resistance was observed
1965 to tobramycin and kanamycin. The varying prevalence of resistance among aminoglycosides could
1966 be attributed to the different mechanisms of resistance. For example, resistance to amikacin and
1967 gentamycin is associated with the presence of aminoglycoside modifying enzymes (AME) and/or
1968 16S ribosomal RNA methyltransferase (16S-RMTases) (3,49,51), whereas tobramycin resistance
1969 has been associated with the presence of AAC (6')-Ib(-like) protein and not AME or 16S-RMTase
1970 genes (52). Despite the nephrotoxicity of aminoglycosides (53), this group of antimicrobials have
1971 been used effectively in the treatment of *K. pneumoniae* infections in both human and veterinary
1972 medicine (3).

1973 Consistent with findings from both human and animal studies (17,18,47), resistance to
1974 enrofloxacin and orbifloxacin among *K. pneumoniae* isolates was low in this study. Similar to other
1975 studies, resistance to trimethoprim-sulphamethoxazole was observed in this study (18,37). The low
1976 resistance in this study is encouraging, as trimethoprim-sulphamethoxazole is the drug of choice in
1977 the treatment of UTIs (18,54). In addition, trimethoprim-sulphamethoxazole is effective in the
1978 treatment of patients with carbapenemase-producing *K. pneumoniae* infections (55).

1979 Almost all *K. pneumoniae* isolates in this study were MDR. This is not unusual, as
1980 antimicrobial resistance genes are frequently observed in this organism (18). What is of concern is
1981 that the role of companion animals as reservoirs for human infections associated with resistant *K.*

1982 *pneumoniae* is not well described in the literature. Therefore, further studies are needed to
1983 investigate the transmission of resistant genes between humans and animals.

1984 **4.5 Limitations**

1985 The data used for the study was limited to one veterinary hospital and did not include other
1986 veterinary medical facilities. Since the hospital that provided the data is a referral hospital, it is
1987 possible that most isolates may have had previous exposure to antibiotics.

1988 **4.6 Conclusion**

1989 *Acinetobacter baumannii* and *K. pneumoniae* were identified from various clinical samples
1990 suggesting that they are important causes of infections in dogs and can infect various body systems.
1991 Both organisms exhibited a high prevalence of resistance to multiple antimicrobials. This has serious
1992 veterinary public health implications due to the negative impact on patient treatment and prognosis.
1993 Molecular studies are needed to identify genetic drivers of antimicrobial resistance among *A.*
1994 *baumannii* and *K. pneumoniae* organisms. In light of the high prevalence of AMR and MDR observed
1995 in this study, the need for strict infection prevention and control measures to prevent the transmission
1996 of these organisms in hospital settings cannot be overemphasised.

1997 **4.7 References**

- 1998 1. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to
1999 combat ESKAPE pathogens in the era of antimicrobial resistance: a review. *Frontiers in*
2000 *microbiology*. 2019 Apr 1;10:539.
- 2001 2. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of
2002 ESKAPE pathogens in Kwazulu-Natal, South Africa: a five-year retrospective analysis. *African*
2003 *journal of laboratory medicine*. 2018 Jun 1;7(2):1-8.
- 2004 3. Argudín MA, Deplano A, Meghraoui A, Dodémont M, Heinrichs A, Denis O, Nonhoff C,
2005 Roisin S. Bacteria from animals as a pool of antimicrobial resistance genes. *Antibiotics*. 2017 Jun
2006 6;6(2):12.
- 2007 4. Ng S, Abdul Aziz S, Bejo SK, Dhaliwal GK. Occurrence of multidrug resistant *Acinetobacter*
2008 *baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *Jurnal*
2009 *Veterinar Malaysia*. 2016;28(2):12-16.
- 2010 5. Francey T, Gaschen F, Nicolet J, Burnens AP. The role of *Acinetobacter baumannii* as a
2011 nosocomial pathogen for dogs and cats in an intensive care unit. *Journal of Veterinary Internal*
2012 *Medicine*. 2000 Mar;14(2):177-83.
- 2013 6. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens.
2014 *Expert review of anti-infective therapy*. 2013 Mar 1;11(3):297-308.
- 2015 7. Roberts DE, McClain HM, Hansen DS, Currin P, Howerth EW. An outbreak of *Klebsiella*
2016 *pneumoniae* infection in dogs with severe enteritis and septicemia. *Journal of veterinary diagnostic*
2017 *investigation*. 2000 Mar;12(2):168-73.
- 2018 8. Marques C, Belas A, Aboim C, Cavaco-Silva P, Trigueiro G, Gama LT, Pomba C. Evidence
2019 of sharing of *Klebsiella pneumoniae* strains between healthy companion animals and cohabiting
2020 humans. *Journal of Clinical Microbiology*. 2019 Jun;57(6):10-128.

- 2021 9. De Oliveira DM, Forde BM, Kidd TJ, Harris PN, Schembri MA, Beatson SA, Paterson DL,
2022 Walker MJ. Antimicrobial resistance in ESKAPE pathogens. *Clinical microbiology reviews*. 2020
2023 Jun 17;33(3):10-128.
- 2024 10. Brink A, Moolman J, Da Silva MC, Botha M. Antimicrobial susceptibility profile of selected
2025 bacteraemic pathogens from private institutions in South Africa. *South African Medical Journal*.
2026 2007;97(4):273-9.
- 2027 11. Crichton H, O'Connell N, Rabie H, Whitelaw AC, Dramowski A. Neonatal and paediatric
2028 bloodstream infections: Pathogens, antimicrobial resistance patterns and prescribing practice at
2029 Khayelitsha District Hospital, Cape Town, South Africa. *South African Medical Journal*. 2018 Feb
2030 8;108(2):99-104.
- 2031 12. Ricketts SW. *Clinical veterinary microbiology* PJ Quinn, ME Carter and GR Carter Wolfe
2032 Publishing.
- 2033 13. CLSI. *Performance Standard for Antimicrobial Susceptibility Testing*. 30th ed. CLSI
2034 supplement M100 Wayne. PA: Clinical and Laboratory Standards Institute; 2020.
- 2035 14. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S,
2036 Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL. Multidrug-resistant, extensively drug-
2037 resistant and pandrug-resistant bacteria: an international expert proposal for interim standard
2038 definitions for acquired resistance. *Clinical microbiology and infection*. 2012 Mar 1;18(3):268-81.
- 2039 15. Pailhoriès H, Belmonte O, Kempf M, Lemarié C, Cuziat J, Quinqueneau C, Ramont C, Joly-
2040 Guillou ML, Eveillard M. Diversity of *Acinetobacter baumannii* strains isolated in humans,
2041 companion animals, and the environment in Reunion Island: an exploratory study. *International*
2042 *Journal of Infectious Diseases*. 2015 Aug 1;37:64-9.
- 2043 16. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of *Acinetobacter*
2044 *baumannii* in health care facilities. *Clinical infectious diseases*. 2006 Mar 1;42(5):692-9.

- 2045 17. Muggeo A, Guillard T, Klein F, Reffuveille F, François C, Babosan A, Bajolet O, Bertrand X,
2046 de Champs C. Spread of *Klebsiella pneumoniae* ST395 non-susceptible to carbapenems and
2047 resistant to fluoroquinolones in North-Eastern France. *Journal of Global Antimicrobial Resistance*.
2048 2018 Jun 1;13:98-103.
- 2049 18. Marques C, Menezes J, Belas A, Aboim C, Cavaco-Silva P, Trigueiro G, Telo Gama L,
2050 Pomba C. *Klebsiella pneumoniae* causing urinary tract infections in companion animals and
2051 humans: population structure, antimicrobial resistance and virulence genes. *Journal of*
2052 *Antimicrobial Chemotherapy*. 2019 Mar 1;74(3):594-602.
- 2053 19. Hung KH, Wang MC, Huang AH, Yan JJ, Wu JJ. Heteroresistance to cephalosporins and
2054 penicillins in *Acinetobacter baumannii*. *Journal of Clinical Microbiology*. 2012;50: 721–726.
- 2055 20. Wyres KL, Holt KE. *Klebsiella pneumoniae* as a key trafficker of drug resistance genes from
2056 environmental to clinically important bacteria. *Current opinion in microbiology*. 2018 Oct 1;45:131-
2057 9.
- 2058 21. Boerlin P, Eugster S, Gaschen F, Straub R, Schawalder P. Transmission of opportunistic
2059 pathogens in a veterinary teaching hospital. *Veterinary Microbiology*. 2001 Oct 1;82(4):347-59.
- 2060 22. Lee D, Oh JY, Sum S, Park HM. Prevalence and antimicrobial resistance of *Klebsiella*
2061 species isolated from clinically ill companion animals. *Journal of Veterinary Science*. 2021
2062 Mar;22(2).
- 2063 23. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of *Acinetobacter*
2064 *baumannii* on dry surfaces: comparison of outbreak and sporadic isolates. *Journal of clinical*
2065 *microbiology*. 1998 Jul 1;36(7):1938-41.
- 2066 24. Jaggi N, Sissodia P, Sharma L. *Acinetobacter baumannii* isolates in a tertiary care hospital:
2067 Antimicrobial resistance and clinical significance. *Journal of Microbiology and Infectious Diseases*.
2068 2012 Jun 1;2(02):57-63.

- 2069 25. Eveillard M, Soltner C, Kempf M, Saint-André JP, Lemarié C, Randrianarivelo C, Seifert H,
2070 Wolff M, Joly-Guillou ML. The virulence variability of different *Acinetobacter baumannii* strains in
2071 experimental pneumonia. *Journal of Infection*. 2010 Feb 1;60(2):154-61.
- 2072 26. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology,
2073 antimicrobial resistance, and treatment options. *Clinical infectious diseases*. 2008 Apr
2074 15;46(8):1254-63.
- 2075 27. Bonnin RA, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in
2076 *Acinetobacter baumannii*: a state of the art. *Expert review of anti-infective therapy*. 2013 Jun
2077 1;11(6):571-83.
- 2078 28. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. *Acinetobacter baumannii* antibiotic
2079 resistance mechanisms. *Pathogens*. 2021 Mar 19;10(3):373.
- 2080 29. Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A, Pournaras S. In vitro bactericidal
2081 activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against
2082 carbapenem-resistant *Acinetobacter baumannii* clinical isolates. *Antimicrobial agents and
2083 chemotherapy*. 2016 Nov;60(11):6903-6.
- 2084 30. Brolund A, Sundqvist M, Kahlmeter G, Grape M. Molecular characterisation of trimethoprim
2085 resistance in *Escherichia coli* and *Klebsiella pneumoniae* during a two year intervention on
2086 trimethoprim use. *PLoS One*. 2010 Feb 16;5(2):e9233.
- 2087 31. Konca C, Tekin M, Geyik M. Susceptibility patterns of multidrug-resistant *Acinetobacter*
2088 *baumannii*. *The Indian Journal of Pediatrics*. 2021 Feb;88:120-6.
- 2089 32. Raz-Pasteur A, Liron Y, Amir-Ronen R, Abdelgani S, Ohanyan A, Geffen Y, Paul M.
2090 Trimethoprim-sulfamethoxazole vs. colistin or ampicillin–sulbactam for the treatment of
2091 carbapenem-resistant *Acinetobacter baumannii*: A retrospective matched cohort study. *Journal of
2092 global antimicrobial resistance*. 2019 Jun 1;17:168-72.

- 2093 33. Tahbaz SV, Azimi L, Lari AR. Characterization of aminoglycoside resistance mechanisms
2094 in *Acinetobacter Baumannii* isolates from burn wound colonization. *Annals of Burns and Fire*
2095 *Disasters*. 2019 Jun 6;32(2):115.
- 2096 34. Upadhyay S, Khyriem AB, Bhattacharya P, Bhattacharjee A, Joshi SR. High-level
2097 aminoglycoside resistance in *Acinetobacter baumannii* recovered from Intensive Care Unit patients
2098 in Northeastern India. *Indian Journal of Medical Microbiology*. 2018 Jan 1;36(1):43-8.
- 2099 35. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, Dahraoui S,
2100 Belyamani L, Bait A, Haimeur C, Louzi L. *Acinetobacter* infections prevalence and frequency of the
2101 antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan*
2102 *African Medical Journal*. 2016 Jul 13;23(1).
- 2103 36. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of
2104 resistance. *Survey of ophthalmology*. 2004 Mar 1;49(2):S73-8.
- 2105 37. Lautenbach E, Fishman NO, Bilker WB, Castiglioni A, Metlay JP, Edelstein PH, Strom BL.
2106 Risk factors for fluoroquinolone resistance in nosocomial *Escherichia coli* and *Klebsiella*
2107 *pneumoniae* infections. *Archives of Internal Medicine*. 2002 Nov 25;162(21):2469-77.
- 2108 38. Schneiders T, Amyes SG, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance
2109 in clinical *Klebsiella pneumoniae* isolates from Singapore. *Antimicrobial agents and chemotherapy*.
2110 2003 Sep;47(9):2831-7.
- 2111 39. Piddock LJ. Fluoroquinolone resistance: overuse of fluoroquinolones in human and
2112 veterinary medicine can breed resistance. *Bmj*. 1998 Oct 17;317(7165):1029-30.
- 2113 40. Cheng VC, Chen JH, So SY, Wong SC, Yan MK, Chau PH, Lee WM, To KK, Chan JF,
2114 Hung IF, Ho PL. Use of fluoroquinolones is the single most important risk factor for the high
2115 bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant
2116 *Acinetobacter baumannii*. *European Journal of Clinical Microbiology & Infectious Diseases*. 2015
2117 Dec;34:2359-66.

- 2118 41. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-
2119 Curiel A, Caballero FJ, Moreno I, Jiménez-Mejías ME. Imipenem, doxycycline and amikacin in
2120 monotherapy and in combination in *Acinetobacter baumannii* experimental pneumonia. Journal of
2121 Antimicrobial Chemotherapy. 2000 Apr 1;45(4):493-501.
- 2122 42. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating
2123 multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. Intensive care
2124 medicine. 2003 Nov;29:2072-6.
- 2125 43. Mishra SK, Rijal BP, Pokhrel BM. Emerging threat of multidrug resistant bugs–
2126 *Acinetobacter calcoaceticus baumannii* complex and methicillin resistant *Staphylococcus aureus*.
2127 BMC research notes. 2013 Dec;6:1-6.
- 2128 44. Hetzler L, Kollef MH, Yuenger V, Micek ST, Betthausen KD. New antimicrobial treatment
2129 options for severe Gram-negative infections. Current Opinion in Critical Care. 2022 Oct
2130 1;28(5):522-33.
- 2131 45. Haenni M, Ponsin C, Métayer V, Médaille C, Madec JY. Veterinary hospital-acquired
2132 infections in pets with a ciprofloxacin-resistant CTX-M-15-producing *Klebsiella pneumoniae* ST15
2133 clone. Journal of antimicrobial chemotherapy. 2012 Mar 1;67(3):770-1.
- 2134 46. Doorduyn DJ, Rooijackers SH, van Schaik W, Bardoel BW. Complement resistance
2135 mechanisms of *Klebsiella pneumoniae*. Immunobiology. 2016 Oct 1;221(10):1102-9.
- 2136 47. Piperaki ET, Syrogiannopoulos GA, Tzouvelekis LS, Daikos GL. *Klebsiella pneumoniae*:
2137 virulence, biofilm and antimicrobial resistance. The Pediatric infectious disease journal. 2017 Oct
2138 1;36(10):1002-5.
- 2139 48. Schmidt, J.S., Kuster, S.P., Nigg, A., Dazio, V., Brillhante, M., Rohrbach, H., Bernasconi,
2140 O.J., Büdel, T., Campos-Madueno, E.I., Gobeli Brawand, S. and Schuller, S., 2020. Poor infection
2141 prevention and control standards are associated with environmental contamination with

- 2142 carbapenemase-producing Enterobacterales and other multidrug-resistant bacteria in Swiss
2143 companion animal clinics. *Antimicrobial Resistance & Infection Control*, 9, pp.1-13.
- 2144 49. Shields RK, Clancy CJ, Press EG, Nguyen MH. Aminoglycosides for treatment of
2145 bacteremia due to carbapenem-resistant *Klebsiella pneumoniae*. *Antimicrobial agents and*
2146 *chemotherapy*. 2016 May;60(5):3187-92.
- 2147 50. Liang C, Xing B, Yang X, Fu Y, Feng Y, Zhang Y. Molecular epidemiology of
2148 aminoglycosides resistance on *Klebsiella pneumonia* in a hospital in China. *International journal of*
2149 *clinical and experimental medicine*. 2015;8(1):1381.
- 2150 51. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J. Evolution of
2151 antimicrobial resistance among *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella*
2152 *pneumoniae* in Brooklyn, NY. *Journal of antimicrobial chemotherapy*. 2007 Jul 1;60(1):78-82.
- 2153 52. Yousfi M, Touati A, Muggeo A, Mira B, Asma B, Brasme L, Guillard T, de Champs C.
2154 Clonal dissemination of OXA-48-producing *Enterobacter cloacae* isolates from companion animals
2155 in Algeria. *Journal of Global Antimicrobial Resistance*. 2018 Mar 1;12:187-91.
- 2156 53. Foudraine DE, Strepis N, Stingl C, Ten Kate MT, Verbon A, Klaassen CH, Goessens WH,
2157 Luider TM, Dekker LJ. Exploring antimicrobial resistance to beta-lactams, aminoglycosides and
2158 fluoroquinolones in *E. coli* and *K. pneumoniae* using proteogenomics. *Scientific Reports*. 2021 Jun
2159 14;11(1):12472.
- 2160 54. Li Y, Fernández R, Durán I, Molina-López RA, Darwich L. Antimicrobial resistance in
2161 bacteria isolated from cats and dogs from the Iberian Peninsula. *Frontiers in microbiology*. 2021
2162 Jan 20;11:621597.
- 2163 55. Murri R, Fiori B, Spanu T, Mastroiosa I, Giovannenze F, Taccari F, Palazzolo C,
2164 Scoppettuolo G, Ventura G, Sanguinetti M, Cauda R. Trimethoprim–sulfamethoxazole therapy for
2165 patients with carbapenemase-producing *Klebsiella pneumoniae* infections: retrospective single-
2166 center case series. *Infection*. 2017 Apr;45:209-13

2167

Chapter 5

2168 **Occurrence and characterization of ESKAPE organisms on the hands of veterinary students**
2169 **before patient contact at a veterinary academic hospital, South Africa**

2170 **Dikeledi C. Sebola¹**, James W. Oguttu², Mogaugedi N. Malahlela¹, Marleen M. Kock^{3,4}, Daniel N.
2171 Qekwana¹.

2172

2173 ¹Section Veterinary Public Health, Department of Paraclinical Sciences, Faculty of Veterinary
2174 Science, University of Pretoria, Pretoria, South Africa

2175 ²Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences,
2176 University of South Africa, Johannesburg, South Africa

2177 ³Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa

2178 ⁴Tshwane Academic Division, National Health Laboratory Service, Pretoria, South Africa

2179

2180

2181 This chapter is under review in BMC Veterinary Research, all edits have been done following the
2182 requirements of the journal.

2183

2184 My contribution to the paper includes study design, data analysis, interpretation of results, writing
2185 of manuscript as well as extensive editing of the manuscript

2186

2187 **Abstract**

2188 **Objective:** *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*,
2189 *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species termed 'ESKAPE'
2190 organisms are responsible for most hospital-acquired infections (HAIs). Although these organisms
2191 are known to spread via the hands of healthcare workers (HCWs), there is a paucity of information
2192 on the occurrence of these organisms in veterinary settings. The aim of this study was to determine
2193 the presence of ESKAPE organisms on the hands of students working in the intensive care unit
2194 (ICU) at a veterinary academic hospital.

2195 **Methods:** A cross-sectional study was conducted among students working in an ICU at a
2196 veterinary academic hospital in South Africa. Students were sampled before the start of the ICU shift
2197 using a modified glove-juice method. Standard microbiological techniques and a series of
2198 polymerase chain reaction (PCR) assays were used to identify and characterize the bacteria. All the
2199 isolates were tested for resistance against a specific panel of antibiotics using the disk diffusion
2200 method. Proportions of bacterial species and their antimicrobial-susceptibility profiles were
2201 calculated.

2202 **Results:** At screening, all the veterinary students (n=62) carried at least one of the ESKAPE
2203 organisms on their hands. *Escherichia coli* was the most isolated organism (76%, 47/62), followed
2204 by *E. faecium* (52%, 22/62), *P. aeruginosa* (48%, 30/62), *A. baumannii* (47%, 29/62), *K. pneumoniae*
2205 (27%, 17/62), and *S. aureus* (24%, 15/62). A reduced proportion of isolates were recovered from the
2206 samples, *E. coli* (26%, 12/47), *E. faecium* (27%, 6/22), *P. aeruginosa* (43%, 13/30), *A. baumannii*
2207 (21%, 7/29), *K. pneumoniae* (41%, 7/17), and *S. aureus* (20%, 3/15). Most of the organisms showed
2208 a high proportion of resistance to at least one antibiotic. Multidrug resistance (MDR) was reported
2209 among (42%, 5/12) of *E. coli*, 40% (2/5) of *E. faecium*, 100% (13/13) of *P. aeruginosa*, and 33% (1/3)
2210 of *S. aureus* isolates.

2211 **Conclusion:** Students working in the ICU carry several organisms from the ESKAPE group
2212 before contact with patients. Moreover, MDR was common among this group of organisms. The
2213 findings of the present study underscore the importance of infection prevention and control (IPC)

2214 strategies to help reduce the likelihood of the spread of these organisms to personnel, owners, family
2215 members, and patients.

2216 **Keywords:** ESKAPE pathogens, Veterinary, Intensive care unit, Antimicrobial resistance,
2217 Multidrug resistance, *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*,
2218 *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species

2219

2220 **5.1 Introduction**

2221 Effective hand hygiene has been shown to reduce the transmission of hospital-acquired
2222 infections (HAIs) in healthcare facilities (1–5). However, available evidence similar to studies in
2223 human medicine, indicates that hand hygiene compliance among healthcare workers (HCWs) in
2224 veterinary medicine remains low (6,7). This heightens the risk of transmission of infectious diseases
2225 and zoonotic organisms within the hospital setting (3,6,8). In addition to low hand hygiene
2226 compliance, patient-to-patient contact, and contact with contaminated surfaces have also been
2227 shown to increase the transmission of organisms associated with HAIs (4,9–11).

2228 *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter*
2229 *baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species referred to as ESKAPE are the
2230 leading cause of HAIs in the intensive care unit (ICU) in both human (12,13) and animal hospitals
2231 (14). Moreover, infections associated with these bacteria are less responsive to commonly used
2232 antibiotics resulting in limited treatment options and poor patient prognosis, especially in under-
2233 resourced developing countries (9–11,15). Additionally, some of these bacteria including
2234 enterococci, can survive in hospital environments for longer periods (approximately 5 days to 4
2235 months) thus remaining a source of infection to susceptible individuals (10,11,16).

2236 The intensive care unit of both the human and veterinary hospitals remains a high-risk area
2237 for infections associated with ESKAPE organisms due to the poor health status of the patients, the
2238 high antibiotic usage, the higher prevalence of invasive procedures, the use of indwelling devices,
2239 and the higher frequency of contact between patients and HCWs (11,17,18). This problem is
2240 compounded by the fact that animals and people can be carriers of these organisms, therefore,
2241 becoming sources of infections to susceptible individuals (19).

2242 Given, hand hygiene compliance remains the most effective strategy to reduce the risk of
2243 transmission of organisms associated with HAIs in hospital settings (7,19–21). This study
2244 investigated the presence of ESKAPE bacteria on the hands of students working in the ICU at a
2245 veterinary academic hospital prior to contact with patients. The results shed light on the importance
2246 of hand hygiene compliance in the ICU setting.

2247 **5.2 Materials and methods**

2248 *5.2.1 Study area*

2249 The study was conducted at a veterinary teaching hospital in South Africa. The faculty to
2250 which the hospital belongs has five departments: Veterinary tropical diseases, Paraclinical sciences,
2251 Companion animal clinical studies (CACS), Production animal clinical studies, and Anatomy and
2252 Physiology. This study focuses on the ICU servicing the Department of CACS. The Department has
2253 three sections: small animal surgery, small animal medicine, and outpatient. All patients from these
2254 sections requiring critical care are referred to the same ICU, excluding those with contagious
2255 infectious diseases like canine parvovirus, which are admitted to a separate isolation ward. In
2256 addition, the hospital serves as a referral for internal medicine and surgical cases for clients in and
2257 around Pretoria. The study was done during routine clinical rotations of veterinary students. The
2258 clinical rotation is divided into the day shift starting from 08h00 to 16:00 and night shifts starting from
2259 20h00 to 08h00.

2260 *5.2.2 Study population*

2261 A cross-sectional study design was adopted in this study. Final-year students were sampled
2262 during their clinical rotation in the ICU between September 2022 and March 2023. The students were
2263 randomly selected on different days based on the shift as they entered the ICU at the start of the
2264 shift. Each student was sampled once.

2265 *5.2.3 Sample collection*

2266 The study used the glove-juice technique which is well documented in human medicine
2267 studies (1,14,21). This method is more sensitive compared to the imprint method as it allows for the
2268 quantification of the entire bacterial load on the hands of the HCWs (22,23). To sample for the
2269 presence of ESKAPE organisms, the dominant hand of each participant was inserted into a sterile
2270 latex-free glove containing 20ml buffered phosphate water (PBW) and massaged for one minute as
2271 described by (25) Matuka et al (24). After massaging, the fluid was aseptically retrieved and pipetted

2272 into sterile 15ml tubes then transported on ice within an hour to the veterinary public health (VPH)
2273 laboratory of the faculty of veterinary science for further processing.

2274 5.2.4 Screening

2275 Samples brought to the laboratory in PBW were incubated in a shaker at 200 RPM for 16-24
2276 hours at 37°C. After enrichment, 100µl aliquot of the overnight broth was spread on horse blood agar
2277 and incubated aerobically at 37°C for 16-24 hours.

2278 5.2.5 Identification of ESKAPE bacteria

2279 5.2.5.1 DNA Extraction

2280 All blood agar plates with growth: the bacterial colony was harvested using a sterile loop in
2281 preparation for extraction of genomic Deoxyribose nucleic Acid (DNA) using the boiling method as
2282 previously described (25). A loopful of the culture sweep was suspended in 1000µL of sterile FA
2283 buffer (Bacto™ FA Buffer, Becton and Dickson & Company) in a 1.5mL Eppendorf tube, vortexed
2284 and centrifuged at 12,000rpm for 5 minutes. The supernatant was discarded, and the bacterial pellet
2285 was re-suspended in 1000µL of sterile FA buffer and centrifuged. This process was repeated twice.
2286 After the last centrifugation cycle, the supernatant was discarded completely. The pellet was re-
2287 suspended in 500µL of sterile distilled water, boiled for 20 minutes on a heating block, cooled on ice
2288 for 10 minutes, and then stored at -20°C for further processing.

2289 5.2.5.2 Polymerase Chain Reaction

2290 The extracted genomic DNA was used as a template to determine the presence of each of
2291 the ESKAPE organisms using polymerase chain reaction (PCR). Primers and PCR cycling
2292 conditions as previously described were used to identify the different bacteria (**Table 5.1**). Briefly,
2293 for each PCR reaction of 25µL, the following components were added: 2.5µL of 10X Thermopol
2294 reaction buffer, 2.0µl of 2.5mM dNTPs (deoxynucleotide triphosphates), 0.25µl of 100mM MgCl₂,
2295 1.6µl of each primer (0.64µM final concentration), 1U of *Thermus aquaticus* polymerase (Taq) DNA
2296 Polymerase (New England BioLabs® Inc.) and 5µl of DNA lysate template. Positive controls included
2297 DNA from the ATCC strains *E. coli* (25922), *S. aureus* (25923), *K. pneumonia* (700603), *E. faecalis*

2298 (29212), and *P. aeruginosa* (27853). Sterile nuclease-free water was used as a negative control. All
 2299 PCR reagents were supplied by New England BioLabs (NEB, USA), except for the primers, which
 2300 were sourced from Inqaba Biotec (South Africa) and Integrated DNA Technologies (IDT) (San Diego,
 2301 USA).

2302 A Veriti™ (Applied Biosystems®, USA) or a C1000 Touch™ (Bio-Rad, USA) thermal cycler
 2303 was used for all PCR reactions. Thereafter, the PCR products were electrophoresed on 2% (w/v)
 2304 agarose gels in TAE (Tris–acetate–ethylenediamine tetra acetic acid) buffer, stained with ethidium
 2305 bromide (0.05mg/μl) for 15 minutes, and visualized under ultraviolet (UV) light with a Gel Doc system
 2306 (Bio-Rad, USA).

2307 **Table 5. 1:** Nucleotide sequences used as primers in the PCR reaction to identify ESKAPE
 2308 organisms.

organism	Primer Sequences	Amplicon size ^a (bp)	Reference
<i>Enterococcus faecium</i>	^b F:GAAAAACAATAGAAGAATTAT ^c R:TGCTTTTTTTGAATTCTTCTTA	215	(26)
<i>Staphylococcus aureus</i>	^b F:AATCTTTGTCGGTACACGATATTCTTCACG ^c R:CGTAATGAGATTTTCAGTAGATAATAACA	108	(27)
<i>Klebsiella pneumoniae</i>	^b F:GGATATCTGACCAGTCGG ^c R:GGGTTTTGCGTAATGATCTG	176	(28)
<i>Acinetobacter baumannii</i>	^b F: CACGCCGTA-AGAGTGCATTA ^c R: AACGGAGCTTGT CAGGGTT	490	(29)
<i>Pseudomonas aeruginosa</i>	^b F: AATACCTTGCTGTTTTGACGTTAC ^c R:TCAGTGT CAGTATCAGTCCAGGTG	295	(30)
<i>Escherichia coli</i>	^b F:GATGAAATGGCGTTGGCGCAAG ^c R:GGCGGAAGTCCAGACGATATCC	373	(31)

2309 ^aBase pairs, ^bForward primer, ^cReverse primer

2310 5.2.5.3 Single Colony Streaking

2311 Plates that tested positive in the initial screening were streaked onto differential media to
 2312 differentiate each bacterium to obtain single colonies. *Staphylococcus aureus* and *A. baumannii*
 2313 were streaked on blood agar, *P. aeruginosa* on Cetramide agar, and *E. faecium*, *E. coli* and *K.*
 2314 *pneumoniae* were streaked on McConkey agar. The plates were then incubated at 37°C for 16-24
 2315 hours. Five single colonies of each isolate were selected from each plate and multiplied separately

2316 on Luria Bertani (LB) agar (Difco™ Becton and Dickson & Company) for purification. The plates
2317 were then incubated at 37°C for 16-24 hours. Genomic DNA was extracted, and PCR was performed
2318 on the colonies using primers as described above to identify them.

2319 5.2.6 Antimicrobial sensitivity

2320 All the identified isolates were tested against a panel of antibiotics using the disk diffusion
2321 method to determine their susceptibility profile following the Clinical and Laboratory Standards
2322 Institute (CLSI) guidelines (**Table 5.2**) (32).

2323 Antimicrobial resistance testing was performed on Mueller Hinton agar (MHA) (Oxoid, UK)
2324 as described by the CLSI (32). Bacterial suspensions of individual pure colonies of 0.5 McFarland
2325 were prepared in 0.85% physiological saline. A sterile cotton swab was used to inoculate MHA plates
2326 to achieve confluent growth. Antimicrobial discs were placed on the inoculated plates using an Oxoid
2327 disk dispenser and incubated aerobically at 37°C for 16-24 hours. Each isolate was tested against
2328 different panels of antibiotics using disks obtained from Oxoid Company as outlined in **Table 5.2**.
2329 *Escherichia coli* (25922), *S. aureus* (25923), *K. pneumonia* (700603), *E. faecalis* (29212), and *P.*
2330 *aeruginosa* (27853) were used as reference strains. The results of the antibiogram were classified
2331 as susceptible, resistant, or intermediate according to CLSI criteria (32). However, the intermediate
2332 readings were re-classified as resistant for data analysis.

2333 **Table 5. 2:** Panel of antibiotics tested against the ESKAPE organisms isolated from the hands of healthcare workers in the intensive care unit.

Antibiotics	<i>Enterococcus faecium</i>	<i>Staphylococcus aureus</i>	<i>Klebsiella Pneumoniae</i>	<i>Acinetobacter baumannii</i>	<i>Pseudomonas aeruginosa</i>	<i>Escherichia coli</i>
Ampicillin (10µg)	✓		✓		✓	✓
Penicillin-G (10µg)	✓	✓			✓	
Cefotaxime (30µg)			✓	✓	✓	✓
Tobramycin (10µg)			✓	✓	✓	✓
Ciprofloxacin (5µg)	✓	✓	✓	✓	✓	
Ceftazidime (30µg)			✓	✓	✓	✓
Ampicillin-sulbactam (10/10µg)			✓	✓	✓	✓
Gentamicin (10µg)	✓	✓	✓	✓	✓	✓
Imipenem (10µg)	✓	✓	✓	✓	✓	✓
Trimethoprim-sulfamethoxazole (25µg)	✓	✓			✓	
Amikacin (30µg)					✓	
Oxytetracycline (30µg)		✓	✓	✓		
Erythromycin (15µg)	✓	✓				
Chloramphenicol (30µg)	✓	✓				✓
Linezolid (30µg)		✓				
Oxacillin (1µg)		✓				
Tetracycline (30µg)	✓	✓				✓
Total antibiotics	9	11	9	8	11	9

2334

2335 **5.3 Results**

2336 *5.3.1 Isolated bacteria*

2337 Sixty-two (n=62) students gave consent to be sampled, and all the students who participated
2338 in the study, carried at least one of the ESKAPE organisms on their hands. *Escherichia coli* (76%)
2339 was the most identified bacteria and *S. aureus* (24%) was the least identified during the screening.
2340 A reduced proportion of isolates were recovered from single colony streaking (**Table 5.3**).

2341 *5.3.2 Antimicrobial susceptibility profile*

2342 All the isolated ESKAPE organisms exhibited a high proportion of resistance to at least one
2343 antibiotic. Among the *E. coli* isolates, resistance was high to ampicillin, cefotaxime, and tobramycin.
2344 While two of the three *S. aureus* isolates exhibited resistance to penicillin G. Most *K. pneumoniae*
2345 isolates were resistant to ampicillin and none were resistant to ceftazidime, gentamycin, and
2346 imipenem. *Acinetobacter baumannii* isolates exhibited resistance to ampicillin-sulbactam and one
2347 isolate showed resistance to imipenem. All *P. aeruginosa* isolates showed resistance to ampicillin,
2348 penicillin-G, and ampicillin-sulbactam, three of the isolates were resistant to imipenem, and two to
2349 tobramycin. Three *Enterococcus faecium* isolates were resistant to penicillin-G and two to
2350 ciprofloxacin, erythromycin, and ampicillin (**Table 5.4**).

2351 *5.3.3 Multidrug-resistant Organisms*

2352 Only *E. coli*, *P. aeruginosa*, *E. faecium*, and *S. aureus* had isolates that were resistant to
2353 three or more antibiotics and thus considered MDR (**Table 5.3**)

2354 **Table 5. 3:**The proportions of bacteria isolated from the hands of students before contact with
 2355 patients in the intensive care unit at a veterinary academic hospital; South Africa

Bacterial organism	Isolates		Resistant Isolates	
	Screening % (n/N)	Recovered % (n/N)	AMR ^b % (n/N)	MDR ^c % (n/N)
<i>Enterococcus faecium</i>	35 (22/62)	23 (5/22)	80 (4/5)	40 (2/5)
<i>Staphylococcus aureus</i>	24 (15/62)	20 (3/15)	67 (2/3)	33 (1/3)
<i>Klebsiella pneumoniae</i>	27 (17/62)	41 (7/17)	100 (7/7)	0 (0/7)
<i>Acinetobacter baumannii</i>	47 (29/62)	24 (7/29)	57 (4/7)	0 (0/7)
<i>Pseudomonas aeruginosa</i>	48(30/62)	43 (13/30)	100 (13/13)	100 (13/13)
<i>Escherichia coli</i>	76 (47/62)	26 (12/47)	100 (12/12)	42 (5/12)

2356 ^bAntimicrobial resistance, ^cMultidrug resistance

2357 **Table 5. 4:** Antimicrobial resistance profile of ESKAPE organisms isolated from hand samples of students working at a veterinary academic hospital,
 2358 in South Africa.

Antibiotics	<i>Enterococcus faecium</i> % (n/N)	<i>Staphylococcus aureus</i> % (n/N)	<i>Klebsiella Pneumoniae</i> % (n/N)	<i>Acinetobacter baumannii</i> % (n/N)	<i>Pseudomonas aeruginosa</i> % (n/N)	<i>Escherichia coli</i> % (n/N)
Ampicillin	40 (2/5)		86 (6/7)		100 (13/13)	89 (8/9)
Penicillin-G	60 (3/5)	67 (2/3)			100 (13/13)	
Cefotaxime			14 (1/7)	25 (1/4)	69 (9/13)	67 (6/9)
Tobramycin			14 (1/7)	0 (0/4)	15 (2/13)	56 (5/9)
Ciprofloxacin	40 (2/5)	0 (0/3)	14 (1/7)	0 (0/4)	0 (0/13)	
Ceftazidime			0 (0/7)	25 (1/4)	0 (0/13)	44 (4/9)
Ampicillin-sulbactam			14 (1/7)	50 (2/4)	100 (13/13)	33 (3/9)
Gentamicin	0 (0/5)	0 (0/3)	0 (0/7)	25 (1/4)	69 (9/13)	22 (2/9)
Imipenem	0 (0/5)	0 (0/3)	0 (0/7)	25 (1/4)	23 (3/13)	
Trimethoprim-sulfamethoxazole	0 (0/5)	0 (0/3)			69 (9/13)	
Amikacin					0 (0/13)	
Oxytetracycline		33 (1/3)	0 (0/7)	0 (0/4)		
Erythromycin	40 (2/5)	33 (1/3)				
Chloramphenicol	0 (0/5)	0 (0/3)				11 (1/9)
Linezolid		0 (0/3)				
Oxacillin		0 (0/3)				
Tetracycline .	40 (2/5)	33 (1/3)				44 (4/9)

2359

2360 **5.4 Discussion**

2361 This is the first study in South Africa to investigate the occurrence of ESKAPE organisms
2362 from the hands of HCWs in a veterinary hospital and their antimicrobial susceptibility profiles. During
2363 screening, at least one of the ESKAPE organisms was isolated from the hands of students before
2364 entering the ICU. The presence of these bacteria is concerning as they are known to cause
2365 opportunistic infections and are responsible for many HAIs (10,11,33–38). Moreover, these bacteria
2366 have zoonotic potential and can be transmitted between humans and animals, posing a health threat
2367 to susceptible individuals (16,38). The high prevalence of antimicrobial resistance observed among
2368 the isolates is also a matter of public health concern. The danger caused by these bacteria to public
2369 health is exacerbated by the fact that they can adapt and survive in hospital environments (12,38).

2370 *5.4.1 Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium*

2371 In the current study, *E. coli* was isolated from 76% of students working in the ICU. This is
2372 consistent with what other studies have reported the *E. coli* from the fingertips of HCWs in a human
2373 hospital (24) and the hands of HCWs in a veterinary hospital (39). *Klebsiella pneumoniae* and *E.*
2374 *faecium* were also isolated in this study. A study done in a small animal hospital in Korea (10) also
2375 reported the occurrence of these bacteria on the hands of HCWs. Of interest is that *K. pneumoniae*
2376 and *E. faecium* have been isolated from equipment and the hospital environment in other studies
2377 (16,40). The presence of these pathogens on environmental surfaces has been associated with
2378 faecal contamination (10,11,39). Therefore, it is important to implement measures that reduce the
2379 risk of faecal contamination, such as regularly cleaning and disinfecting surfaces within the veterinary
2380 hospital.

2381 *5.4.2 Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa*

2382 *Staphylococcus aureus* and *A. baumannii* are commensals on the skin of humans and
2383 animals as well as human nasal cavities (12,16,24,41). They are among the most prevalent
2384 opportunistic organisms in both human and veterinary hospitals (12). Humans remain important
2385 reservoirs for the transmission of these organisms (42). Similar findings have also been observed
2386 by other studies that investigated these bacteria from the hands of HCWs (11,24,43,44).

2387 Concerning *P. aeruginosa*, to our knowledge, this is the first study in 20 years to report the
2388 occurrence of *P. aeruginosa* in the hands of HCWs in veterinary medicines, previous reports were
2389 on veterinary clinical cases and the environmental samples (45,46). The use of alcohol-based hand
2390 rubs and gels remains the most effective method of reducing the transmission of *S. aureus*, *A.*
2391 *baumannii*, and *P. aeruginosa* in hospital settings (24,42,47).

2392 5.4.3 Antimicrobial resistance

2393 Resistance against β -lactams was observed among *Enterococcus faecium*, *S. aureus*, *K.*
2394 *pneumoniae*, *P. aeruginosa*, and *E. coli* isolates which is consistent with what other studies have
2395 reported (48,49). However, the presence of resistance to imipenem in one *A. baumannii* and three
2396 *P. aeruginosa* isolates was concerning, given that imipenem is considered a high priority critically
2397 important antibiotic by the World Health Organization (WHO) (34,46,48,50).

2398 Multidrug resistance was observed among *E. coli*, *P. aeruginosa*, *E. Faecium*, and *S. aureus*
2399 isolates. This was expected in light of reports by various studies that have demonstrated that
2400 ESKAPE organisms tend to exhibit high levels of resistance against commonly used antibiotics
2401 including the last resort antibiotics (38,48,50). Ng et al (51) also isolated MDR *A. baumannii* and
2402 MDR *E. coli* from doorknobs, labcoats, stethoscopes, and weighing scales. The observed MDR
2403 among these organisms implies the heightened likelihood of treatment failure among patients if they
2404 contracted HAIs (11,49,52).

2405 5.5 Conclusion

2406 Students in this study carried on their hands bacteria associated with HAIs and zoonotic
2407 diseases. These bacteria exhibited a high prevalence of resistance to the β -lactams antibiotics and
2408 two of them were resistant to imipenem. Therefore, veterinary hospitals should prioritize pathogen
2409 surveillance to control the spread of MDR organisms. Since these organisms are opportunistic and
2410 likely to survive in harsh environments, adherence to hand hygiene and other IPC practices at the
2411 veterinary academic hospital is recommended.

2412 5.6 Declarations

2413 5.6.1 Ethics approval and consent to participate

2414 The Faculty of Veterinary Science Research Ethics Committee, Faculty of Humanities
2415 Research Ethics Committee (Project number: REC009-21), and Faculty of Health Sciences
2416 Research Ethics Committee (Reference No:187/2022) approved this study. Students were informed
2417 of the study during their clinical orientation week and gave consent before participating. All the data
2418 was kept anonymous for confidentiality.

2419 *5.6.2 Consent for publication*

2420 Not applicable

2421 *5.6.3 Availability of data and materials*

2422 The datasets used and/or analysed during the current study are available from the
2423 corresponding author upon reasonable request.

2424 *5.6.4 Competing interests*

2425 The authors declare that they have no competing interests.

2426 *5.6.5 Funding*

2427 There was no external funding received for this study.

2428 *5.6.6 Authors' Contribution*

2429 DCS, JWO, MK, and DNQ have made a substantial contribution to the conception and
2430 design of the study. DCS was involved in the acquisition, initial analysis, and interpretation of data,
2431 and the drafting of the article. JWO, MM, MK, and DNQ were involved in the extensive review of
2432 the manuscript. All the authors read and approved the final version of the manuscript.

2433 *5.6.7 Acknowledgements*

2434 The authors express their gratitude to all the healthcare workers at the veterinary academic
2435 hospital for allowing us to conduct this study. We would also like to thank the Veterinary Public Health
2436 (VPH) laboratory for their assistance. Additionally, the authors would like to extend their appreciation
2437 to the National Research Foundation for providing the scholarship funding for the program.

2438

2439 **5.7 References**

- 2440 1. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, Boyce JM.
2441 Evidence-based model for hand transmission during patient care and the role of improved
2442 practices. *The Lancet Infectious Diseases*. 2006 Oct 1;6(10):641-52. DOI:
2443 [https://doi.org/10.1016/s1473-3099\(06\)70600-4](https://doi.org/10.1016/s1473-3099(06)70600-4)
- 2444 2. O'Boyle CA, Henly SJ, Larson E. Understanding adherence to hand hygiene
2445 recommendations: the theory of planned behavior. *American Journal of Infection Control*. 2001
2446 Dec 1;29(6):352-60. DOI: <https://doi.org/10.1067/mic.2001.18405>
- 2447 3. Nakamura RK, Tompkins E, Braasch EL, Martinez Jr JG, Bianco D. Hand hygiene practices
2448 of veterinary support staff in small animal private practice. *Journal of Small Animal Practice*. 2012
2449 Mar;53(3):155-60. DOI: <https://doi.org/10.1111/j.1748-5827.2011.01180.x>
- 2450 4. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention.
2451 *Journal of Hospital Infection*. 2009 Dec 1;73(4):305-15. DOI:
2452 <https://doi.org/10.1016/j.jhin.2009.04.019>
- 2453 5. Willemsen A, Cobbold R, Gibson J, Wilks K, Lawler S, Reid S. Infection control practices
2454 employed within small animal veterinary practices—A systematic review. *Zoonoses Public Health*.
2455 2019 Aug 31;66(5):439–57. DOI: <https://doi.org/10.1111/zph.12589>
- 2456 6. Shea A, Shaw S. Evaluation of an educational campaign to increase hand hygiene at a
2457 small animal veterinary teaching hospital. *Journal of the American Veterinary Medical Association*.
2458 2012 Jan 1;240(1):61-4. DOI: <https://doi.org/10.2460/javma.240.1.61>
- 2459 7. Sebola DC, Boucher C, Maslo C, Qekwana DN. Hand hygiene compliance in the intensive
2460 care unit of the Onderstepoort Veterinary Academic Hospital. [Preprint] 2019 [Accessed 2024 April
2461 10]. Available from: <https://doi.org/10.21203/rs.2.17130/v1>
- 2462 8. Anderson ME. Contact precautions and hand hygiene in veterinary clinics. *Veterinary
2463 Clinics: Small Animal Practice*. 2015 Mar 1;45(2):343-60. DOI:
2464 <https://doi.org/10.1016/j.cvsm.2014.11.003>

- 2465 9. Weber KL, LeSassier DS, Kappell AD, Schulte KQ, Westfall N, Albright NC, Godbold GD,
2466 Palsikar V, Acevedo CA, Ternus KL, Hewitt FC. Simulating transmission of ESKAPE pathogens
2467 plus *C. difficile* in relevant clinical scenarios. BMC Infectious Diseases. 2020 Dec; 20:1-5. DOI:
2468 <https://doi.org/10.1186/s12879-020-05121-4>
- 2469 10. Oh YI, Baek JY, Kim SH, Kang BJ, Youn HY. Antimicrobial susceptibility and distribution of
2470 multidrug-resistant organisms isolated from environmental surfaces and hands of healthcare
2471 workers in a small animal hospital. Japanese Journal of Veterinary Research. 2018 Aug;66(3):193-
2472 202. DOI: <https://doi.org/10.14943/jjvr.66.3.193>
- 2473 11. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens.
2474 Expert Review of Anti-Infective Therapy. 2013 Mar 1;11(3):297-308. DOI:
2475 <https://doi.org/10.1586/eri.13.12>
- 2476 12. Asokan GV, Ramadhan T, Ahmed E, Sanad H. WHO global priority pathogens list: a
2477 bibliometric analysis of Medline-PubMed for knowledge mobilization to infection prevention and
2478 control practices in Bahrain. Oman Medical Journal. 2019 May;34(3): 184. DOI:
2479 <https://doi.org/10.5001/omj.2019.37>
- 2480 13. Anastasiades P, Pratt TL, Rousseau LH, Steinberg WH, Joubert G. Staphylococcus aureus
2481 on computer mice and keyboards in intensive care units of the Universitas Academic Hospital,
2482 Bloemfontein, and ICU staff's knowledge of its hazards and cleaning practices. Southern African
2483 Journal of Epidemiology and Infection. 2009;24(2):22–6
- 2484 14. Ghosh A, Dowd SE, Zurek L. Dogs leaving the ICU carry a very large multi-drug resistant
2485 enterococcal population with a capacity for biofilm formation and horizontal gene transfer. Webber
2486 MA, editor. PLoS One. 2011 Jul 19;6(7):e22451.
- 2487 15. De la Rosa-Zamboni D, Ochoa SA, Laris-González A, Cruz-Córdova A, Escalona-Venegas
2488 G, Pérez-Avendaño G, Torres-García M, Suárez-Mora R, Castellanos-Cruz C, Sánchez-Flores
2489 YV, Vázquez-Flores A. Everybody hands-on to avoid ESKAPE: effect of sustained hand hygiene
2490 compliance on healthcare-associated infections and multidrug resistance in a paediatric hospital.

- 2491 Journal of Medical Microbiology. 2018 Dec;67(12):1761-71. DOI:
2492 <https://doi.org/10.1099/jmm.0.000863>
- 2493 16. Sebola DC, Oguttu JW, Kock MM, Qekwana DN. Hospital-acquired and zoonotic bacteria
2494 from a veterinary hospital and their associated antimicrobial-susceptibility profiles: A systematic
2495 review., *Frontiers in Veterinary Science*. 2023 Jan; 9. DOI:
2496 <https://doi.org/10.3389/fvets.2022.1087052>
- 2497 17. Aksoy E, Boag A, Brodbelt D, Grierson J. Evaluation of surface contamination with
2498 *Staphylococci* in a veterinary hospital using a quantitative microbiological method. *Journal of Small*
2499 *Animal Practice*. 2010 Nov 1;51(11):574–80. DOI: [https://doi.org/10.1111/j.1748-](https://doi.org/10.1111/j.1748-5827.2010.00994.x)
2500 [5827.2010.00994.x](https://doi.org/10.1111/j.1748-5827.2010.00994.x)
- 2501 18. Eggimann P, Pittet D. Infection control in the ICU. *Chest*. 2001 Dec 1;120(6):2059-93. DOI:
2502 <https://doi.org/10.1378/chest.120.6.2059>
- 2503 19. Wright JG, Jung S, Holman RC, Marano NN, McQuiston JH. Infection control practices and
2504 zoonotic disease risks among veterinarians in the United States. *Journal of the American*
2505 *Veterinary Medical Association*. 2008 Jun 15;232(12):1863-72. DOI:
2506 <https://doi.org/10.2460/javma.232.12.1863>
- 2507 20. Lau T, Tang G, Mak K lun, Leung G. Moment-specific compliance with hand hygiene. *The*
2508 *Clinical Teacher*. 2014 Jun 1;11(3):159–64. DOI: <https://doi.org/10.1111/tct.12088>
- 2509 21. World Health Organization. WHO Guidelines on Hand Hygiene in Health Care: First Global
2510 Patient Safety Challenge Clean Care is Safer Care [Internet]. 2009 [cited 2019 Oct 30]. Available
2511 from: <https://www.who.int/gpsc/5may/tools/9789241597906/en/>.
- 2512 22. Monistrol O, Liboria López M, Riera M, Font R, Nicolás C, Escobar MA, et al. Hand
2513 contamination during routine care in medical wards: The role of hand hygiene compliance. *Journal*
2514 *of Medical Microbiology*. 2013;62(PART4):623–9. DOI: <https://doi.org/10.1099/jmm.0.050328-0>

- 2515 23. Visalachy S, Palraj KK, Kopula SS, Sekar U. Carriage of multidrug resistant bacteria on
2516 frequently contacted surfaces and hands of health care workers. *Journal of Clinical And Diagnostic*
2517 *Research: JCDR*. 2016 May;10(5):DC18. DOI: <https://doi.org/10.7860/jcdr/2016/19692.7772>
- 2518 24. Matuka DO, Binta B, Carman HA, Singh T. *Staphylococcus aureus* and *Escherichia coli*
2519 levels on the hands of theatre staff in three hospitals in Johannesburg, South Africa, before and
2520 after handwashing. *South African Medical Journal*. 2018 May 25;108(6):474. DOI:
2521 <https://doi.org/10.7196/samj.2018.v108i6.12485>
- 2522 25. Monday SR, Beisaw A, Feng PCH. Identification of Shiga toxigenic *Escherichia coli*
2523 seropathotypes A and B by multiplex PCR. *Molecular and Cellular Probes*. 2007 Aug 1;21(4):308–
2524 11. DOI: <https://doi.org/10.1016/j.mcp.2007.02.002>
- 2525 26. Jackson CR, Fedorka-Cray PJ, Barrett JB. Use of a genus-and species-specific multiplex
2526 PCR for identification of enterococci. *Journal of Clinical Microbiology*. 2004 Aug;42(8):3558-65.
2527 DOI: <https://doi.org/10.1128/jcm.42.8.3558-3565.2004>
- 2528 27. Morot-Bizot SC, Talon R, Leroy S. Development of a multiplex PCR for the identification of
2529 *Staphylococcus* genus and four *Staphylococcal* species isolated from food. *Journal of Applied*
2530 *Microbiology*. 2004 Nov 1;97(5):1087-94. DOI: <https://doi.org/10.1111/j.1365-2672.2004.02399.x>
- 2531 28. Dong D, Liu W, Li H, Wang Y, Li X, Zou D, Yang Z, Huang S, Zhou D, Huang L, Yuan J.
2532 Survey and rapid detection of *Klebsiella pneumoniae* in clinical samples targeting the rcsA gene in
2533 Beijing, China. *Frontiers in Microbiology*. 2015 May 22;6:519. DOI:
2534 <https://doi.org/10.3389/fmicb.2015.00519>
- 2535 29. Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate
2536 between *Acinetobacter baumannii* and *Acinetobacter* genomic species 13TU. *Clinical Microbiology*
2537 *and Infection*. 2007 Dec;13(12):1199-201. DOI: <https://doi.org/10.1111/j.1469-0691.2007.01819.x>
- 2538 30. Tajbakhsh E, Tajbakhsh S, Khamesipour F. Isolation and molecular detection of Gram-
2539 negative bacteria causing urinary tract infection in patients referred to Shahrekord hospitals, Iran.

- 2540 Iranian Red Crescent Medical Journal. 2015 May;17(5). DOI:
2541 [https://doi.org/10.5812/ircmj.17\(5\)2015.24779](https://doi.org/10.5812/ircmj.17(5)2015.24779)
- 2542 31. Doumith M, Day MJ, Hope R, Wain J, Woodford N. Improved multiplex PCR strategy for
2543 rapid assignment of the four major *Escherichia coli* phylogenetic groups. Journal of Clinical
2544 Microbiology. 2012 Sep;50(9):3108–10. DOI: <https://doi.org/10.1128/jcm.01468-12>
- 2545 32. CLSI. Performance Standard for Antimicrobial Susceptibility Testing. 30th ed. CLSI
2546 supplement M100 Wayne. PA: Clinical and Laboratory Standards Institute; 2020.
- 2547 33. De Oliveira DM, Forde BM, Kidd TJ, Harris PN, Schembri MA, Beatson SA, Paterson DL,
2548 Walker MJ. Antimicrobial resistance in ESKAPE pathogens. Clinical Microbiology Reviews. 2020
2549 Jun 17;33(3):10-128. DOI: <https://doi.org/10.1128/cmr.00181-19>
- 2550 34. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to
2551 combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Frontiers in
2552 Microbiology. 2019 Apr 1;10:539. DOI: <https://doi.org/10.3389/fmicb.2019.00539>
- 2553 35. Boerlin P, Eugster S, Gaschen F, Straub R, Schawalder P. Transmission of opportunistic
2554 pathogens in a veterinary teaching hospital. Veterinary Microbiology. 2001 Oct 1;82(4):347-59.
2555 DOI: [https://doi.org/10.1016/s0378-1135\(01\)00396-0](https://doi.org/10.1016/s0378-1135(01)00396-0)
- 2556 36. Comerlato CB, Resende MC, Caierão J, d'Azevedo PA. Presence of virulence factors in
2557 *Enterococcus faecalis* and *Enterococcus faecium* susceptible and resistant to vancomycin.
2558 Memórias do Instituto Oswaldo Cruz. 2013;108:590-5. DOI: [https://doi.org/10.1590/s0074-
2559 02762013000500009](https://doi.org/10.1590/s0074-02762013000500009)
- 2560 37. Dotto G, Berlanda M, Pasotto D, Mondin A, Zambotto G, Menandro ML. Pets as potential
2561 carriers of multidrug-resistant *enterococcus faecium* of significance to public health. New
2562 Microbiologica. 2018 Apr 1;41(2):168–72.
- 2563 38. Walther B, Tedin K, Lübke-Becker A. Multidrug-resistant opportunistic pathogens
2564 challenging veterinary infection control. Veterinary Microbiology. 2017 Feb 1;200:71–8. DOI:
2565 <https://doi.org/10.1016/j.vetmic.2016.05.017>

- 2566 39. Sanchez S, Stevenson MAMC, Hudson CR, Maier M, Buffington T, Dam Q, et al.
2567 Characterization of multidrug-resistant *Escherichia coli* isolates associated with nosocomial
2568 infections in dogs. *Journal of Clinical Microbiology*. 2002;40(10):3586–95. DOI:
2569 <https://doi.org/10.1128/jcm.40.12.4806.2002>
- 2570 40. Feng Y, Wei L, Zhu S, Qiao F, Zhang X, Kang Y, Cai L, Kang M, McNally A, Zong Z.
2571 Handwashing sinks as the source of transmission of ST16 carbapenem-resistant *Klebsiella*
2572 *pneumoniae*, an international high-risk clone, in an intensive care unit. *Journal of Hospital*
2573 *Infection*. 2020 Apr 1;104(4):492-6. DOI: <https://doi.org/10.1016/j.jhin.2019.10.006>
- 2574 41. Qekwana DN, Sebola D, Oguttu JW, Odoi A. Antimicrobial resistance patterns of
2575 *Staphylococcus* species isolated from cats presented at a veterinary academic hospital in South
2576 Africa. *BMC Veterinary Research*. 2017 Sep 15;13(1). DOI [https://doi.org/10.1186/s12917-017-](https://doi.org/10.1186/s12917-017-1204-3)
2577 [1204-3](https://doi.org/10.1186/s12917-017-1204-3)
- 2578 42. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of *Acinetobacter*
2579 *baumannii* in health care facilities. *Clinical infectious diseases*. 2006 Mar 1;42(5):692-9. DOI:
2580 <https://doi.org/10.1086/500202>
- 2581 43. Loeffler A, Pfeiffer DU, Lloyd DH, Smith H, Soares-Magalhaes R, Lindsay JA. Meticillin-
2582 resistant *Staphylococcus aureus* carriage in UK veterinary staff and owners of infected pets: new
2583 risk groups. *Journal of Hospital Infection*. 2010 Mar 1;74(3):282-8. DOI:
2584 <https://doi.org/10.1016/j.jhin.2009.09.020>
- 2585 44. Pandey R, Mishra SK, Shrestha A. Characterisation of ESKAPE pathogens with special
2586 reference to multidrug resistance and biofilm production in a Nepalese hospital. *Infection and Drug*
2587 *Resistance*. 2021 Jun 14:2201-12. DOI: <https://doi.org/10.2147/idr.s306688>
- 2588 45. Eliasi UL, Sebola D, Oguttu JW, Qekwana DN. Antimicrobial resistance patterns of
2589 *Pseudomonas aeruginosa* isolated from canine clinical cases at a veterinary academic hospital in
2590 South Africa. *Journal of the South African Veterinary Association*. 2020 Jan 1;91(1):1-6. DOI:
2591 <https://doi.org/10.4102/jsava.v91i0.2052>

- 2592 46. Santaniello A, Sansone M, Fioretti A, Menna LF. Systematic review and meta-analysis of
2593 the occurrence of ESKAPE bacteria group in dogs, and the related zoonotic risk in animal-assisted
2594 therapy, and in animal-assisted activity in the health context. *International Journal of Environmental
2595 Research and Public Health*. 2020 May;17(9):3278. DOI: <https://doi.org/10.3390/ijerph17093278>
- 2596 47. Traub-Dargatz JL, Weese JS, Rousseau JD, Dunowska M, Morley PS, Dargatz DA. Pilot
2597 study to evaluate 3 hygiene protocols on the reduction of bacterial load on the hands of veterinary
2598 staff performing route equine physical examinations. *Canadian Veterinary Journal*.
2599 2006;47(7):671–6.
- 2600 48. Argudín MA, Deplano A, Meghraoui A, Dodémont M, Heinrichs A, Denis O, Nonhoff C,
2601 Roisin S. Bacteria from animals as a pool of antimicrobial resistance genes. *Antibiotics*. 2017 Jun
2602 6;6(2):12. DOI:
2603 <https://doi.org/10.3390/antibiotics6020012>
- 2604 49. LaBauve AE, Wargo MJ. Growth and laboratory maintenance of *Pseudomonas aeruginosa*.
2605 *Current Protocols in Microbiology*. 2012 May;25(1):6E-1. DOI:
2606 <https://doi.org/10.1002/9780471729259.mc06e01s25>
- 2607 50. Theelen MJ, Wilson WD, Byrne BA, Edman JM, Kass PH, Mughini-Gras L, Magdesian KG.
2608 Differences in isolation rate and antimicrobial susceptibility of bacteria isolated from foals with
2609 sepsis at admission and after \geq 48 hours of hospitalization. *Journal of Veterinary Internal Medicine*.
2610 2020 Mar;34(2):955-63. DOI: <https://doi.org/10.1111/jvim.15692>
- 2611 51. Ng S, Abdul Aziz S, Bejo SK, Dhaliwal GK. Occurrence of multidrug resistant *Acinetobacter*
2612 *baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *Jurnal
2613 Veterinar Malaysia*. 2016;28(2):12-6.
- 2614 52. Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, Quale J. Evolution of
2615 antimicrobial resistance among *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella*
2616 *pneumoniae* in Brooklyn, NY. *Journal of Antimicrobial Chemotherapy*. 2007 Jul 1;60(1):78-82. DOI:
2617 <https://doi.org/10.1093/jac/dkm129>

2618

Chapter 6

2619 **Knowledge of veterinary students on the transmission of hospital-acquired infections and**
2620 **zoonotic diseases at the veterinary academic hospital**

2621 **Dikeledi C. Sebola¹**

2622 ¹Section Veterinary Public Health, Department of Paraclinical Sciences, Faculty of Veterinary
2623 Science, University of Pretoria, Pretoria, South Africa

2624

2625

2626

2627 My contribution to the paper includes study design, data analysis, interpretation of results, writing
2628 of manuscript as well as extensive editing of the manuscript

Abstract

Background: Compliance with hand hygiene measures remains low among healthcare workers (HCWs) in veterinary medicine. The knowledge about infection prevention and control (IPC) is among the factors that drive the low level of hand hygiene compliance. This study assesses the knowledge of IPC and the transmission of hospital acquired infections (HAIs) among veterinary students entering the final year of clinical training.

Methods: The questionnaire survey was conducted among 147 final-year veterinary students at the Faculty of Veterinary Science addressing knowledge of the transmission of organisms associated with HAIs, zoonotic diseases, and IPC. The format of responses included yes or no and 5-point Likert scale answers. The Likert scale responses ranged from “Strongly disagree” to “Strongly agree. Proportions of categoric variables and 95% confidence intervals were calculated and presented in tables.

Results: Of the 147 students interviewed, most were female (69.4%) followed by male (29.2%). Most (59.2%) of the respondents indicated they had not heard about IPC programs, and it was emphasized before the start of the clinical training (92,2%, 130/141) and the clinical rotation (91,9%, 103/112). Thirty-nine percent (54/137) of respondents indicated the topic of transmission of HAIs was lightly emphasized pre-clinical and 43% (47/110) indicated that the topic was emphasized in multiple courses during clinical training. Students indicated that they were adequately trained on hand hygiene compliance, cleaning and disinfection, and the use of personal protective equipment (PPE). However, half indicated they were not adequately trained in IPC regarding patient management and disease surveillance. However, students knew that jewellery, stethoscopes, ward telephones, and leashes are possible sources of pathogens associated with HAIs.

Conclusion: Veterinary students have a poor understanding of IPC practices in this study. The students also reported that training on the topic is not given enough attention during lectures compared to during clinical training. Therefore, teaching and training at the undergraduate level must continue to ensure that students are adequately capacitated on IPC.

2656 **6.1 Introduction**

2657 The transmission of most organisms associated with hospital-acquired infections (HAIs) is
2658 mostly through the contaminated hands of healthcare workers (1,2). Studies in both human and
2659 veterinary medicine have demonstrated that effective hand hygiene compliance such as hand
2660 washing using water and soap and disinfecting hands with alcohol-based hand sanitizers (ABHS)
2661 reduce the transmission of bacteria associated with HAIs and zoonotic diseases. However,
2662 compliance among healthcare workers remains low in both humans and animals (1–7). In South
2663 Africa, Sebola et al (8) also reported poor infection prevention and control (IPC) practices such as
2664 the use of personal phones and the wearing of wristwatches among hospital personnel when
2665 attending to patients.

2666 Studies attribute the low level of compliance to high workload, lack of resources, underlying
2667 clinical conditions including skin irritation, forgetfulness, and lack of knowledge (3,4,7,9). The
2668 absence of written IPC protocols in hospitals and the lack of awareness among medical staff are
2669 also considered one of the drivers of low levels of hand hygiene compliance (10). Katz-Hulana (11)
2670 suggests that implementing standardized IPC strategies across clinical rotations will likely improve
2671 the overall level of hand hygiene compliance. Furthermore, emphasizing IPC measures at an
2672 undergraduate level may assist in improving the knowledge, attitude, as well as practice of students
2673 on hand hygiene (8,10,12).

2674 Knowledge, attitude, and practice (KAP) surveys are important in providing useful baseline
2675 data to inform awareness strategies on IPC and guide interventions for the reduction of HAIs and
2676 zoonotic pathogens in veterinary facilities (13). Therefore, this study aims to investigate the
2677 knowledge of veterinary students regarding the transmission of HAIs in the intensive care unit (ICU).
2678 Information collected will be used to identify knowledge gaps and behavioral patterns to guide the
2679 development of intervention programs including curriculum change.

2680 **6.2 Materials and methods**

2681 *6.2.1 Study area and study population*

2682 This study was conducted among the final year veterinary students at the University of
2683 Pretoria, Faculty of Veterinary Science in South Africa. The faculty is the only one in South Africa

2684 doing training in veterinary medicine. Veterinary science is a 6-year program, consisting of 4 years
2685 and 6 months of didactic teaching and 18 months of clinical training. This study targets final-year
2686 veterinary students (147) in their clinical training program.

2687 6.2.1.1 *Questionnaire design*

2688 The questionnaire was designed in Epi Info™ and consisted of closed questions in the form
2689 of checklists and selection types. It included questions that assessed the students' knowledge and
2690 of the transmission of organisms associated with HAIs, zoonotic diseases, and IPC in veterinary
2691 settings. The formats of responses were yes or no and 5-point Likert scale answers. The range of
2692 the Likert scale responses were "Strongly disagree = 1, Disagree = 2, Neither agree nor disagree =
2693 3, Agree = 4, and Strongly agree = 5". The questionnaire was adapted from the one by the World
2694 Health Organization (14). Pre-testing of the questionnaire was done among employees, students,
2695 and clinicians at the Faculty of Veterinary Sciences. Where necessary the questionnaire was
2696 modified to improve its quality and accuracy.

2697 6.2.1.2 *Data Collection*

2698 The questionnaire survey was conducted in July 2022. An information session was held by
2699 the principal investigator (DC) with all the students explaining the objective of the study. All students
2700 who attended the session were given hard copies of the questionnaires. The survey was estimated
2701 to take approximately 10 to 15 minutes to complete.

2702 6.2.1.3 *Data management and Data analyses*

2703 The data from hard copies was captured using Epi Info™(15) and stored as a Microsoft
2704 access file type. Before the analysis, the data was assessed for any inconsistencies. Proportions of
2705 categorical variables and 95% confidence intervals were calculated and tabulated using IBM SPSS
2706 Statistics (Version 29.0.0.0(241)). The analysis and interpretation of the 5-point Likert scale were
2707 done as shown in **Table 6.1**.

2708 **Table 6. 1:** The analysis and interpretation of the 5-point Likert scale based on the weighted
 2709 average of students working in the ICU at a veterinary academic hospital.

Weighted average	Results	Interpretation
1-1.8	Strongly disagree	Very low perception
1.81-2.6	Disagree	Low perception
2.61-3.4	Neutral	Neutral
3.41-4.2	Agree	Perception
4.21-5.0	Strongly agree	High perception

2710 *6.2.2 Ethics and confidentiality*

2711 This study was approved by the Faculty of Veterinary Sciences Research Ethics Committee
 2712 (REC009-21) and the University of Pretoria Survey Coordinating Committee. Consent forms were
 2713 given to students before the beginning of the study and students were free to decline participation in
 2714 the study. Participants were requested not to include their names or any form for anonymity.

2715 **6.3 Results**

2716 Of the 147 students interviewed most were female (69.4%, 102/147) followed by male
 2717 (29.2%, 43/147). Two (1.4%, 2/147) students did not indicate their sex.

2718 *6.3.1 Knowledge of respondents on infection prevention control program*

2719 Most (59.2%) of the respondents indicated they had not heard about IPC programs. Of those
 2720 who heard about IPC practices, 81% indicated they heard during lectures. Almost 82% of
 2721 respondents indicated that the topic of infection prevention and control was emphasized before start
 2722 of the clinical training. A similar proportion (80%) of respondents indicated that IPC is emphasized
 2723 during the clinical rotation. Based on the results, the respondents were adequately trained on hand
 2724 hygiene compliance, cleaning and disinfection, and the use of PPE. Almost half of the respondents
 2725 indicated they were not adequately trained in IPC as it relates to patient management and disease
 2726 surveillance.

2727 Of those who indicated that the topic of transmission of HAIs was covered during the pre-
 2728 clinical training, almost forty percent (39.4%) indicated that the topic was lightly emphasized. While
 2729 42.7% of the respondents indicated that the topic was emphasized in multiple courses during clinical
 2730 rotations (**Table 6. 2**).

2731
 2732

Table 6. 2: Questions relating to the knowledge of students on infection prevention and control as well as hospital-acquired infections.

Variable	Frequency	Percentages	^d CI
Have you heard of the infection prevention and control program (N=147)			
Yes	60	40.8	33.2-48.9
No	87	59.2	51.1-66.8
Where did you hear (n=54)			
Class	49	90.7	80.09-95.98
Word of mouth	3	5.6	1.91-15.11
Clinical training	1	1.9	0.33-9.77
Online	1	1.9	0.33-9.77
Is Infection prevention and control emphasized pre-clinics (n=141)			
Topic not covered	11	7.8	4.41-13.43
Lightly emphasized	46	32.6	25.44-40.73
Only covered in one course	41	29.1	22.22-37.05
Only covered in multiple courses	43	30.5	23.5-38.53
Is Infection prevention and control emphasized during clinics (n=112)			
Topic not covered	9	8.0	4.28-14.57
Lightly emphasized	36	32.1	24.21-41.26
Only covered in one course	26	23.2	16.36-31.84
Only covered in multiple courses	41	36.6	28.27-45.83
Which of the following infection prevention and control practices have you professionally trained^e (n=147)			
Hand hygiene	121	82.3	75.35-87.63
Cleaning and disinfection	109	74.1	66.29-81.01
Use of personal protective equipment	109	74.1	66.29-81.01
Patient management	82	55.8	47.71-63.56
Disease Surveillance	76	51.7	43.68-59.63
None	9	6.1	3.25-11.23
Is the transmission of hospital-acquired infections emphasized in the pre-clinical syllabus (n=137)			
Topic not covered	10	7.3	4.01-12.91
Lightly emphasized	54	39.4	31.63-47.78
Only covered in one course	35	25.5	18.98-33.45
Emphasized in multiple courses	38	27.7	20.93-35.76
Is the transmission of hospital-acquired infections emphasized in your clinical training year (n=110)			
Topic not covered	12	10.9	6.35-18.1
Lightly emphasized.	31	28.2	20.62-37.21
Only covered in one course	20	18.2	12.09-26.42
Emphasized in multiple courses	47	42.7	33.88-52.06

 2733 ^dConfidence interval

 2734 ^eTrained at an accredited or registered training institution

2735

2736 Most of the respondents highly perceived the use of personal cellphones, thermometers, and
 2737 contaminated hands of HCWs as routes for the transmission of organisms associated with HAIs.
 2738 Respondents also perceived the wearing of jewellery, use of stethoscope, use of ward telephone,
 2739 and use of leashes as possible routes for the transmission of pathogens associated with HAIs (**Table**
 2740 **6.3**).

2741 **Table 6. 3:** The perception of students on whether equipment could lead to possible transmission
 2742 of hospital-acquired infection.

Items (n=143)	SD ^a		D ^b		NA ^c		A ^d		SA ^e		Mean	Decision
	n	%	n	%	n	%	n	%	n	%		
Cellphone	1	0.7	2	1.4	6	4.2	55	38.5	79	55.2	4.46	High perception
Jewellery	3	2.1	10	7.0	15	10.5	70	49.0	45	31.5	4.01	Perception
Stethoscope	0	0	5	3.5	19	13.3	62	43.4	57	39.9	4.20	Perception
Thermometer	0	0	2	1.4	6	4.2	37	25.9	98	68.5	4.62	High perception
Ward telephone	1	0.7	11	7.7	21	14.7	63	44.1	47	32.9	4.01	Perception
Use of leashes	1	0.7	7	4.9	18	12.6	67	46.9	50	35.0	4.10	Perception
Contaminated hands	0	0	0	0	1	0.7	27	19.0	114	80.3	4.80	High perception

2743 ^aStrongly disagree, ^bDisagree, ^cNeither agree nor disagree, ^dAgree, ^eStrongly agree

2744 **6.4 Discussions**

2745 This study aimed to investigate the knowledge of veterinary students on IPC practices, and
 2746 transmission of organisms associated with HAIs. As the first study in South Africa to investigate this
 2747 area, the data collected will be used to guide intervention strategies for IPC in the veterinary
 2748 academic hospital.

2749 *6.4.1 Knowledge of respondents on infection prevention control program and hospital*
 2750 *acquired infections*

2751 The students in this study had a low overall knowledge of IPC programs. In contrast, studies
 2752 have reported good knowledge of IPC among HCWs in human hospitals (16–18). The low knowledge
 2753 among the students in this study is puzzling as the same students indicated that IPC and topics on
 2754 HAIs were covered during clinical and pre-clinical training although in varying degrees. The lengthy
 2755 duration of the veterinary program could also be contributing to students' recall bias, leading to a
 2756 higher recall of emphasis during clinics as the information is recent (19). Nonetheless, the results
 2757 seem to suggest that student do not have a good understanding of infection prevention and control
 2758 measures and their role in the prevention of HAIs and zoonotic diseases. Since most students
 2759 indicated that their knowledge of IPC was acquired during lectures, emphasis on IPC must be done
 2760 both in undergraduate lectures and during clinical training (13,20).

2761 It is noteworthy that a few respondents indicated they received training in disease
 2762 surveillance and patient management when compared to other IPC strategies. This is not surprising,
 2763 as there is insufficient reporting on the knowledge of HCWs on disease surveillance and patient

2764 management in relation to IPC (21–23). The authors hypothesise that this could be due to the
2765 integrated nature of teaching and training on patient management and disease surveillance rather
2766 than a standalone module. Moreover, the current undergraduate syllabus contains an epidemiology
2767 module that includes disease surveillance. Therefore, an undergraduate curriculum review is needed
2768 to identify potential gaps and make recommendations for changes if needed.

2769 Students agreed that cellphones, thermometers, jewellery, stethoscopes, ward telephone,
2770 leashes and contaminated hands could be potential sources for the transmission of organisms
2771 associated with HAIs. Although the expectation is that this will translate to behavioral change.
2772 Studies have shown that a high perception of IPC measures does not correspond with compliance
2773 (8,13,16). Duerink et al (24) in Indonesian. reported better compliance among HCWs with more
2774 knowledge compared to those with less knowledge of IPC. Therefore, knowledge of IPC measures
2775 alone is not enough to improve compliance, other factors must also be considered (25).

2776 **6.5 Conclusion**

2777 Student do not have a good understanding of IPC measures and their role in the prevention
2778 of HAIs and zoonotic diseases in this study. It is possible that the integrated nature of teaching and
2779 training could be contributing to a lack of understanding, therefore, a review of the undergraduate
2780 curriculum could be helpful in bridging the gap. Of noteworthy is that students are aware that the
2781 different equipment used during patient care could be potential sources for organisms associated
2782 with HAIs.

2783 **6.6 References**

- 2784 1. Nakamura RK, Tompkins E, Braasch EL, Martinez Jr JG, Bianco D. Hand hygiene practices
2785 of veterinary support staff in small animal private practice. *Journal of Small Animal Practice*. 2012
2786 Mar;53(3):155-60.
- 2787 2. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention.
2788 *Journal of hospital infection*. 2009 Dec 1;73(4):305-15.
- 2789 3. Weese JS. Barrier precautions, isolation protocols, and personal hygiene in veterinary
2790 hospitals. *Veterinary Clinics: Equine Practice*. 2004 Dec 1;20(3):543-59.
- 2791 4. Anderson ME. Contact precautions and hand hygiene in veterinary clinics. *Veterinary*
2792 *Clinics: Small Animal Practice*. 2015 Mar 1;45(2):343-60.
- 2793 5. Salama MF, Jamal WY, Al Mousa H, Al-AbdulGhani KA, Rotimi VO. The effect of hand
2794 hygiene compliance on hospital-acquired infections in an ICU setting in a Kuwaiti teaching hospital.
2795 *Journal of infection and public health*. 2013 Feb 1;6(1):27-34.
- 2796 6. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, Boyce JM.
2797 Evidence-based model for hand transmission during patient care and the role of improved
2798 practices. *The Lancet infectious diseases*. 2006 Oct 1;6(10):641-52.
- 2799 7. Shea A, Shaw S. Evaluation of an educational campaign to increase hand hygiene at a
2800 small animal veterinary teaching hospital. *Journal of the American Veterinary Medical Association*.
2801 2012 Jan 1;240(1):61-4.
- 2802 8. Sebola DC, Boucher C, Maslo C, Qekwana DN. Hand hygiene compliance in the intensive
2803 care unit of the Onderstepoort Veterinary Academic Hospital. [Preprint] 2019 [Accessed 2024 April
2804 10]. Available from: <https://doi.org/10.21203/rs.2.17130/v1>
- 2805 9. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV.
2806 Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *The*
2807 *Lancet*. 2000 Oct 14;356(9238):1307-12.
- 2808 10. Lau T, Tang G, Mak K lun, Leung G. Moment-specific compliance with hand hygiene. *Clin*
2809 *Teach*. 2014 Jun 1;11(3):159–64.

- 2810 11. Katz-Hulana L. Improving hand hygiene compliance amongst second-year nursing students
2811 and staff by implementing a standardised aseptic hand wash protocol in hospitals in the Northern
2812 Cape Province, South Africa. *Wound Healing Southern Africa*. 2022 Jun 1;15(1):11-6.
- 2813 12. Ward DJ. The role of education in the prevention and control of infection: a review of the
2814 literature. *Nurse Education Today*. 2011 Jan 1;31(1):9-17.
- 2815 13. Dramowski A, Whitelaw A, Cotton MF. Healthcare-associated infections in children:
2816 knowledge, attitudes and practice of paediatric healthcare providers at Tygerberg Hospital, Cape
2817 Town. *Paediatrics and international child health*. 2016 Jul 2;36(3):225-31..
- 2818 14. World Health Organization. A guide to developing knowledge , attitude and practice
2819 surveys. 2008.
- 2820 15. Centers for Disease Control and Prevention. USA.gov. 2018 [cited 2020 Jan 25]. Epi
2821 InfoTM. Available from: <https://www.cdc.gov/epiinfo/index.html>.
- 2822 16. Ogoina D, Pondei K, Adetunji B, Chima G, Isichei C, Gidado S. Knowledge, attitude and
2823 practice of standard precautions of infection control by hospital workers in two tertiary hospitals in
2824 Nigeria. *Journal of infection prevention*. 2015 Jan;16(1):16-22.
- 2825 17. Aldhamy H, Maniopoulos G, McCune VL, Mansi I, Althaqafy M, Pearce MS. Knowledge,
2826 attitude and practice of infection prevention and control precautions among laboratory staff: a
2827 mixed-methods systematic review. *Antimicrobial Resistance & Infection Control*. 2023 Dec;12(1):1-
2828 4.
- 2829 18. Hamid HA, Mustafa MM, Al-Rasheedi M, Balkhi B, Suliman N, Alshaafee W, Mohammed
2830 SA. Assessment of hospital staff knowledge, attitudes and practices (KAPS) on activities related to
2831 prevention and control of hospital acquired infections. *J Infect Prev*. 2019;10.
- 2832 19. Van De Mortel TF, Kermode S, Prozano T, Sansoni J. A comparison of the hand hygiene
2833 knowledge, beliefs and practices of Italian nursing and medical students. *Journal of advanced
2834 nursing*. 2012 Mar;68(3):569-79.
- 2835 20. Zingg W, Storr J, Park BJ, Ahmad R, Tarrant C, Castro-Sanchez E, Tomczyk S, Kilpatrick
2836 C, Allegranzi B, Cardo D, Pittet D. Implementation research for the prevention of antimicrobial
2837 resistance and healthcare-associated infections; 2017 Geneva infection prevention and control
2838 (IPC)-think tank (part 1). *Antimicrobial Resistance & Infection Control*. 2019 Dec;8:1-9.

- 2839 21. Aworh MK, Kwaga JK, Okolocha EC. Assessing knowledge, attitude, and practices of
2840 veterinarians towards antimicrobial use and stewardship as drivers of inappropriate use in Abuja,
2841 Nigeria. *One Health Outlook*. 2021 Dec;3(1):1-2.
- 2842 22. Geberemariam BS, Donka GM, Wordofa B. Assessment of knowledge and practices of
2843 healthcare workers towards infection prevention and associated factors in healthcare facilities of
2844 West Arsi District, Southeast Ethiopia: a facility-based cross-sectional study. *Archives of Public
2845 Health*. 2018 Dec;76(1):1-1.
- 2846 23. Nathwani D, Sneddon J. Practical guide to antimicrobial stewardship in hospitals.
2847 BiomérieuxR. Disponível em: [http://bsac.org.uk/wpcontent/uploads/2013/07/Stewardship-Booklet-
2848 Practical-Guide-to-Antimicrobial-Stewardship-in-Hospitals.pdf](http://bsac.org.uk/wpcontent/uploads/2013/07/Stewardship-Booklet-Practical-Guide-to-Antimicrobial-Stewardship-in-Hospitals.pdf). 2015.
- 2849 24. Duerink DO, Hadi U, Lestari ES, Roeshadi D, Wahyono H, Nagelkerke NJ, Meulen RG, van
2850 den Broek PJ. A tool to assess knowledge, attitude and behavior of Indonesian health care
2851 workers regarding infection control. 2013
- 2852 25. World Health Organization. A guide to the implementation of the WHO multimodal hand
2853 hygiene improvement strategy. World Health Association Press. Geneva; 2009
- 2854

2855 **Chapter 7 Summary of Discussions and Recommendations**

2856 **7.1 Discussions and conclusions**

2857 This chapter reviews the objectives of the study and summarizes the key findings. It also
2858 provides conclusions and recommendations for future research. The study aimed to assess the pre-
2859 intervention IPC practices required to reduce the transmission of organisms associated with hospital-
2860 acquired infections (HAIs) and zoonotic diseases at a veterinary hospital. The pre-intervention
2861 assessments included the level of knowledge of veterinary students on HAIs, identification of
2862 organisms associated with HAIs and zoonotic diseases from the hands of healthcare workers
2863 (HCWs). The information generated from this study will contribute to a better understanding of the
2864 epidemiology of zoonotic and HAI organisms in veterinary medicine. The objectives of this study
2865 were: (1) To describe organisms associated with HAIs and zoonotic infections and their
2866 antimicrobial-resistant patterns in veterinary hospitals; (2) To describe the antimicrobial resistance
2867 patterns of *Klebsiella pneumoniae* and *Acinetobacter baumannii* from clinical samples of dogs
2868 presented to a veterinary academic hospital in South Africa between 2007 and 2013; (3) To
2869 Investigate the Knowledge of students on the transmission of HAIs in the intensive care unit (ICU);
2870 (4) To investigate the occurrence of organisms associated with HAIs on the hands of students
2871 working in the ICU; and (5) describe their antimicrobial resistance patterns.

2872 Studies have suggested that improving the surveillance system is critical in the prevention of
2873 HAIs and in reducing the emergence of antimicrobial-resistant pathogens. Bacterial organisms
2874 associated with HAIs and zoonotic diseases were reported from clinical cases, environmental
2875 surfaces, and commonly used equipment in veterinary settings. The hospital environment with
2876 human contact was the most reported source of bacteria associated with HAIs. These results
2877 suggest that humans play a crucial role in transmitting HAIs in veterinary hospitals. Among the
2878 bacteria reported, Methicillin-resistant *Staphylococcus aureus* was the most reported HAI bacteria
2879 in veterinary facilities. Other bacteria identified include Methicillin-resistant *Staphylococcus*
2880 *pseudintermedius*, *Escherichia coli*, *Clostridium difficile*, *Acinetobacter baumannii*, *Salmonella*
2881 species, and *Enterococcus* spp. Some of these isolates reported in veterinary settings share similar
2882 clonal lineage to those reported in humans. Some bacteria exhibited a high prevalence of

2883 antimicrobial resistance and contain genes known to be associated with antibiotic resistance. From
2884 these results, the author recommends strict and continuous infection prevention and control (IPC)
2885 practices in veterinary medicine. In addition, veterinary hospitals must implement continuous
2886 surveillance of organisms associated with HAIs and their antimicrobial resistance patterns.

2887 In South Africa, studies of ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*,
2888 *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter*
2889 species) bacteria have been well-documented in human medicine. However, studies investigating
2890 antimicrobial drug resistance among the ESKAPE group in veterinary medicine are limited. In the
2891 current study, multidrug resistance (MDR) *A. baumannii* and *K. pneumoniae* were identified from
2892 various tissues such as bone, urine, skin, blood, ear, nasal, bronchoalveolar lavage, and oral cavity
2893 isolated from dogs admitted in a veterinary hospital in South Africa. This suggests that these
2894 pathogens are associated with various clinical infections in dogs and can infect different body
2895 systems. In addition, these bacteria exhibited a high level of resistance to commonly used antibiotics
2896 for treatment in small animal practices. *Acinetobacter baumannii* showed resistance towards
2897 antibiotics from classes of β -lactams, cephalosporins, and trimethoprim-sulphamethoxazole.
2898 However, a low prevalence of resistance was observed against antibiotics from classes such as
2899 carbapenems, colistin, and fluoroquinolones. These results as well as combination antimicrobials
2900 suggest the possible choice of treatment for MDR *A. baumannii*. *Klebsiella pneumoniae* showed low
2901 resistance towards imipenem, amikacin, gentamycin, and trimethoprim-sulphamethoxazole, which
2902 can still be investigated for treatment options.

2903 Furthermore, this study isolated ESKAPE organisms from the hands of students working in
2904 the ICU before patient contact. *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecium*
2905 were among the bacteria identified. Similarly, *Staphylococcus aureus*, *Acinetobacter baumannii*, and
2906 *Pseudomonas aeruginosa* were also isolated in this study. This suggests that human-environment
2907 interaction could have led to hand contamination. Therefore, the isolation of these bacteria indicates
2908 that effective hand hygiene compliance in the veterinary hospital should be emphasized. In addition,
2909 veterinary environmental surfaces and commonly touched equipment are to be thoroughly cleaned
2910 and disinfected after every use to minimize the bacterial load, especially on surfaces with constant
2911 human contact.

2912 Most of the isolated ESKAPE organisms in this study were resistant to the β -lactams and *A.*
2913 *baumannii* and *P. aeruginosa* showed resistance towards imipenem. Furthermore, MDR was
2914 observed in *E. coli*, *P. aeruginosa*, *E. Faecium*, and *S. aureus*. The presence of MDR bacteria is
2915 likely to impact treatment options and patient outcomes in zoonotic and HAI cases, therefore,
2916 antimicrobial stewardship must be prioritized in veterinary hospitals.

2917 The knowledge of IPC practices seems to be low among the students while knowledge of the
2918 potential instrument that can lead to the transmission of organisms associated with HAIs in the ICU
2919 was adequate. However, students lacked an understanding of individual IPC measures and
2920 suggested the pre-clinical program was not adequate. Therefore, recommends a review of the
2921 undergraduate curriculum as it could be helpful in bridging the gap.

2922 The results of this study provide baseline data for understanding the prevalence and
2923 antimicrobial sensitivity profile of bacteria associated with HAIs in veterinary medicine. In addition,
2924 the information generated will contribute to the development and implementation of the South African
2925 national AMR framework.

2926 *7.1.1 Limitations of the study*

2927 The study is not without limitations; for example,

- 2928 1. This study was limited to one veterinary hospital and did not include other veterinary
2929 medical facilities, thus the results cannot be generalized to the entire South African
2930 veterinary medicine sector.
- 2931 2. This study of knowledge focused only on veterinary students and not all veterinary HCWs
2932 were interviewed or sampled.
- 2933 3. The data for the knowledge survey were self-reported which could be subject to the
2934 respondent's memory and biases.

2935 **7.2 Recommendations**

2936 In line with the multimodal strategies to promote effective IPC practices the following
2937 strategies are proposed:

- 2938 1. **Hand hygiene training** should be provided to both veterinary students and other HCWs.
2939 The training can be conducted through presentations, discussions, and demonstrations. The

2940 key concepts of the training should include, but not be limited to, epidemiology, the incidence
2941 and burden of MDR bacteria (ESKAPE) within veterinary medicine, the national strategic plan
2942 on antimicrobial resistance, and one health concept.

2943 2. **Educational and reminder posters** should be created and placed in specific areas of the
2944 veterinary hospital. These areas include entry doors, locations where hand hygiene is crucial
2945 (such as near sinks), and treatment rooms. The posters should provide information about the
2946 five hand hygiene moments and emphasize the significance of IPC practices in reducing the
2947 spread of MDR bacteria.

2948 3. **Different educational platforms** should be established and utilized to spread the knowledge
2949 of IPC practices. An example could be social media platforms.

2950 4. **Infection prevention and control champions** should be identified and selected based on
2951 the need and area of expertise.

2952 5. **Regular feedback on IPC inspections and audits** must be done. The feedback session
2953 should be conducted by the IPC champion and can be done during group meetings.

2954

2955

Chapter 8 Annexures

2956 **Table 8. 1:** List of documents in the annexure section with chapters associated.

Document	Chapter associated
Publication 1	Chapter 3
Risk of Bias	Chapter 3
Publication 2	Chapter 4
Questionnaire Survey	Chapter 6
REC Renewal approval	All Chapters
Ethical approval amendment	All Chapters
Survey committee approval	Chapter 6
Section 20 approval	All Chapters
Humanities ethics approval	All Chapters
Health Science ethics approval	Chapter 5

2957



AMENDMENT LETTER OF APPROVAL

Ethics Reference No REC009-21 Line 1
Protocol Title Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital
Principal Investigator Ms DC Sebola
Supervisors Prof DN Qekwana

Dear Ms DC Sebola,

We are pleased to inform you that the **Amendment** conforms to the requirements of the Faculty of Veterinary Sciences Research Ethics committee.

Please note the following about your ethics approval:

1. Please use your reference number (REC009-21) on any documents or correspondence with the Research Ethics Committee regarding your research.
2. Please note that the Research Ethics Committee may ask further questions, seek additional information, require further modification, monitor the conduct of your research, or suspend or withdraw ethics approval.
3. Please note that ethical approval is granted for the duration of the research as stipulated in the original application (for Post graduate studies e.g. Honours studies: 1 year, Masters studies: two years, and PhD studies: three years) and should be extended when the approval period lapses.
4. The digital archiving of data is a requirement of the University of Pretoria. The data should be accessible in the event of an enquiry or further analysis of the data.


Ethics approval is subject to the following:

1. The ethics approval is conditional on the research being conducted as stipulated by the details of all documents submitted to the Committee. In the event that a further need arises to change who the investigators are, the methods or any other aspect, such changes must be submitted as an Amendment for approval by the Committee.
2. **Applications using Animals: FVS ethics recommendation does not imply that AEC approval is granted. The application has been pre-screened and recommended for review by the AEC. Research may not proceed until AEC approval is granted.**

CONDITIONALLY APPROVED NOTE: UP Survey committee approval letter still to be uploaded

We wish you the best with your research.

Yours sincerely



PROF M. OOSTHUIZEN
Chairperson: Research Ethics Committee



ANNUAL RENEWAL LETTER OF APPROVAL

Ethics Reference No	REC009-21 Line 2
Protocol Title	Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital
Principal Investigator	Ms DC Sebola
Supervisors	Prof DN Qekwana

Dear Ms DC Sebola,

We are pleased to inform you that the **Annual Renewal** conforms to the requirements of the Faculty of Veterinary Sciences Research Ethics committee.

Please note the following about your ethics approval:

1. Please use your reference number (REC009-21) on any documents or correspondence with the Research Ethics Committee regarding your research.
2. Please note that the Research Ethics Committee may ask further questions, seek additional information, require further modification, monitor the conduct of your research, or suspend or withdraw ethics approval.
3. Please note that ethical approval is granted for the duration of the research as stipulated in the original application (for Post graduate studies e.g. Honours studies: 1 year, Masters studies: two years, and PhD studies: three years) and should be extended when the approval period lapses.
4. The digital archiving of data is a requirement of the University of Pretoria. The data should be accessible in the event of an enquiry or further analysis of the data.


Ethics approval is subject to the following:

1. The ethics approval is conditional on the research being conducted as stipulated by the details of all documents submitted to the Committee. In the event that a further need arises to change who the investigators are, the methods or any other aspect, such changes must be submitted as an Amendment for approval by the Committee.
2. **Note: All FVS animal research applications for ethical clearance will be automatically rerouted to the Animal Ethics committee (AEC) once the applications meet the requirements for FVS ethical clearance. As such, all FVS REC applications for ethical clearance related to human health research will be automatically rerouted to the Health Sciences Research Ethics Committee, and all FVS applications involving a questionnaire will be automatically rerouted to the Humanities Research Ethics Committee. Also take note that, should the study involve questionnaires aimed at UP staff or students, permission must also be obtained from the relevant Dean and the UP Survey Committee. Research may not proceed until all approvals are granted.**

PLEASE NOTE: Conditionally approved pending the following: 1. Obtaining ALL other relevant approvals. 2. The upload of an updated letter from the Director (current one outdated). 3. UP Survey committee approval letter still to be uploaded

We wish you the best with your research.

Yours sincerely



PROF M. OOSTHUIZEN
Chairperson: Research Ethics Committee



agriculture, land reform
& rural development

Department
Agriculture, Land Reform and Rural Development
REPUBLIC OF SOUTH AFRICA

Directorate Animal Health, Department of Agriculture, Land Reform & Rural Development
Private Bag X138, Pretoria 0001

Enquiries: Ms Marna Laing • Tel: +27 12 319 7532 • Fax: +27 12 319 7470 • E-mail: MarnaL@Dalrrd.gov.za
Reference: 12/11/1/1/MG (2193)

Professor Daniel Nenene Qekwana
Faculty of Veterinary Sciences
University of Pretoria
Department of Paraclinical Sciences
Onderstepoort, Pretoria
0110

E-mail: nenene.gekwana@up.ac.za

Dear Professor Daniel Nenene Qekwana,

**RE: PERMISSION TO DO RESEARCH IN TERMS OF SECTION 20 OF THE
ANIMAL DISEASES ACT, 1984 (ACT NO. 35 OF 1984)**

Your application received per email and with the attachments on 4 November 2021, requesting permission under Section 20 of the Animal Disease Act, 1984 (Act No. 35 of 1984) to perform a research project or study, refers. I am pleased to inform you that permission is hereby granted to perform the following study, with the following conditions:

Conditions:

1. This permission does not relieve the researcher of any responsibility which may be placed by any other act of the Republic of South Africa;
2. The study is approved as per the application and the correspondence thereafter. Written permission from the Director: Animal Health must be obtained prior to any deviation from the conditions approved for this study under this Section 20 permit. Please apply in writing to MarnaL@Dalrrd.gov.za;
3. All potentially infectious material utilised, collected or generated during the study are to be destroyed at the completion of the study. A registered waste

removal company must dispose the material generated from the study.
Records must be kept for five years for auditing purposes;

4. Samples to be used in this study shall not be collected from animals, but from animal handlers and their personal belongings and equipment used in the animal hospital;
5. Bacterial isolation and identification shall be performed at the Veterinary public health (VPH) Laboratory at the University of Pretoria;
6. Pure samples of the microorganisms may be kept under strict access control at the VPH laboratory. Any further usage of the stored samples must be authorised by the Director Animal Health;
7. If required, an application for an extension must be made by the responsible researcher at least one month prior to the expiry of this Section 20 approval.

Title of research/study: Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital.

Researcher: Ms Dikeledi Carol Sebola
Institution: University of Pretoria
Our ref Number: 12/11/1/1/MG (2193)
Your ref:
Expiry date: 31 December 2023

Kind regards,

Name: Dr Mpho Maja
Reason:
Date: 2021.12.17 10:32:12 CAT

DR. MPHO MAJA
DIRECTOR OF ANIMAL HEALTH
Date:

SUBJECT: Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital



2022-08-19

Ms DC Sebola
Department of Paraclinical Sciences
Faculty of Veterinary Science
University of Pretoria

Email: dcsebola@gmail.com

Dear Ms Sebola

APPROVAL OF RESEARCH STUDY

The UP Survey Coordinating Committee has granted approval for the research study titled "Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital".

The proposed research study has to strictly adhere to the associated study protocol, as well as the UP Survey Policy and the Ethics Committee of the Faculty of Veterinary Science instructions.

Please liaise with the Market Research Office in the Department of Institutional Planning (carlien.nell@up.ac.za) to officially register the study and to finalise the survey regulations, procedures and the fieldwork dates. In order to register the study, the Market Research Office has to receive the formal ethical approval letter from the Faculty of Veterinary Science.

A final electronic copy of the research outcomes must be submitted to the Survey Coordinating Committee as soon as possible after the completion of the study.

Kind regards

Prof CMA Nicholson
REGISTRAR
CHAIRPERSON: SURVEY COORDINATING COMMITTEE



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

Faculty of Health Sciences

Institution: The Research Ethics Committee, Faculty Health Sciences, University of Pretoria complies with ICH-GCP guidelines and has US Federal wide Assurance.

- FWA 00002567, Approved dd 18 March 2022 and Expires 18 March 2027.
- IORG #: IORG0001762 OMB No. 0990-0278 Approved for use through August 31, 2023.

Faculty of Health Sciences Research Ethics Committee

1 June 2022

Endorsement Notice

Dear Ms DC Sebola

Ethics Reference No: 187/2022

Title: Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital

The **New Application** as supported by documents received between 2022-04-14 and 2022-06-01 for your research, was approved by the Faculty of Health Sciences Research Ethics Committee on 2022-06-01 as resolved by its quorate meeting.

Please note the following about your ethics approval:

- Ethics Approval is valid for 1 year and needs to be renewed annually by 2023-06-01.
- Please remember to use your protocol number (187/2022) on any documents or correspondence with the Research Ethics Committee regarding your research.
- Please note that the Research Ethics Committee may ask further questions, seek additional information, require further modification, monitor the conduct of your research, or suspend or withdraw ethics approval.

Ethics approval is subject to the following:

- The ethics approval is conditional on the research being conducted as stipulated by the details of all documents submitted to the Committee. In the event that a further need arises to change who the investigators are, the methods or any other aspect, such changes must be submitted as an Amendment for approval by the Committee.

We wish you the best with your research.

Yours sincerely



On behalf of the FHS REC, Dr R Sommers

MBChB, MMed (Int), MPharmMed, PhD

Deputy Chairperson of the Faculty of Health Sciences Research Ethics Committee, University of Pretoria

The Faculty of Health Sciences Research Ethics Committee complies with the SA National Act 61 of 2003 as it pertains to health research and the United States Code of Federal Regulations Title 45 and 46. This committee abides by the ethical norms and principles for research, established by the Declaration of Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes, Second Edition 2015 (Department of Health).



Faculty of Humanities

Fakulteit Geesteswetenskappe
Lefapha la Bomotho



17 May 2022

Dear Ms DC Sebola

Project Title: Multimodal approaches to reducing transmission of hospital-acquired infections (HAI) in the intensive care unit (ICU) at a veterinary academic hospital
Researcher: Ms DC Sebola
Supervisor(s): Prof DN Qekwana
Department: Paraclinical Sciences
Reference number: 26235286 (REC009-21)
Degree: Doctoral

I have pleasure in informing you that the above application was **approved** by the Research Ethics Committee on 28 April 2022. Data collection may therefore commence.

Please note that this approval is based on the assumption that the research will be carried out along the lines laid out in the proposal. Should the actual research depart significantly from the proposed research, it will be necessary to apply for a new research approval and ethical clearance.

We wish you success with the project.

Sincerely,

A handwritten signature in black ink, appearing to read 'KHarris'.

Prof Karen Harris
Chair: Research Ethics Committee
Faculty of Humanities
UNIVERSITY OF PRETORIA
e-mail: tracey.andrew@up.ac.za

Research Ethics Committee Members: Prof KL Harris (Chair); Mr A Bizos; Dr A-M de Beer; Dr A dos Santos; Dr P Gutura; Ms KT Govinder Andrew; Dr E Johnson; Dr D Krige; Prof D Maree; Mr A Mohamed; Dr I Noomé; Dr J Okeke; Dr C Puttergill; Prof D Reyburn; Prof M Soer; Prof E Taljard; Ms D Mokalapa